



(11)

EP 3 299 391 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
04.12.2019 Bulletin 2019/49

(51) Int Cl.:
C07K 16/28 (2006.01) **A61P 35/00** (2006.01)
A61K 39/395 (2006.01)

(21) Application number: **17197596.4**(22) Date of filing: **13.03.2014**(54) **ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES**

ANTI-B7-H4-ANTIKÖRPER UND IMMUNKONJUGATE
ANTICORPS ET IMMUNOCONJUGUÉS ANTI-B7-H4

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(30) Priority: **14.03.2013 US 201361784877 P
14.03.2013 US 201361785811 P
05.09.2013 US 201361874175 P**

(43) Date of publication of application:
28.03.2018 Bulletin 2018/13

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
14717318.1 / 2 970 474

(73) Proprietor: **Genentech, Inc.
South San Francisco, CA 94080 (US)**

(72) Inventors:
• **LEONG, Steven R.
South San Francisco, CA 94080 (US)**

- **POLSON, Andrew**
South San Francisco, CA 94080 (US)
- **POLAKIS, Paul**
South San Francisco, CA 94080 (US)
- **WU, Yan**
South San Francisco, CA 94080 (US)
- **LIANG, Wei-Chang**
South San Francisco, CA 94080 (US)
- **FIRESTEIN, Ron**
South San Francisco, CA 94080 (US)

(74) Representative: **Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)**

(56) References cited:
**WO-A1-2013/025779 WO-A2-2004/101756
WO-A2-2006/053110 WO-A2-2008/067283
WO-A2-2009/073533 US-A1- 2009 208 489**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**FIELD OF THE INVENTION**

5 [0001] The present invention relates to anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

BACKGROUND

10 [0002] B7-H4 is a Type I transmembrane protein and is a member of the B7 superfamily of proteins that provides co-signal in conjunction with a T-cell receptor antigenic signal. B7-H4 is a negative regulator of T-cell function and ligation of T-cells inhibits their growth, cytokine secretion and cytotoxicity. Elimination of B7-H4 in mice does not affect immune cell homeostasis and no signs of autoimmunity. Zhu et al., Blood, 113(8): 1759-1767 (2009); Suh et al., Molecular and Cellular Biology, 26(17): 6403-6411 (2006). The receptor for B7-H4 is unknown and unidentified.

15 [0003] Human B7-H4 is a 282 amino acid protein (including the amino-terminal signal sequence), of which ~227 amino acids are predicted to be in the extracellular space following cleavage of the amino-terminal signal sequence. B7-H4 comprises an Ig-like V-domain, an Ig-like C domain, a transmembrane domain and a short cytoplasmic tail.

20 [0004] WO 2009/073533, WO 2008/067283, WO 2004/101756, WO 2006/053110 and WO 2013/025779 describe various anti-B7-H4 antibodies, which are tested in vitro and bind to recombinant B7-H4 target protein. US 2009/0208489 describes the isolation and sequencing of mouse (4G10, 8G5, 3A4 and 2F3) and human (sc77, sc189 and sc209) anti-B7-H4 antibodies. There is no evidence in US 2009/0208489 that the antibodies cross-react with cynomolgus monkey or rat B7-H4.

25 [0005] There is a need in the art for agents that target B7-H4 for the diagnosis and treatment of B7-H4-associated conditions, such as cancer. The invention fulfills that need and provides other benefits.

SUMMARY

[0006] The invention provides anti-B7-H4 antibodies and immunoconjugates and the same for use in methods, as defined in the claims.

30 [0007] In some embodiments, an isolated antibody that binds to B7-H4 is provided as defined in the claims. The antibody binds to B7-H4 and has at least one of the following characteristics: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4) or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4). The antibody binds to B7-H4 with an affinity of ≤ 50 nM. The antibody is a monoclonal antibody. In some embodiments, the antibody is a humanized, or chimeric antibody. In some embodiments, the antibody is an IgG1, IgG2a or IgG2b antibody. In some embodiments, the antibody is an antibody fragment that binds B7-H4. In some embodiments, B7-H4 is human B7-H4 has the sequence of SEQ ID NO: 73.

40 [0008] The antibody comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41.

[0009] In some embodiments, the antibody further comprising a heavy chain framework FR3 sequence of SEQ ID NO: 51, 52 or 53.


45 [0010] The antibody further comprises: (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

50 [0011] In some embodiments, an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 35; or (c) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 37; or (d) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 38.


55 [0012] In some embodiments, an isolated antibody comprises a VH sequence of SEQ ID NO: 36 and a VL sequence of SEQ ID NO: 35; or a VH sequence of SEQ ID NO: 37 and a VL sequence of SEQ ID NO: 35; or a VH sequence of SEQ ID NO: 38 and a VL sequence of SEQ ID NO: 35.

[0013] In some embodiments, an isolated nucleic acid that encodes an antibody described herein is provided. In some embodiments, a host cell comprising the nucleic acid is provided. In some embodiments, a method of producing an antibody described herein is provided. In some embodiments, the method comprises culturing the host cell comprising the nucleic acid that encodes an antibody.


[0014] In some embodiments, immunoconjugates are provided as defined in the claims. An immunoconjugate comprises an anti-B7-H4 antibody and a cytotoxic agent. In some embodiments, an immunoconjugate has the formula Ab-(L-D)p, wherein: (a) Ab is the an antibody described herein; (b) L is a linker; (c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and (d) p ranges from 1-8. In some embodiments, D is an auristatin. In some such embodiments, D has formula D_F




15 wherein R² and R⁶ are each methyl, R³ and R⁴ are each isopropyl, R⁵ is H, R⁷ is sec-butyl, each R⁸ is independently selected from CH₃, O-CH₃, OH, and H; R⁹ is H; and R¹⁸ is -C(R⁸)₂-C(R⁸)₂-aryl. In some embodiments, D is MMAE having the structure:



[0015] In some embodiments, D is a pyrrolobenzodiazepine of Formula A:






wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R² is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo; R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo; R⁷ is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo; Q is independently selected from O, S and NH; R¹¹ is either H, or R or, where Q is O, SO₃M, where M is a metal cation; R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₁₋₁₂ alkyl, C₃₋₈ heterocyclyl, C₃₋₂₀ heterocyclyl, and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; R¹², R¹⁶, R¹⁹ and R¹⁷ are as defined for R², R⁶, R⁹ and R⁷ respectively; R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and X and X' are independently selected from O, S and N(H). In some such embodiments, D is




wherein n is 0 or 1.

[0016] In some embodiments, D is a pyrrolobenzodiazepine having a structure selected from:




and



wherein R^E and R^E are each independently selected from H or R^D, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo; wherein Ar¹ and Ar² are each independently optionally substituted C₅₋₂₀ aryl; and wherein n is 0 or 1.

[0017] In some embodiments, D is a pyrrolobenzodiazepine of Formula B:



wherein the horizontal wavy line indicates the covalent attachment site to the linker; R^{V1} and R^{V2} are independently selected from H, methyl, ethyl, phenyl, fluoro-substituted phenyl, and C₅₋₆ heterocycl; and n is 0 or 1.

[0018] In some embodiments, D is a nemorubicin derivative. In some embodiments, D has a structure selected from:


5

10

15

and

20



25


30

35

[0019] In some embodiments, an immunoconjugate comprises a linker that is cleavable by a protease. In some embodiments, the linker comprises a Val-Cit dipeptide, a Phe-Lys dipeptide, or a Phe-homoLys dipeptide. In some embodiments, an immunoconjugate comprises a linker that is acid-labile. In some such embodiments, the linker comprises hydrazone.

[0020] In some embodiments, an immunoconjugate has a formula selected from:




45




50


wherein S is a sulfur atom;

55






•
9



P ; and



In some embodiments, p ranges from 2-5.

[0021] In some embodiments, an immunoconjugate comprises an antibody that comprises a VH sequence of SEQ ID NO: 36 and a VL sequence of SEQ ID NO: 35; or a VH sequence of SEQ ID NO: 37 and a VL sequence of SEQ ID NO:

35; or a VH sequence of SEQ ID NO: 38 and a VL sequence of SEQ ID NO: 35.

[0022] In some embodiments, an immunoconjugate comprises an antibody that comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (j) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0023] In some embodiments, pharmaceutical formulations are provided as defined in the claims. A pharmaceutical formulation comprises an immunoconjugate comprising an antibody that binds B7-H4, e.g., as described herein. In some embodiments, a pharmaceutical formulation further comprises an additional therapeutic agent. In some embodiments, the additional therapeutic agent is Avastin® (bevacizumab).

[0024] The immunoconjugates as described herein are for use in a method of treating an individual having a B7-H4-positive cancer, the method comprising administering to the individual an effective amount of said immunoconjugate as set out in the claims.

In some such embodiments, the method comprises administering a pharmaceutical formulation comprising an immunoconjugate comprising an antibody that binds to the extracellular domain of B7-H4. In some embodiments, the B7-H4-positive cancer is selected from breast cancer, ovarian cancer, and endometrial cancer. In some embodiments, a method comprises administering an additional therapeutic agent to the individual. In some such embodiments, the additional therapeutic agent is Avastin® (bevacizumab).

[0025] Also described are methods of inhibiting proliferation of a B7-H4-positive cell. In some embodiments, the method comprising exposing the cell to an immunoconjugate comprising an antibody that binds B7-H4 under conditions permissive for binding of the immunoconjugate to B7-H4 on the surface of the cell. In some embodiments, an antibody that binds B7-H4 is an antibody described herein. In some embodiments, proliferation of the cell is thereby inhibited. In some embodiments, the cell is a breast, ovarian, or endometrial cancer cell.

[0026] Also described is an antibody that binds B7-H4 is conjugated to a label. In some embodiments, an antibody that binds B7-H4 is an antibody described herein. In some embodiments, the label is a positron emitter. In some embodiments, the positron emitter is ⁸⁹Zr.

[0027] Also described is a method of detecting human B7-H4 in a biological sample is provided. In some embodiments, a method comprises contacting the biological sample with an anti-B7-H4 antibody under conditions permissive for binding of the anti-B7-H4 antibody to a naturally occurring human B7-H4, and detecting whether a complex is formed between the anti-B7-H4 antibody and a naturally occurring human B7-H4 in the biological sample. In some embodiments, an anti-B7-H4 antibody is an antibody described herein. In some embodiments, the biological sample is a breast cancer sample, ovarian cancer sample, or endometrial cancer sample.

[0028] Also described is, a method for detecting an B7-H4-positive cancer is provided. In some such embodiments, a method comprises (i) administering a labeled anti-B7-H4 antibody to a subject having or suspected of having an B7-H4-positive cancer, and (ii) detecting the labeled anti-B7-H4 antibody in the subject, wherein detection of the labeled anti-B7-H4 antibody indicates a B7-H4-positive cancer in the subject. In some embodiments, an anti-B7-H4 antibody is an antibody described herein. In some such embodiments, the labeled anti-B7-H4 antibody comprises an anti-B7-H4 antibody conjugated to a positron emitter. In some embodiments, the positron emitter is ⁸⁹Zr.

40 BRIEF DESCRIPTION OF THE FIGURES

[0029]

Figure 1 shows a graphic representation of the levels of human B7-H4 gene expression in various tissues, as described in Example A.

Figure 2 shows expression of B7-H4 in breast carcinoma samples by in situ hybridization, as described in Example B.

Figure 3 shows (A) the prevalence of B7-H4 expression in all breast cancer subtypes, (B) the prevalence of 0, 1+, 2+, and 3+ levels of B7-H4 staining in breast cancer subtypes, (C) the overall expression of B7-H4 in breast tumors (by Western analysis), (D) the expression of B7-H4 in primary breast tumors (by Western analysis), (E) the expression of B7-H4 in ovarian tumors, as described in Example B.

Figure 4 (A) shows the properties of certain anti-B7-H4 monoclonal antibodies developed as described in the Examples. (B) shows the epitope grouping of the anti-B7-H4 monoclonal antibodies described herein.

Figure 5 shows an alignment of the light chain and heavy chain variable regions sequences of murine antibodies 1D11, 32D6, 9B9 and 22C10.

Figure 6 shows an alignment of the light chain variable region sequences of murine antibody mu1D11 and humanized variants thereof.

Figure 7 shows an alignment of the heavy chain variable region sequences of murine antibody mu1D11 and humanized variants thereof.

Figure 8 shows the light chain variable region sequences of murine antibody mu22C10 and humanized variants thereof.

Figure 9 shows the heavy chain variable region sequences of murine antibody mu22C10 and humanized variants thereof.

5 Figure 10 show an alignment of B7-H4 from human, chimp, cynomolgus monkey, rat, and mouse.

Figure 11 shows species cross-reactivity of anti-B7-H4 antibodies.

Figure 12 shows affinity measurements of chimeric antibody ch1D11 and ch22C10 and various humanized variants.

Figure 13 shows the internalization of anti-B7-H4 antibody, as demonstrated by the overlap of staining for anti-B7-H4 9B9 antibody and EGF staining in SK-BR3 cells.

10 Figure 14 shows that anti-B7-H4 antibodies can reach lysosomes of MX-1.

Figure 15 shows that anti-B7-H4 immunoconjugates demonstrate efficacy in MX-1 breast cancer xenografts.

Figure 16 shows that anti-B7-H4 immunoconjugates demonstrate efficacy in HBCX-24 breast cancer xenografts.

Figure 17 shows that anti-B7-H4 immunoconjugates demonstrate efficacy in MX-1 breast cancer xenografts.

Figure 18 shows that anti-B7-H4 immunoconjugates demonstrate efficacy in MX-1 breast cancer xenografts.

15 Figure 19 shows (A) expression of B7-H4 on HCC-1569x2 breast cancer xenografts by FACS and immunohistochemistry and (B) that anti-B7-H4 immunoconjugates demonstrate efficacy in HCC-1569x2 breast cancer xenografts.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

20 I. DEFINITIONS

[0030] An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

25 **[0031]** "Affinity" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific 30 illustrative and exemplary embodiments for measuring binding affinity are described in the following.

[0032] An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

35 **[0033]** The terms "anti-B7-H4 antibody" and "an antibody that binds to B7-H4" refer to an antibody that is capable of binding B7-H4 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting B7-H4. In one embodiment, the extent of binding of an anti-B7-H4 antibody to an unrelated, non-B7-H4 protein is less than about 10% of the binding of the antibody to B7-H4 as measured, e.g., by a radioimmunoassay (RIA). In certain 40 embodiments, an antibody that binds to B7-H4 has a dissociation constant (Kd) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 5 \text{ nM}$, $\leq 4 \text{ nM}$, $\leq 3 \text{ nM}$, $\leq 2 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g., 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M). In certain embodiments, an anti- B7-H4 antibody binds to an epitope of B7-H4 that is conserved among B7-H4 from different species.

45 **[0034]** The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

50 **[0035]** An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

55 **[0036]** An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.

[0037] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically

characterized by unregulated cell growth/proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.

[0038] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

[0039] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

[0040] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.

[0041] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

[0042] An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0043] The term "epitope" refers to the particular site on an antigen molecule to which an antibody binds.

[0044] The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0045] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0046] The terms "full length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0047] The term "glycosylated forms of B7-H4" refers to naturally occurring forms of B7-H4 that are post-translationally modified by the addition of carbohydrate residues.

[0048] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0049] A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

[0050] A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of

sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., *supra*. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., *supra*.

[0051] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0052] The term "hypervariable region" or "HVR," as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops"). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the "complementarity determining regions" (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).) With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise "specificity determining residues," or "SDRs," which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., *supra*.

[0053] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

[0054] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0055] An "isolated antibody" is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., *J. Chromatogr. B* 848:79-87 (2007).

[0056] An "isolated nucleic acid" refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0057] "Isolated nucleic acid encoding an anti-B7-H4 antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0058] The term "B7-H4," as used herein, refers to any native, mature B7-H4 which results from processing of a B7-H4 precursor protein in a cell. The term includes B7-H4 from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of B7-H4, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human B7-H4 precursor protein, with signal sequence (with signal sequence, amino acids 1-28) is shown in SEQ ID NO: 73. The amino acid sequence of an exemplary mature human B7-H4 is shown in SEQ ID NO: 74. The predicted sequence of an exemplary cynomolgus monkey B7-H4 precursor (with signal sequence, amino acids 1-28) and mature sequences are shown in SEQ ID NOs: 75 and 76, respectively. The amino acid sequences for exemplary rat B7-H4 precursor (with signal sequence, amino acids 1-28) and mature sequences are shown in SEQ ID NOs: 77 and 78, respectively. The amino acid sequences for exemplary mouse B7-H4 precursor (with signal sequence, amino acids 1-28) and mature sequences are shown in SEQ ID NOs: 79 and 80, respectively. The amino acid sequences for exemplary chimp B7-H4 precursor (with signal sequence, amino acids 1-24) and mature sequences are shown in SEQ ID NOs: 81 and 82, respectively.

[0059] The term "B7-H4-positive cancer" refers to a cancer comprising cells that express B7-H4 on their surface. In some embodiments, expression of B7-H4 on the cell surface is determined, for example, using antibodies to B7-H4 in

a method such as immunohistochemistry, FACS, etc. Alternatively, B7-H4 mRNA expression is considered to correlate to B7-H4 expression on the cell surface and can be determined by a method selected from in situ hybridization and RT-PCR (including quantitative RT-PCR).

[0060] The term "B7-H4-positive cell" refers to a cell that expresses B7-H4 on its surface.

[0061] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0062] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0063] "Native antibodies" refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0064] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

[0065] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0066] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

50 100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0067] The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological

activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[0068] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[0069] As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

[0070] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., *J. Immunol.* 150:880-887 (1993); Clarkson et al., *Nature* 352:624-628 (1991).

[0071] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0072] "Alkyl" is C₁-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH₃), ethyl (Et, -CH₂CH₃), 1-propyl (n-Pr, n-propyl, -CH₂CH₂CH₃), 2-propyl (i-Pr, i-propyl, -CH(CH₃)₂), 1-butyl (n-Bu, n-butyl, -CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (i-Bu, i-butyl, -CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl, -CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH₃)₃), 1-pentyl (n-pentyl, -CH₂CH₂CH₂CH₂CH₃), 2-pentyl (-CH(CH₃)CH₂CH₂CH₃), 3-pentyl (-CH(CH₂CH₃)₂), 2-methyl-2-butyl (-C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl (-CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (-CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl (-CH₂CH(CH₃)CH₂CH₃), 1-hexyl (-CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl (-CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (-CH(CH₂CH₃)(CH₂CH₂CH₃)), 2-methyl-2-pentyl (-C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl (-CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (-CH(CH₃)CH₂CH(CH₃)₂), 3-methyl-3-pentyl (-C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl (-CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (-C(CH₃)₂CH(CH₃)₂), 3,3-dimethyl-2-butyl (-CH(CH₃)C(CH₃)₃).

[0073] The term "C₁-C₈ alkyl," as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 8 carbon atoms. Representative "C₁-C₈ alkyl" groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl; while branched C₁-C₈ alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, unsaturated C₁-C₈ alkyls include, but are not limited to, -vinyl, -allyl, -1-but enyl, -2-but enyl, -isobut enyl, -1-pent enyl, -2-pent enyl, -3-methyl-1-but enyl, -2-methyl-2-but enyl, -2,3-dimethyl-2-but enyl, -1-hexyl, -2-hexyl, -3-hexyl, -acetyl enyl, -propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, -3-methyl-1-butynyl, -2-pentynyl, -3-methyl-1-butynyl, -1-hexynyl, -2-hexynyl, -3-hexynyl, -2,3-dimethyl-1-butynyl, -1-heptynyl, -2-heptynyl, -3-heptynyl, -4-heptynyl, -1-octynyl, -2-octynyl, -3-octynyl, -4-octynyl, -5-octynyl, -1-hexyl, -2-hexyl, -3-hexyl, -4-hexyl, -5-hexyl, -6-hexyl, -1-heptyl, -2-heptyl, -3-heptyl, -4-heptyl, -5-heptyl, -6-heptyl, -7-heptyl, -1-octyl, -2-octyl, -3-octyl, -4-octyl, -5-octyl, -6-octyl, -7-octyl, -8-octyl, -1-nonyl, -2-nonyl, -3-nonyl, -4-nonyl, -5-nonyl, -6-nonyl, -7-nonyl, -8-nonyl, -9-nonyl, -1-decyl, -2-decyl, -3-decyl, -4-decyl, -5-decyl, -6-decyl, -7-decyl, -8-decyl, -9-decyl, -10-decyl, -11-decyl, -12-decyl, -13-decyl, -14-decyl, -15-decyl, -16-decyl, -17-decyl, -18-decyl, -19-decyl, -20-decyl, -21-decyl, -22-decyl, -23-decyl, -24-decyl, -25-decyl, -26-decyl, -27-decyl, -28-decyl, -29-decyl, -30-decyl, -31-decyl, -32-decyl, -33-decyl, -34-decyl, -35-decyl, -36-decyl, -37-decyl, -38-decyl, -39-decyl, -40-decyl, -41-decyl, -42-decyl, -43-decyl, -44-decyl, -45-decyl, -46-decyl, -47-decyl, -48-decyl, -49-decyl, -50-decyl, -51-decyl, -52-decyl, -53-decyl, -54-decyl, -55-decyl, -56-decyl, -57-decyl, -58-decyl, -59-decyl, -60-decyl, -61-decyl, -62-decyl, -63-decyl, -64-decyl, -65-decyl, -66-decyl, -67-decyl, -68-decyl, -69-decyl, -70-decyl, -71-decyl, -72-decyl, -73-decyl, -74-decyl, -75-decyl, -76-decyl, -77-decyl, -78-decyl, -79-decyl, -80-decyl, -81-decyl, -82-decyl, -83-decyl, -84-decyl, -85-decyl, -86-decyl, -87-decyl, -88-decyl, -89-decyl, -90-decyl, -91-decyl, -92-decyl, -93-decyl, -94-decyl, -95-decyl, -96-decyl, -97-decyl, -98-decyl, -99-decyl, -100-decyl, -101-decyl, -102-decyl, -103-decyl, -104-decyl, -105-decyl, -106-decyl, -107-decyl, -108-decyl, -109-decyl, -110-decyl, -111-decyl, -112-decyl, -113-decyl, -114-decyl, -115-decyl, -116-decyl, -117-decyl, -118-decyl, -119-decyl, -120-decyl, -121-decyl, -122-decyl, -123-decyl, -124-decyl, -125-decyl, -126-decyl, -127-decyl, -128-decyl, -129-decyl, -130-decyl, -131-decyl, -132-decyl, -133-decyl, -134-decyl, -135-decyl, -136-decyl, -137-decyl, -138-decyl, -139-decyl, -140-decyl, -141-decyl, -142-decyl, -143-decyl, -144-decyl, -145-decyl, -146-decyl, -147-decyl, -148-decyl, -149-decyl, -150-decyl, -151-decyl, -152-decyl, -153-decyl, -154-decyl, -155-decyl, -156-decyl, -157-decyl, -158-decyl, -159-decyl, -160-decyl, -161-decyl, -162-decyl, -163-decyl, -164-decyl, -165-decyl, -166-decyl, -167-decyl, -168-decyl, -169-decyl, -170-decyl, -171-decyl, -172-decyl, -173-decyl, -174-decyl, -175-decyl, -176-decyl, -177-decyl, -178-decyl, -179-decyl, -180-decyl, -181-decyl, -182-decyl, -183-decyl, -184-decyl, -185-decyl, -186-decyl, -187-decyl, -188-decyl, -189-decyl, -190-decyl, -191-decyl, -192-decyl, -193-decyl, -194-decyl, -195-decyl, -196-decyl, -197-decyl, -198-decyl, -199-decyl, -200-decyl, -201-decyl, -202-decyl, -203-decyl, -204-decyl, -205-decyl, -206-decyl, -207-decyl, -208-decyl, -209-decyl, -210-decyl, -211-decyl, -212-decyl, -213-decyl, -214-decyl, -215-decyl, -216-decyl, -217-decyl, -218-decyl, -219-decyl, -220-decyl, -221-decyl, -222-decyl, -223-decyl, -224-decyl, -225-decyl, -226-decyl, -227-decyl, -228-decyl, -229-decyl, -230-decyl, -231-decyl, -232-decyl, -233-decyl, -234-decyl, -235-decyl, -236-decyl, -237-decyl, -238-decyl, -239-decyl, -240-decyl, -241-decyl, -242-decyl, -243-decyl, -244-decyl, -245-decyl, -246-decyl, -247-decyl, -248-decyl, -249-decyl, -250-decyl, -251-decyl, -252-decyl, -253-decyl, -254-decyl, -255-decyl, -256-decyl, -257-decyl, -258-decyl, -259-decyl, -260-decyl, -261-decyl, -262-decyl, -263-decyl, -264-decyl, -265-decyl, -266-decyl, -267-decyl, -268-decyl, -269-decyl, -270-decyl, -271-decyl, -272-decyl, -273-decyl, -274-decyl, -275-decyl, -276-decyl, -277-decyl, -278-decyl, -279-decyl, -280-decyl, -281-decyl, -282-decyl, -283-decyl, -284-decyl, -285-decyl, -286-decyl, -287-decyl, -288-decyl, -289-decyl, -290-decyl, -291-decyl, -292-decyl, -293-decyl, -294-decyl, -295-decyl, -296-decyl, -297-decyl, -298-decyl, -299-decyl, -300-decyl, -301-decyl, -302-decyl, -303-decyl, -304-decyl, -305-decyl, -306-decyl, -307-decyl, -308-decyl, -309-decyl, -310-decyl, -311-decyl, -312-decyl, -313-decyl, -314-decyl, -315-decyl, -316-decyl, -317-decyl, -318-decyl, -319-decyl, -320-decyl, -321-decyl, -322-decyl, -323-decyl, -324-decyl, -325-decyl, -326-decyl, -327-decyl, -328-decyl, -329-decyl, -330-decyl, -331-decyl, -332-decyl, -333-decyl, -334-decyl, -335-decyl, -336-decyl, -337-decyl, -338-decyl, -339-decyl, -340-decyl, -341-decyl, -342-decyl, -343-decyl, -344-decyl, -345-decyl, -346-decyl, -347-decyl, -348-decyl, -349-decyl, -350-decyl, -351-decyl, -352-decyl, -353-decyl, -354-decyl, -355-decyl, -356-decyl, -357-decyl, -358-decyl, -359-decyl, -360-decyl, -361-decyl, -362-decyl, -363-decyl, -364-decyl, -365-decyl, -366-decyl, -367-decyl, -368-decyl, -369-decyl, -370-decyl, -371-decyl, -372-decyl, -373-decyl, -374-decyl, -375-decyl, -376-decyl, -377-decyl, -378-decyl, -379-decyl, -380-decyl, -381-decyl, -382-decyl, -383-decyl, -384-decyl, -385-decyl, -386-decyl, -387-decyl, -388-decyl, -389-decyl, -390-decyl, -391-decyl, -392-decyl, -393-decyl, -394-decyl, -395-decyl, -396-decyl, -397-decyl, -398-decyl, -399-decyl, -400-decyl, -401-decyl, -402-decyl, -403-decyl, -404-decyl, -405-decyl, -406-decyl, -407-decyl, -408-decyl, -409-decyl, -410-decyl, -411-decyl, -412-decyl, -413-decyl, -414-decyl, -415-decyl, -416-decyl, -417-decyl, -418-decyl, -419-decyl, -420-decyl, -421-decyl, -422-decyl, -423-decyl, -424-decyl, -425-decyl, -426-decyl, -427-decyl, -428-decyl, -429-decyl, -430-decyl, -431-decyl, -432-decyl, -433-decyl, -434-decyl, -435-decyl, -436-decyl, -437-decyl, -438-decyl, -439-decyl, -440-decyl, -441-decyl, -442-decyl, -443-decyl, -444-decyl, -445-decyl, -446-decyl, -447-decyl, -448-decyl, -449-decyl, -450-decyl, -451-decyl, -452-decyl, -453-decyl, -454-decyl, -455-decyl, -456-decyl, -457-decyl, -458-decyl, -459-decyl, -460-decyl, -461-decyl, -462-decyl, -463-decyl, -464-decyl, -465-decyl, -466-decyl, -467-decyl, -468-decyl, -469-decyl, -470-decyl, -471-decyl, -472-decyl, -473-decyl, -474-decyl, -475-decyl, -476-decyl, -477-decyl, -478-decyl, -479-decyl, -480-decyl, -481-decyl, -482-decyl, -483-decyl, -484-decyl, -485-decyl, -486-decyl, -487-decyl, -488-decyl, -489-decyl, -490-decyl, -491-decyl, -492-decyl, -493-decyl, -494-decyl, -495-decyl, -496-decyl, -497-decyl, -498-decyl, -499-decyl, -500-decyl, -501-decyl, -502-decyl, -503-decyl, -504-decyl, -505-decyl, -506-decyl, -507-decyl, -508-decyl, -509-decyl, -510-decyl, -511-decyl, -512-decyl, -513-decyl, -514-decyl, -515-decyl, -516-decyl, -517-decyl, -518-decyl, -519-decyl, -520-decyl, -521-decyl, -522-decyl, -523-decyl, -524-decyl, -525-decyl, -526-decyl, -527-decyl, -528-decyl, -529-decyl, -530-decyl, -531-decyl, -532-decyl, -533-decyl, -534-decyl, -535-decyl, -536-decyl, -537-decyl, -538-decyl, -539-decyl, -540-decyl, -541-decyl, -542-decyl, -543-decyl, -544-decyl, -545-decyl, -546-decyl, -547-decyl, -548-decyl, -549-decyl, -550-decyl, -551-decyl, -552-decyl, -553-decyl, -554-decyl, -555-decyl, -556-decyl, -557-decyl, -558-decyl, -559-decyl, -560-decyl, -561-decyl, -562-decyl, -563-decyl, -564-decyl, -565-decyl, -566-decyl, -567-decyl, -568-decyl, -569-decyl, -570-decyl, -571-decyl, -572-decyl, -573-decyl, -574-decyl, -575-decyl, -576-decyl, -577-decyl, -578-decyl, -579-decyl, -580-decyl, -581-decyl, -582-decyl, -583-decyl, -584-decyl, -585-decyl, -586-decyl, -587-decyl, -588-decyl, -589-decyl, -590-decyl, -591-decyl, -592-decyl, -593-decyl, -594-decyl, -595-decyl, -596-decyl, -597-decyl, -598-decyl, -599-decyl, -600-decyl, -601-decyl, -602-decyl, -603-decyl, -604-decyl, -605-decyl, -606-decyl, -607-decyl, -608-decyl, -609-decyl, -610-decyl, -611-decyl, -612-decyl, -613-decyl, -614-decyl, -615-decyl, -616-decyl, -617-decyl, -618-decyl, -619-decyl, -620-decyl, -621-decyl, -622-decyl, -623-decyl, -624-decyl, -625-decyl, -626-decyl, -627-decyl, -628-decyl, -629-decyl, -630-decyl, -631-decyl, -632-decyl, -633-decyl, -634-decyl, -635-decyl, -636-decyl, -637-decyl, -638-decyl, -639-decyl, -640-decyl, -641-decyl, -642-decyl, -643-decyl, -644-decyl, -645-decyl, -646-decyl, -647-decyl, -648-decyl, -649-decyl, -650-decyl, -651-decyl, -652-decyl, -653-decyl, -654-decyl, -655-decyl, -656-decyl, -657-decyl, -658-decyl, -659-decyl, -660-decyl, -661-decyl, -662-decyl, -663-decyl, -664-decyl, -665-decyl, -666-decyl, -667-decyl, -668-decyl, -669-decyl, -670-decyl, -671-decyl, -672-decyl, -673-decyl, -674-decyl, -675-decyl, -676-decyl, -677-decyl, -678-decyl, -679-decyl, -680-decyl, -681-decyl, -682-decyl, -683-decyl, -684-decyl, -685-decyl, -686-decyl, -687-decyl, -688-decyl, -689-decyl, -690-decyl, -691-decyl, -692-decyl, -693-decyl, -694-decyl, -695-decyl, -696-decyl, -697-decyl, -698-decyl, -699-decyl, -700-decyl, -701-decyl, -702-decyl, -703-decyl, -704-decyl, -705-decyl, -706-decyl, -707-decyl, -708-decyl, -709-decyl, -710-decyl, -711-decyl, -712-decyl, -713-decyl, -714-decyl, -715-decyl, -716-decyl, -717-decyl, -718-decyl, -719-decyl, -720-decyl, -721-decyl, -722-decyl, -723-decyl, -724-decyl, -725-decyl, -726-decyl, -727-decyl, -728-decyl, -729-decyl, -730-decyl, -731-decyl, -732-decyl, -733-decyl, -734-decyl, -735-decyl, -736-decyl, -737-decyl, -738-decyl, -739-decyl, -740-decyl, -741-decyl, -742-decyl, -743-decyl, -744-decyl, -745-decyl, -746-decyl, -747-decyl, -748-decyl, -749-decyl, -750-decyl, -751-decyl, -752-decyl, -753-decyl, -754-decyl, -755-decyl, -756-decyl, -757-decyl, -758-decyl, -759-decyl, -760-decyl, -761-decyl, -762-decyl, -763-decyl, -764-decyl, -765-decyl, -766-decyl, -767-decyl, -768-decyl, -769-decyl, -770-decyl, -771-decyl, -772-decyl, -773-decyl, -774-decyl, -775-decyl, -776-decyl, -777-decyl, -778-decyl, -779-decyl, -780-decyl, -781-decyl, -782-decyl, -783-decyl, -784-decyl, -785-decyl, -786-decyl, -787-decyl, -788-decyl, -789-decyl, -790-decyl, -791-decyl, -792-decyl, -793-decyl, -794-decyl, -795-decyl, -796-decyl, -797-decyl, -798-decyl, -799-decyl, -800-decyl, -801-decyl, -802-decyl, -803-decyl, -804-decyl, -805-decyl, -806-decyl, -807-decyl, -808-decyl, -809-decyl, -810-decyl, -811-decyl, -812-decyl, -813-decyl, -814-decyl, -815-decyl, -816-decyl, -817-decyl, -818-decyl, -819-decyl, -820-decyl, -821-decyl, -822-decyl, -823-decyl, -824-decyl, -825-decyl, -826-decyl, -827-decyl, -828-decyl, -829-decyl, -830-decyl, -831-decyl, -832-decyl, -833-decyl, -834-decyl, -835-decyl, -836-decyl, -837-decyl, -838-decyl, -839-decyl, -840-decyl, -841-decyl, -842-decyl, -843-decyl, -844-decyl, -845-decyl, -846-decyl, -847-decyl, -848-decyl, -849-decyl, -850-decyl, -851-decyl, -852-decyl, -853-decyl, -854-decyl, -855-decyl, -856-decyl, -857-decyl, -858-decyl, -859-decyl, -860-decyl, -861-decyl, -862-decyl, -863-decyl, -864-decyl, -865-decyl, -866-decyl, -867-decyl, -868-decyl, -869-decyl, -870-decyl, -871-decyl, -872-decyl, -873-decyl, -874-decyl, -875-decyl, -876-decyl, -877-decyl, -878-decyl, -879-decyl, -880-decyl, -881-decyl, -882-decyl, -883-decyl, -884-decyl, -885-decyl, -886-decyl, -887-decyl, -888-decyl, -889-decyl, -890-decyl, -891-decyl, -892-decyl, -893-decyl, -894-decyl, -895-decyl, -896-decyl, -897-decyl, -898-decyl, -899-decyl, -900-decyl, -901-decyl, -902-decyl, -903-decyl, -904-decyl, -905-decyl, -906-decyl, -907-decyl, -908-decyl, -909-decyl, -910-decyl, -911-decyl, -912-decyl, -913-decyl, -914-decyl, -915-decyl, -916-decyl, -917-decyl, -918-decyl, -919-decyl, -920-decyl, -921-decyl, -922-decyl, -923-decyl, -924-decyl, -925-decyl, -926-decyl, -927-decyl, -928-decyl, -929-decyl, -930-decyl, -931-decyl, -932-decyl, -933-decyl, -934-decyl, -935-decyl, -936-decyl, -937-decyl, -938-decyl, -939-decyl, -940-decyl, -941-decyl, -942-decyl, -943-decyl, -944-decyl, -945-decyl, -946-decyl, -947-decyl, -948-decyl, -949-decyl, -950-decyl, -951-decyl, -952-decyl, -953-decyl, -954-decyl, -955-decyl, -956-decyl, -957-decyl, -958-decyl, -959-decyl, -960-decyl, -961-decyl, -962-decyl, -963-decyl, -964-decyl, -965-decyl, -966-decyl, -967-decyl, -968-decyl, -969-decyl, -970-decyl, -971-decyl, -972-decyl, -973-decyl, -974-decyl, -975-decyl, -976-decyl, -977-decyl, -978-decyl, -979-decyl, -980-decyl, -981-decyl, -982-decyl, -983-decyl, -984-decyl, -985-decyl, -986-decyl, -987-decyl, -988-decyl, -989-decyl, -990-decyl, -991-decyl, -992-decyl, -993-decyl, -994-decyl, -995-decyl, -996-decyl, -997-decyl, -998-decyl, -999-decyl, -1000-decyl, -1001-decyl, -1002-decyl, -1003-decyl, -1004-decyl, -1005-decyl, -1006-decyl, -1007-decyl, -1008-decyl, -1009-decyl, -1010-decyl, -1011-decyl, -1012-decyl, -1013-decyl, -1014-decyl, -1015-decyl, -1016-decyl, -1017-decyl, -1018-decyl, -1019-decyl, -1020-decyl, -1021-decyl, -1022-decyl, -1023-decyl, -1024-decyl, -1025-decyl, -1026-decyl, -1027-decyl, -1028-decyl, -1029-decyl, -1030-decyl, -1031-decyl, -1032-decyl, -1033-decyl, -1034-decyl, -1035-decyl, -1036-decyl, -1037-decyl, -1038-decyl, -1039-decyl, -1040-decyl, -1041-decyl, -1042-decyl, -1043-decyl, -1044-decyl, -1045-decyl, -1046-decyl, -1047-decyl, -1048-decyl, -1049-decyl, -1050-decyl, -1051-decyl, -1052-decyl, -1053-decyl, -1054-decyl, -1055-decyl, -1056-decyl, -1057-decyl, -1058-decyl, -1059-decyl, -1060-decyl, -1061-decyl, -1062-decyl, -1063-decyl, -1064-decyl, -1065-decyl, -1066-decyl, -1067-decyl, -1068-decyl, -1069-decyl, -1070-decyl, -1071-decyl, -1072-decyl, -1073-decyl, -1074

carbon having from 1 to 4 carbon atoms. Representative "C₁-C₄ alkyl" groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl; while branched C₁-C₄ alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl; unsaturated C₁-C₄ alkyls include, but are not limited to, -vinyl, -allyl, -1-but enyl, -2-but enyl, and -isobut enyl. A C₁-C₄ alkyl group can be unsubstituted or substituted with one or more groups, as described above for C₁-C₈ alkyl group.

5 [0077] "Alkoxy" is an alkyl group singly bonded to an oxygen. Exemplary alkoxy groups include, but are not limited to, methoxy (-OCH₃) and ethoxy (-OCH₂CH₃). A "C₁-C₅ alkoxy" is an alkoxy group with 1 to 5 carbon atoms. Alkoxy groups may be unsubstituted or substituted with one or more groups, as described above for alkyl groups.

10 [0078] "Alkenyl" is C₂-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp² double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH₂), allyl (-CH₂CH=CH₂), cyclopentenyl (-C₅H₇), and 5-hexenyl (-CH₂CH₂CH₂CH=CH₂). A "C₂-C₈ alkenyl" is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp² double bond.

15 [0079] "Alkynyl" is C₂-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond. Examples include, but are not limited to: acetylenic (-C≡CH) and propargyl (-CH₂C≡CH). A "C₂-C₈ alkynyl" is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.

20 [0080] "Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH₂), 1,2-ethyl (-CH₂CH₂), 1,3-propyl (-CH₂CH₂CH₂), 1,4-butyl (-CH₂CH₂CH₂CH₂), and the like.

25 [0081] A "C₁-C₁₀ alkylene" is a straight chain, saturated hydrocarbon group of the formula -(CH₂)₁₋₁₀. Examples of a C₁-C₁₀ alkylene include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene and decalene.


30 [0082] "Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene radicals include, but are not limited to: 1,2-ethylene (-CH=CH-).

35 [0083] "Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene radicals include, but are not limited to: acetylene (-C≡C-), propargyl (-CH₂C≡C-), and 4-pentyne (-CH₂CH₂CH₂C≡C-).

40 [0084] "Aryl" refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A carbocyclic aromatic group or a heterocyclic aromatic group can be unsubstituted or substituted with one or more groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

45 [0085] A "C₅-C₂₀ aryl" is an aryl group with 5 to 20 carbon atoms in the carbocyclic aromatic rings. Examples of C₅-C₂₀ aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A C₅-C₂₀ aryl group can be substituted or unsubstituted as described above for aryl groups. A "C₅-C₁₄ aryl" is an aryl group with 5 to 14 carbon atoms in the carbocyclic aromatic rings. Examples of C₅-C₁₄ aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A C₅-C₁₄ aryl group can be substituted or unsubstituted as described above for aryl groups.

50 [0086] An "arylene" is an aryl group which has two covalent bonds and can be in the ortho, meta, or para configurations as shown in the following structures:



in which the phenyl group can be unsubstituted or substituted with up to four groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

55 [0087] "Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp³ carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl,

naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.

[0088] "Heteroarylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with a heteroaryl radical. Typical heteroarylalkyl groups include, but are not limited to, 2-benzimidazolylmethyl, 2-furyethyl, and the like. The heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. The heteroaryl moiety of the heteroarylalkyl group may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms or a bicyclic having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.

[0089] "Substituted alkyl," "substituted aryl," and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, $-X$, $-R$, $-O^-$, $-OR$, $-SR$, $-S^-$, $-NR_2$, $-NR_3$, $=NR$, $-CX_3$, $-CN$, $-OCN$, $-SCN$, $-N=C=O$, $-NCS$, $-NO$, $-NO_2$, $=N_2$, $-N_3$, $NC(=O)R$, $-C(=O)R$, $-C(=O)NR_2$, $-SO_3^-$, $-SO_3H$, $-S(=O)_2R$, $-OS(=O)_2OR$, $-S(=O)_2NR$, $-S(=O)R$, $-OP(=O)(OR)_2$, $-P(=O)(OR)_2$, $-PO^-_3$, $-PO_3H_2$, $-C(=O)R$, $-C(=S)R$, $-CO_2R$, $-CO_2^-$, $-C(=S)OR$, $-C(=O)SR$, $-C(=S)SR$, $-C(=O)NR_2$, $-C(=S)NR_2$, $-C(=NR)NR_2$, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently $-H$, C_2-C_{18} alkyl, C_6-C_{20} aryl, C_3-C_{14} heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups as described above may also be similarly substituted.

[0090] "Heteroaryl" and "heterocycle" refer to a ring system in which one or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and sulfur. The heterocycle radical comprises 3 to 20 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicyclic having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.

[0091] Exemplary heterocycles are described, e.g., in Paquette, Leo A., "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.

[0092] Examples of heterocycles include by way of example and not limitation pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuran, bis-tetrahydrofuran, tetrahydropyran, bis-tetrahydropyran, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β -carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl.

[0093] By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thifuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

[0094] By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β -carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetidyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

[0095] A "C₃-C₈ heterocycle" refers to an aromatic or non-aromatic C₃-C₈ carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. Representative examples of a C₃-C₈ heterocycle include, but are not limited to, benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl, isoquinolinyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl, isoxazolyl and tetrazolyl. A C₃-C₈ heterocycle can be unsubstituted

or substituted with up to seven groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0096] "C₃-C₈ heterocyclo" refers to a C₃-C₈ heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond. A C₃-C₈ heterocyclo can be unsubstituted or substituted with up to six groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0097] A "C₃-C₂₀ heterocycle" refers to an aromatic or non-aromatic C₃-C₈ carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. A C₃-C₂₀ heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0098] "C₃-C₂₀ heterocyclo" refers to a C₃-C₂₀ heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond.

[0099] "Carbocycle" means a saturated or unsaturated ring having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g. arranged as a bicyclo [4.5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cycloheptyl, and cyclooctyl.

[0100] A "C₃-C₈ carbocycle" is a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring. Representative C₃-C₈ carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl. A C₃-C₈ carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂-NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; where each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0101] A "C₃-C₈ carbocyclo" refers to a C₃-C₈ carbocycle group defined above wherein one of the carbocycle groups' hydrogen atoms is replaced with a bond.

[0102] "Linker" refers to a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches an antibody to a drug moiety. In various embodiments, linkers include a divalent radical such as an alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: -(CR₂)_nO(CR₂)_n-, repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethylenoxy) and alkylamino (e.g. polyethyleneamino, JeffamineTM); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. In various embodiments, linkers can comprise one or more amino acid residues, such as valine, phenylalanine, lysine, and homolysine.

[0103] The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

[0104] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0105] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

[0106] "Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0107] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0108] "Leaving group" refers to a functional group that can be substituted by another functional group. Certain leaving groups are well known in the art, and examples include, but are not limited to, a halide (e.g., chloride, bromide, iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate.

[0109] The term "protecting group" refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc). For a general description of protecting groups and their use, see T. W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, New York, 1991, or a later edition.

II. COMPOSITIONS AND METHODS

[0110] In one aspect, the invention is based, in part, on antibodies that bind to B7-H4 and immunoconjugates comprising such antibodies. Antibodies and immunoconjugates of the invention are useful, e.g., for the diagnosis or treatment of B7-H4-positive cancers.

A. Exemplary Anti-B7-H4 Antibodies

[0111] In some embodiments, the invention provides isolated antibodies that bind to B7-H4. B7-H4 is a Type I trans-membrane protein found, for example, on the surface of antigen presenting cells (APC). As demonstrated herein, B7-H4 is expressed in about 80% of breast carcinoma specimens and in about 60% of ovarian tumor samples examined.

[0112] An exemplary naturally occurring human B7-H4 precursor protein sequence, with signal sequence (amino acids 1-28) is provided in SEQ ID NO: 73, and the corresponding mature B7-H4 protein sequence is shown in SEQ ID NO: 74 (corresponding to amino acids 29-282 of SEQ ID NO: 73).

[0113] In certain embodiments of the disclosure, an anti-B7-H4 antibody has at least one or more of the following characteristics, in any combination:

- (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4), and
- (b) binds B7-H4 with an affinity of \leq 100 nM, \leq 50 nM, \leq 10 nM, or \leq 9 nM, or \leq 8 nM, or \leq 7 nM, or \leq 6 nM, or \leq 5 nM, or \leq 4 nM, or \leq 3 nM, or \leq 2 nM, or \leq 1 nM, and optionally \geq 0.0001 nM, or \geq 0.001 nM, or \geq 0.01 nM.

[0114] A nonlimiting exemplary such antibody is 1D11, 22C10, 9B9, and 32D6 and humanized variants thereof, described herein. In some embodiments, B7-H4 is human B7-H4. In some embodiments, B7-H4 is selected from human, cynomolgus monkey, mouse, and rat B7-H4.

[0115] In some embodiments, an anti-B7-H4 antibody binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73). In some embodiments, an anti-B7-H4 antibody binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73). In some embodiments, an anti-B7-H4 antibody binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73). In some embodiments, an anti-B7-H4 antibody binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4). In some embodiments, an anti-B7-H4 antibody binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4). In some such embodiments, the anti-B7-H4 antibody binds B7-H4 with an affinity of \leq 100 nM, \leq 50 nM, \leq 10 nM, or \leq 9 nM, or \leq 8 nM, or \leq 7 nM, or \leq 6 nM, or \leq 5 nM, or \leq 4 nM, or \leq 3 nM, or \leq 2 nM, or \leq 1 nM, and optionally \geq 0.0001 nM, or \geq 0.001 nM, or \geq 0.01 nM. Nonlimiting exemplary such antibodies include 1D11, 22C10, 9B9, and 32D6 and humanized variants thereof, described herein. In some embodiments, B7-H4 is human B7-H4. In some embodiments, B7-H4 is human B7-H4 or cynomolgus monkey B7-H4. In some embodiments, B7-H4 is mouse B7-H4 or rat B7-H4.

Assays

[0116] To determine whether an anti-B7-H4 antibody "binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73)" or "binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73)" or "binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73)" or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4)" or "binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor

human B7-H4)," is determined as described herein in Example F by competitive binding as assessed by FACS.

[0117] Whether an anti-B7-H4 antibody "binds with an affinity of ≤ 100 nM, ≤ 50 nM, ≤ 10 nM, or ≤ 9 nM, or ≤ 8 nM, or ≤ 7 nM, or ≤ 6 nM, or ≤ 5 nM, or ≤ 4 nM, or ≤ 3 nM, or ≤ 2 nM, or ≤ 1 nM," is determined as described herein in Example E. The dissociation constants of selected humanized variants were determined using a radioligand cell binding assay.

5 Briefly, ^{125}I -antibody tracer at $\sim 250\text{pM}$ (same as the unlabeled antibody competitor) was incubated with 100,000 MX-1 cells or 293 B7-H4 stable cell lines in the presence of 2-fold dilutions of unlabeled antibody starting at 1000nM. The antibody/cell mixture was incubated in DMEM (1% BSA, 300nM human IgG, 0.1% azide) at 25°C for 2 hours and then collected and filtered using a Millipore Multiscreen filtration plate. The Durapore membrane filters were counted for 10 minutes using Perkin Elmer Wizard 1470 Auto Gamma Counter. Antibody affinity constants (Kd) were determined by

10 Scatchard Analysis using the NewLigand software.

Antibody 1D11 and other embodiments

15 **[0118]** In some embodiments, the disclosure provides an anti-B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10. In another embodiment, the invention provides an anti-B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a)

20 (b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

25 **[0119]** In one aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7.

30 **[0120]** In one aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41.

35 **[0121]** In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10.

40 **[0122]** In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

45 **[0123]** In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6, and (iii) HVR-H3 comprising an amino acid sequence

selected from SEQ ID NO: 7; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10.

[0124] In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 41; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0125] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10.

[0126] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0127] In any of the above embodiments, an anti-B7-H4 antibody is humanized. In one embodiment, an anti- B7-H4 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In certain embodiments, the human acceptor framework is the human VL kappa I consensus (VL_{KI}) framework and/or the VH framework VH₁. In certain embodiments, the human acceptor framework is the human VL kappa I consensus (VL_{KI}) framework and/or the VH framework VH₁ comprising any one of the following mutations: Y49H, V58I, T69R and/or F71Y mutation in the light chain framework region FR3; V67A, I69L, R71A, T73K and/or T75S mutation in the heavy chain framework region FR3.

[0128] In some embodiments, an anti-B7-H4 antibody comprises HVRs as in any of the above embodiments, and further comprises a heavy chain framework FR3 sequence of SEQ ID NO: 51, 52 or 53. In some such embodiments, the heavy chain variable domain framework is a modified human VH₁ framework having an FR3 sequence of SEQ ID NO: 51, 52 or 53.

[0129] In another aspect, an anti- B7-H4 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 4 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 4. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 4. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-B7-H4 antibody comprises the VH sequence of SEQ ID NO: 4, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 5, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 6, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 7.

[0130] In another aspect, an anti-B7-H4 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 36, 37, 38, 99, 100, 101, 102 or 103. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 36, 37, 38, 99, 100, 101, 102 or 103 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 36, 37, 38, 99, 100, 101, 102 or 103. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 36, 37, 38, 99, 100, 101, 102 or 103. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VH sequence of SEQ ID NO: 36, 37, 38, 99, 100, 101, 102 or 103, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41.

[0131] In another aspect, an anti-B7-H4 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the

amino acid sequence of SEQ ID NO: 3. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 3 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 3. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 3. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VL sequence of SEQ ID NO: 3, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 10.

[0132] In another aspect, an anti- B7-H4 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 35, 93, 94, 95, 96, 97 or 98. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 35, 93, 94, 95, 96, 97 or 98 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 35, 93, 94, 95, 96, 97 or 98. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 35, 93, 94, 95, 96, 97 or 98. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VL sequence of SEQ ID NO: 35, 93, 94, 95, 96, 97 or 98, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0133] In another aspect, an anti-B7-H4 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.

[0134] In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 4 and SEQ ID NO: 3, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 101 and SEQ ID NO: 93, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 101 and SEQ ID NO: 97, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 102 and SEQ ID NO: 98, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 103 and SEQ ID NO: 98, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 101 and SEQ ID NO: 96, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 101 and SEQ ID NO: 95, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 101 and SEQ ID NO: 94, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 100 and SEQ ID NO: 93, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 99 and SEQ ID NO: 93, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 36 and SEQ ID NO: 93, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 36 and SEQ ID NO: 35, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 37 and SEQ ID NO: 35, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 38 and SEQ ID NO: 35, respectively, including post-translational modifications of those sequences.

[0135] In a further aspect, the disclosure provides an antibody that binds to the same epitope as an anti-B7-H4 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 4 and a VL sequence of SEQ ID NO: 3. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 93. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 97. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 102 and a VL sequence of SEQ ID NO: 98. In certain

embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 103 and a VL sequence of SEQ ID NO: 98. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 96. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 95. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 94. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 100 and a VL sequence of SEQ ID NO: 93. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 99 and a VL sequence of SEQ ID NO: 93. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 36 and a VL sequence of SEQ ID NO: 93. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 36 and a VL sequence of SEQ ID NO: 35. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 37 and a VL sequence of SEQ ID NO: 35. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 38 and a VL sequence of SEQ ID NO: 35.

[0136] In certain embodiments, an antibody according to any of the above embodiments is provided that binds to B7-H4 and has at least one of the following characteristics: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4). In some embodiments, the antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4).

[0137] In a further aspect of the disclosure an anti- B7-H4 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti- B7-H4 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG1 antibody or other antibody class or isotype as defined herein.

[0138] In a further aspect, an anti- B7-H4 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in below.

Antibody 22C10 and other embodiments

[0139] In one aspect, the disclosure provides an anti- B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

[0140] In another aspect, the disclosure provides an anti- B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63.

[0141] In one aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31.

[0142] In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60.

5 In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60.

[0143] In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

10 In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

[0144] In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63.

15 20 In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63.

[0145] In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

[0146] In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63.

[0147] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 34.

[0148] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 63.

[0149] In any of the above embodiments, an anti- B7-H4 antibody is a human antibody.

[0150] In another aspect, an anti- B7-H4 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 28. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 28 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 28. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 28. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VH sequence of SEQ ID NO: 28, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 31.

[0151] In another aspect, an anti- B7-H4 antibody is provided, wherein the antibody comprises a light chain variable

domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 27. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 27 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 27. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 27. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-B7-H4 antibody comprises the VL sequence of SEQ ID NO: 27, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 32; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 33; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

[0152] In another aspect, an anti- B7-H4 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 55, 57,104, 105 or 106. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 55, 57,104, 105 or 106 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 55, 57,104, 105 or 106. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 55, 57,104, 105 or 106. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-B7-H4 antibody comprises the VL sequence of SEQ ID NO: 55, 57,104, 105 or 106, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63.

[0153] In another aspect, an anti-B7-H4 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 111 and SEQ ID NO: 104, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 111 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 112 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 113 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 114 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 111 and SEQ ID NO: 105, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 111 and SEQ ID NO: 106, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 110 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 109 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 108 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 107 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 56 and SEQ ID NO: 55, respectively, including post-translational modifications of those sequences. In another embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 56 and SEQ ID NO: 57, respectively, including post-translational modifications of those sequences.

[0154] In a further aspect, the disclosure provides an antibody that binds to the same epitope as an anti-B7-H4 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 28 and a VL sequence of SEQ ID NO: 27. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 111 and a VL sequence of SEQ ID NO: 104. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 111 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 112 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 113 and a VL sequence of SEQ ID NO: 55.

sequence of SEQ ID NO: 113 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 114 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 111 and a VL sequence of SEQ ID NO: 105. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 111 and a VL sequence of SEQ ID NO: 106. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 110 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 109 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 108 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 107 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 56 and a VL sequence of SEQ ID NO: 55. In certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 56 and a VL sequence of SEQ ID NO: 57.

[0155] In certain embodiments, an antibody according to any of the above embodiments is provided that binds to B7-H4 and has at least one of the following characteristics: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4). In some embodiments, the antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4).

[0156] In a further aspect of the disclosure an anti-B7-H4 antibody according to any of the above embodiments is a monoclonal antibody, including a human antibody. In one embodiment, an anti-B7-H4 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG2a antibody or other antibody class or isotype as defined herein.

[0157] In a further aspect, an anti-B7-H4 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in below.

Antibody 32D6 and other embodiments

[0158] In one aspect, the disclosure provides an anti-B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18.

[0159] In one aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15.

[0160] In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18.

[0161] In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18.

[0162] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 18.

[0163] In any of the above embodiments, an anti- B7-H4 antibody is a human antibody.

[0164] In another aspect, an anti- B7-H4 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 12 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 12. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 12. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VH sequence of SEQ ID NO: 12, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15.

[0165] In another aspect, an anti- B7-H4 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 11 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 11. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 11. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-B7-H4 antibody comprises the VL sequence of SEQ ID NO: 11, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 18.

[0166] In another aspect, an anti-B7-H4 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 12 and SEQ ID NO: 11, respectively, including post-translational modifications of those sequences. In another embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 12 and SEQ ID NO: 11, respectively, including post-translational modifications of those sequences.

[0167] In a further aspect, the disclosure provides an antibody that binds to the same epitope as an anti-B7-H4 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 12 and a VL sequence of SEQ ID NO: 11.

[0168] In certain embodiments, an antibody according to any of the above embodiments is provided that binds to B7-H4 and has at least one of the following characteristics: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4). In some embodiments, the antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4).

[0169] In a further aspect of the disclosure an anti-B7-H4 antibody according to any of the above embodiments is a

monoclonal antibody, including a human antibody. In one embodiment, an anti-B7-H4 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG2a antibody or other antibody class or isotype as defined herein.

[0170] In a further aspect, an anti-B7-H4 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in below.

Antibody 9B9 and other embodiments

[0171] In one aspect, the disclosure provides an anti- B7-H4 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

[0172] In one aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.

[0173] In another aspect, the disclosure provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

[0174] In another aspect, an antibody of the disclosure comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

[0175] In another aspect, the disclosure provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 26.

[0176] In any of the above embodiments, an anti- B7-H4 antibody is a human antibody.

[0177] In another aspect, an anti- B7-H4 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 20 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- B7-H4 antibody comprising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 20. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 20. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti- B7-H4 antibody comprises the VH sequence of SEQ ID NO: 20, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 22, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.

[0178] In another aspect, an anti- B7-H4 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 19 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-B7-H4 antibody com-

prising that sequence retains the ability to bind to B7-H4. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 19. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 19. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-B7-H4 antibody comprises the VL sequence of SEQ ID NO: 11, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 25; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

[0179] In another aspect, an anti-B7-H4 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 20 and SEQ ID NO: 19, respectively, including post-translational modifications of those sequences.

[0180] In a further aspect, the disclosure provides an antibody that binds to the same epitope as an anti-B7-H4 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-B7-H4 antibody comprising a VH sequence of SEQ ID NO: 20 and a VL sequence of SEQ ID NO: 19.

[0181] In certain embodiments, an antibody according to any of the above embodiments is provided that to B7-H4 and has at least one of the following characteristics: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4);. In some embodiments, the antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within all or a portion of the B7-H4 Ig-V containing domain (amino acids 29-157 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-C containing domain (amino acids 158-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of the B7-H4 Ig-V and Ig-C domains (amino acids 29-250 of SEQ ID NO: 73); or binds to an epitope within all or a portion of SEQ ID NO: 74 (mature human B7-H4); or binds to an epitope within all or a portion of SEQ ID NO: 73 (precursor human B7-H4).

[0182] In a further aspect of the disclosure, an anti-B7-H4 antibody according to any of the above embodiments is a monoclonal antibody, including a human antibody. In one embodiment, an anti-B7-H4 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG2a antibody or other antibody class or isotype as defined herein.

[0183] In a further aspect, an anti-B7-H4 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in below.

35 1. Antibody Affinity

[0184] In certain embodiments, an antibody provided herein has a dissociation constant (Kd) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 50 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 5 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$, and optionally is $\geq 10^{-13} \text{ M}$. (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M).

[0185] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay. Solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of (¹²⁵I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To establish conditions for the assay, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 $\mu\text{g}/\text{ml}$ of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23°C). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 $\mu\text{l}/\text{well}$ of scintillant (MICROSCINT-2Q™; Packard) is added, and the plates are counted on a TOPCOUNT™ gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.

[0186] According to another embodiment, Kd is measured using surface plasmon resonance assays using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized antigen CM5 chips at ~10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with

5 *N*-ethyl-*N*'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and *N*-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 μ g/ml (~0.2 μ M) before injection at a flow rate of 5 μ l/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20TM) surfactant (PBST) at 25°C at a flow rate of approximately 25 μ l/min. Association rates (k_{on}) and dissociation rates (k_{off}) are calculated using a simple one-to-one Langmuir binding model (BIACORE[®] Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the ratio k_{off}/k_{on} . See, e.g., Chen et al., *J. Mol. Biol.* 293:865-881 (1999). If the on-rate exceeds 10⁶ M⁻¹ s⁻¹ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCO[™] spectrophotometer (ThermoSpectronic) with a stirred cuvette.

10

15

2. Antibody Fragments

20 [0187] In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al., *Nat. Med.* 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046.

25 [0188] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., *Nat. Med.* 9:129-134 (2003); and Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., *Nat. Med.* 9:129-134 (2003).

30 [0189] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).

35 [0190] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. *E. coli* or phage), as described herein.

3. Chimeric and Humanized Antibodies

40 [0191] In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

45 [0192] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

50 [0193] Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., *Nature* 332:323-329 (1988); Queen et al., *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989); US Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmire et al., *Methods* 36:25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, *Mol. Immunol.* 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., *Methods* 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., *Methods* 36:61-68 (2005) and Klimka et al., *Br. J. Cancer*, 83:252-260 (2000) (describing the "guided selection" approach to FR shuffling).

55 [0194] Human framework regions that may be used for humanization include but are not limited to: framework regions

selected using the "best-fit" method (see, e.g., Sims et al. *J. Immunol.* 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); and Presta et al. *J. Immunol.*, 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., *J. Biol. Chem.* 272:10678-10684 (1997) and Rosok et al., *J. Biol. Chem.* 271:22611-22618 (1996)).

4. Human Antibodies

[0195] In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, *Curr. Opin. Pharmacol.* 5: 368-74 (2001) and Lonberg, *Curr. Opin. Immunol.* 20:450-459 (2008).

[0196] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, *Nat. Biotech.* 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

[0197] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor *J. Immunol.*, 133: 3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., *J. Immunol.*, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., *Proc. Natl. Acad. Sci. USA*, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, *Xiandai Mianyixue*, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, *Histology and Histopathology*, 20(3):927-937 (2005) and Vollmers and Brandlein, *Methods and Findings in Experimental and Clinical Pharmacology*, 27(3):185-91 (2005).

[0198] Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

5. Library-Derived Antibodies

[0199] Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et al., *Nature* 348:552-554; Clackson et al., *Nature* 352: 624-628 (1991); Marks et al., *J. Mol. Biol.* 222: 581-597 (1992); Marks and Bradbury, in *Methods in Molecular Biology* 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., *J. Mol. Biol.* 338(2): 299-310 (2004); Lee et al., *J. Mol. Biol.* 340(5): 1073-1093 (2004); Fellouse, *Proc. Natl. Acad. Sci. USA* 101(34): 12467-12472 (2004); and Lee et al., *J. Immunol. Methods* 284(1-2): 119-132(2004).

[0200] In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., *Ann. Rev. Immunol.*, 12: 433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., *EMBO J.*, 12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unarranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement *in vitro*, as described by Hoogenboom and Winter, *J. Mol. Biol.*, 227: 381-388 (1992). Patent publications describing human antibody phage

libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.

[0201] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

5

6. Multispecific Antibodies

[0202] In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for B7-H4 and the other is for any other antigen. In certain embodiments, one of the binding specificities is for B7-H4 and the other is for CD3. See, e.g., U.S. Patent No. 5,821,337. In certain embodiments, bispecific antibodies may bind to two different epitopes of B7-H4. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express B7-H4. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

15

[0203] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, *Nature* 305: 537 (1983)), WO 93/08829, and Traunecker et al., *EMBO J.* 10: 3655 (1991)), and "knob-in-hole" engineering (see, e.g., U.S. Patent No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et al., *Science*, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelnik et al., *J. Immunol.*, 148(5):1547-1553 (1992)); using "diabody" technology for making bispecific antibody fragments (see, e.g., Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g. Gruber et al., *J. Immunol.*, 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. *J. Immunol.* 147: 60 (1991).

25

[0204] Engineered antibodies with three or more functional antigen binding sites, including "Octopus antibodies," are also included herein (see, e.g. US 2006/0025576A1).

[0205] The antibody or fragment herein also includes a "Dual Acting FAb" or "DAF" comprising an antigen binding site that binds to B7-H4 as well as another, different antigen (see, US 2008/0069820, for example).

30

7. Antibody Variants

[0206] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.

40

a) Substitution, Insertion, and Deletion Variants

[0207] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions," and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

50

TABLE 1

55

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser

(continued)

Original Residue	Exemplary Substitutions	Preferred Substitutions
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

Amino acids may be grouped according to common side-chain properties:

(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;

(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

(3) acidic: Asp, Glu;

(4) basic: His, Lys, Arg;

(5) residues that influence chain orientation: Gly, Pro;

(6) aromatic: Trp, Tyr, Phe.

[0208] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0209] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).

[0210] Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR "hotspots," i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, *Methods Mol. Biol.* 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in

which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

[0211] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR "hotspots" or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

[0212] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

[0213] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

25 b) Glycosylation variants

[0214] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.

[0215] Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. *TIBTECH* 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.

[0216] In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about \pm 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to "defucosylated" or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. *J. Mol. Biol.* 336:1239-1249 (2004); Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. *Arch. Biochem. Biophys.* 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, *FUT8*, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004); Kanda, Y. et al., *Biotechnol. Bioeng.*, 94(4):680-688 (2006); and WO2003/085107).

[0217] Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878

(Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

5

c) Fc region variants

[0218] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

[0219] In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody *in vivo* is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. *In vitro* and/or *in vivo* cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc(RIII only, whereas monocytes express Fc(RI), Fc(RII) and Fc(RIII). FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-492 (1991). Non-limiting examples of *in vitro* assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No. 5,500,362 (see, e.g. Hellstrom, I. et al. *Proc. Nat'l Acad. Sci. USA* 83:7059-7063 (1986)) and Hellstrom, I. et al., *Proc. Nat'l Acad. Sci. USA* 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., *J. Exp. Med.* 166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in a animal model such as that disclosed in Clynes et al. *Proc. Nat'l Acad. Sci. USA* 95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., *J. Immunol. Methods* 202:163 (1996); Cragg, M.S. et al., *Blood* 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, *Blood* 103:2738-2743 (2004)). FcRn binding and *in vivo* clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., *Int'l. Immunol.* 18(12):1759-1769 (2006)).

[0220] Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).

[0221] Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al., *J. Biol. Chem.* 9(2): 6591-6604 (2001).)

[0222] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).

[0223] In some embodiments, alterations are made in the Fc region that result in altered (*i.e.*, either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and Idusogie et al. *J. Immunol.* 164: 4178-4184 (2000).

[0224] Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., *J. Immunol.* 117:587 (1976) and Kim et al., *J. Immunol.* 24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826).

[0225] See also Duncan & Winter, *Nature* 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

d) Cysteine engineered antibody variants

55

[0226] In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., "thioMAbs," in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are

thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No. 7,521,541.

5 **e) Antibody Derivatives**

10 [0227] In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

15 [0228] In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but 20 is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature 25 at which cells proximal to the antibody-nonproteinaceous moiety are killed.

B. Recombinant Methods and Compositions

30 [0229] Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-B7-H4 antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising 35 such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster 40 Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-B7-H4 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

45 [0230] For recombinant production of an anti-B7-H4 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

50 [0231] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

55 [0232] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[0233] Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms

(invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

[0234] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0235] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., *J. Gen Virol.* 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., *Annals N.Y. Acad. Sci.* 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al., *Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

C. Assays

[0236] Anti-B7-H4 antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

[0237] In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, BIACore®, FACS, or Western blot.

[0238] In another aspect, competition assays may be used to identify an antibody that competes with any of the antibodies described herein for binding to B7-H4. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by an antibody described herein. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in *Methods in Molecular Biology* vol. 66 (Humana Press, Totowa, NJ).

[0239] In an exemplary competition assay, immobilized B7-H4 is incubated in a solution comprising a first labeled antibody that binds to B7-H4 (e.g., any of the antibodies described herein) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to B7-H4. The second antibody may be present in a hybridoma supernatant. As a control, immobilized B7-H4 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to B7-H4, excess unbound antibody is removed, and the amount of label associated with immobilized B7-H4 is measured. If the amount of label associated with immobilized B7-H4 is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to B7-H4. See Harlow and Lane (1988) *Antibodies: A Laboratory Manual* ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

D. Immunoconjugates

[0240] The invention also provides immunoconjugates comprising an anti-B7-H4 antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes (i.e., a radioconjugate).

[0241] Immunoconjugates allow for the targeted delivery of a drug moiety to a tumor, and, in some embodiments intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Polakis P. (2005) *Current Opinion in Pharmacology* 5:382-387).

[0242] Antibody-drug conjugates (ADC) are targeted chemotherapeutic molecules which combine properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells (Teicher, B.A. (2009) *Current Cancer Drug Targets* 9:982-1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off-target toxicity (Carter, P.J. and Senter P.D. (2008) *The Cancer Jour.* 14(3): 154-169; Chari, R.V. (2008) *Acc. Chem. Res.* 41:98-107).

[0243] The ADC compounds of the invention include those with anticancer activity. In some embodiments, the ADC compounds include an antibody conjugated, i.e. covalently attached, to the drug moiety. In some embodiments, the antibody is covalently attached to the drug moiety through a linker. The antibody-drug conjugates (ADC) of the invention selectively deliver an effective dose of a drug to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved while increasing the therapeutic index ("therapeutic window").

[0244] The drug moiety (D) of the antibody-drug conjugates (ADC) may include any compound, moiety or group that has a cytotoxic or cytostatic effect. Drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including but not limited to tubulin binding, DNA binding or intercalation, and inhibition of RNA polymerase, protein synthesis, and/or topoisomerase. Exemplary drug moieties include, but are not limited to, a maytansinoid, dolastatin, auristatin, calicheamicin, pyrrolobenzodiazepine (PBD), nemorubicin and its derivatives, PNU-159682, anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinavide, and stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity. Nonlimiting examples of such immunoconjugates are discussed in further detail below.

10 **1. Exemplary Antibody-drug Conjugates**

[0245] An exemplary embodiment of an antibody-drug conjugate (ADC) compound comprises an antibody (Ab) which targets a tumor cell, a drug moiety (D), and a linker moiety (L) that attaches Ab to D. In some embodiments, the antibody is attached to the linker moiety (L) through one or more amino acid residues, such as lysine and/or cysteine.

15 [0246] An exemplary ADC has Formula I:



20 where p is 1 to about 20. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues. In some embodiments, free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein. Exemplary ADC of Formula I include, but are not limited to, antibodies that have 1, 2, 3, or 4 engineered cysteine amino acids (Lyon, R. et al (2012) Methods in Enzym. 502:123-138). In some embodiments, one or more free cysteine residues are already present in an antibody, without the use of engineering, in which case the existing free cysteine residues may be used to conjugate the antibody to a drug. In some embodiments, an antibody is exposed to reducing conditions prior to conjugation of the antibody in order to generate one or more free cysteine residues.

25 **a) Exemplary Linkers**

30 [0247] A "Linker" (L) is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties (D) to an antibody (Ab) to form an antibody-drug conjugate (ADC) of Formula I. In some embodiments, antibody-drug conjugates (ADC) can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody. For example, in some embodiments, a cysteine thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.


35 [0248] In one aspect, a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond. Nonlimiting exemplary such reactive functionalities include maleimide, haloacetamides, α -haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. See, e.g., the conjugation method at page 766 of Klussman, et al (2004), Bioconjugate Chemistry 15(4):765-773, and the Examples herein.

40 [0249] In some embodiments, a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody. Exemplary such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some embodiments, a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit. Nonlimiting exemplary such reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.

45 [0250] A linker may comprise one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl (a "PAB"), N-Succinimidyl 4-(2-pyridylthio) pentanoate ("SPP"), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("MCC"). Various linker components are known in the art, some of which are described below.

50 [0251] A linker may be a "cleavable linker," facilitating release of a drug. Nonlimiting exemplary cleavable linkers include acid-labile linkers (e.g., comprising hydrazone), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research 52:127-131 (1992); US 5208020).


[0252] In certain embodiments, a linker has the following Formula II:



55 wherein A is a "stretcher unit", and a is an integer from 0 to 1; W is an "amino acid unit", and w is an integer from 0 to 12; Y is a "spacer unit", and y is 0, 1, or 2; and Ab, D, and p are defined as above for Formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298.


[0253] In some embodiments, a linker component comprises a "stretcher unit" that links an antibody to another linker component or to a drug moiety. Nonlimiting exemplary stretcher units are shown below (wherein the wavy line indicates sites of covalent attachment to an antibody, drug, or additional linker components):

5




MC

10



MP


15



mPEG

20

25




30

[0254] In some embodiments, a linker component comprises an "amino acid unit". In some such embodiments, the amino acid unit allows for cleavage of the linker by a protease, thereby facilitating release of the drug from the immunoconjugate upon exposure to intracellular proteases, such as lysosomal enzymes (Doronina et al. (2003) *Nat. Biotechnol.* 21:778-784). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). An amino acid unit may comprise amino acid residues that occur naturally and/or minor amino acids and/or non-naturally occurring amino acid analogs, such as citrulline. Amino acid units can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.

[0255] In some embodiments, a linker component comprises a "spacer" unit that links the antibody to a drug moiety, either directly or through a stretcher unit and/or an amino acid unit. A spacer unit may be "self-immolative" or a "non-self-immolative." A "non-self-immolative" spacer unit is one in which part or all of the spacer unit remains bound to the drug moiety upon cleavage of the ADC. Examples of non-self-immolative spacer units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit. In some embodiments, enzymatic cleavage of an ADC containing a glycine-glycine spacer unit by a tumor-cell associated protease results in release of a glycine-glycine-drug moiety from the remainder of the ADC. In some such embodiments, the glycine-glycine-drug moiety is subjected to a hydrolysis step in the tumor cell, thus cleaving the glycine-glycine spacer unit from the drug moiety.

[0256] A "self-immolative" spacer unit allows for release of the drug moiety. In certain embodiments, a spacer unit of a linker comprises a p-aminobenzyl unit. In some such embodiments, a p-aminobenzyl alcohol is attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the drug (Hamann et al. (2005) *Expert Opin. Ther. Patents* (2005) 15:1087-1103). In some embodiments, the spacer unit is p-aminobenzylcarbonyl (PAB). In some embodiments, an ADC comprising a self-immolative linker has the structure:

5




wherein Q is $-C_1-C_8$ alkyl, $-O-(C_1-C_8$ alkyl), -halogen, -nitro, or -cyno; m is an integer ranging from 0 to 4; and p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4.

[0257] Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5-methanol derivatives (U.S. Patent No. 7,375,078; Hay et al. (1999) *Bioorg. Med. Chem. Lett.* 9:2237) and ortho- or para-aminobenzylacetals. In some embodiments, spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al (1995) *Chemistry Biology* 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) *J. Amer. Chem. Soc.* 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) *J. Org. Chem.* 55:5867). Linkage of a drug to the α -carbon of a glycine residue is another example of a self-immolative spacer that may be useful in ADC (Kingsbury et al (1984) *J. Med. Chem.* 27:1447).

[0258] In some embodiments, linker L may be a dendritic type linker for covalent attachment of more than one drug moiety to an antibody through a branching, multifunctional linker moiety (Sun et al (2002) *Bioorganic & Medicinal Chemistry Letters* 12:2213-2215; Sun et al (2003) *Bioorganic & Medicinal Chemistry* 11:1761-1768). Dendritic linkers can increase the molar ratio of drug to antibody, i.e. loading, which is related to the potency of the ADC. Thus, where an antibody bears only one reactive cysteine thiol group, a multitude of drug moieties may be attached through a dendritic linker.

[0259] Nonlimiting exemplary linkers are shown below in the context of an ADC of Formula I:


30



35

val-cit


40



45

MC-val-cit


50




55

MC-val-cit-PAB

[0260] Further nonlimiting exemplary ADCs include the structures:




where X is:



40

Y is:




each R is independently H or C₁-C₆ alkyl; and n is 1 to 12.

[0261] Typically, peptide-type linkers can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (e.g., E. Schröder and K. Lübke (1965) "The Peptides", volume 1, pp 76-136, Academic Press).

[0262] In some embodiments, a linker is substituted with groups that modulate solubility and/or reactivity. As a non-limiting example, a charged substituent such as sulfonate (-SO₃⁻) or ammonium may increase water solubility of the linker reagent and facilitate the coupling reaction of the linker reagent with the antibody and/or the drug moiety, or facilitate the coupling reaction of Ab-L (antibody-linker intermediate) with D, or D-L (drug-linker intermediate) with Ab, depending on the synthetic route employed to prepare the ADC. In some embodiments, a portion of the linker is coupled to the antibody and a portion of the linker is coupled to the drug, and then the Ab-(linker portion)^a is coupled to drug-(linker portion)^b to form the ADC of Formula I. In some such embodiments, the antibody comprises more than one (linker

portion)^a substituents, such that more than one drug is coupled to the antibody in the ADC of Formula I.

[0263] The compounds of the invention expressly contemplate, but are not limited to, ADC prepared with the following linker reagents: bis-maleimido-trioxyethylene glycol (BMPEO), N-(β -maleimidopropoxy)-N-hydroxy succinimide ester (BMPS), N-(ε -maleimidocaproyloxy) succinimide ester (EMCS), N-[γ -maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetetyl)aminobenzoate (SIAB), Nsuccinimidyl-3-(2-pyridylidithio) propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(β -maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB), and including bis-maleimide reagents: dithiobismaleimidoethane (DTME), 1,4-Bismaleimidobutane (BMB), 1,4 Bismaleimidyl-2,3-dihydroxybutane (BMD), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), BM(PEG)₂ (shown below), and BM(PEG)₃ (shown below); bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazonium-benzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). In some embodiments, bis-maleimide reagents allow the attachment of the thiol group of a cysteine in the antibody to a thiol-containing drug moiety, linker, or linker-drug intermediate. Other functional groups that are reactive with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.



[0264] Certain useful linker reagents can be obtained from various commercial sources, such as Pierce Biotechnology, Inc. (Rockford, IL), Molecular Biosciences Inc. (Boulder, CO), or synthesized in accordance with procedures described in the art; for example, in Toki et al (2002) *J. Org. Chem.* 67:1866-1872; Dubowchik, et al. (1997) *Tetrahedron Letters*, 38:5257-60; Walker, M.A. (1995) *J. Org. Chem.* 60:5352-5355; Frisch et al (1996) *Bioconjugate Chem.* 7:180-186; US 6214345; WO 02/088172; US 2003130189; US2003096743; WO 03/026577; WO 03/043583; and WO 04/032828.

[0265] Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See, e.g., WO94/11026.

b) Exemplary Drug Moieties

(1) *Maytansine and maytansinoids*

[0266] In some embodiments, an immunoconjugate comprises an antibody conjugated to one or more maytansinoid molecules. Maytansinoids are derivatives of maytansine, and are mitotic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3896111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.

[0267] Maytansinoid drug moieties are attractive drug moieties in antibody-drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation through non-disulfide linkers to antibodies, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.


[0268] Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al (2002) PNAS 99:7968-7973). Maytansinoids may also be prepared synthetically according to known methods.

[0269] Exemplary maytansinoid drug moieties include, but are not limited to, those having a modified aromatic ring, such as: C-19-dechloro (US Pat. No. 4256746) (prepared, for example, by lithium aluminum hydride reduction of ansamycin P2); C-20-hydroxy (or C-20-demethyl) +/-C-19-dechloro (US Pat. Nos. 4361650 and 4307016) (prepared, for example, by demethylation using *Streptomyces* or *Actinomyces* or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), +/-dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those having modifications at other positions of the aromatic ring.

[0270] Exemplary maytansinoid drug moieties also include those having modifications such as: C-9-SH (US Pat. No. 4424219) (prepared, for example, by the reaction of maytansinol with H₂S or P₂S₅); C-14-alkoxymethyl(demethoxy/CH₂ OR)(US 4331598); C-14-hydroxymethyl or acyloxymethyl (CH₂OH or CH₂OAc) (US Pat. No. 4450254) (prepared, for example, from *Nocardia*); C-15-hydroxy/acyloxy (US 4364866) (prepared, for example, by the conversion of maytansinol by *Streptomyces*); C-15-methoxy (US Pat. Nos. 4313946 and 4315929) (for example, isolated from *Trewia nudiflora*); C-18-N-demethyl (US Pat. Nos. 4362663 and 4322348) (prepared, for example, by the demethylation of maytansinol by *Streptomyces*); and 4,5-deoxy (US 4371533) (prepared, for example, by the titanium trichloride/LAH reduction of maytansinol).


[0271] Many positions on maytansinoid compounds are useful as the linkage position. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. In some embodiments, the reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In some embodiments, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

[0272] Maytansinoid drug moieties include those having the structure:






where the wavy line indicates the covalent attachment of the sulfur atom of the maytansinoid drug moiety to a linker of an ADC. Each R may independently be H or a C₁-C₆ alkyl. The alkylene chain attaching the amide group to the sulfur atom may be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (US 633410; US 5208020; Chari et al (1992) Cancer Res. 52:127-131; Liu et al (1996) Proc. Natl. Acad. Sci USA 93:8618-8623).

[0273] All stereoisomers of the maytansinoid drug moiety are contemplated for the ADC of the invention, i.e. any combination of R and S configurations at the chiral carbons (US 7276497; US 6913748; US 6441163; US 633410 (RE39151); US 5208020; Widdison et al (2006) J. Med. Chem. 49:4392-4408). In some embodiments, the maytansinoid drug moiety has the following stereochemistry:





[0274] Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, DM1; DM3; and DM4, having the structures:






20 wherein the wavy line indicates the covalent attachment of the sulfur atom of the drug to a linker (L) of an antibody-drug conjugate.

[0275] Other exemplary maytansinoid antibody-drug conjugates have the following structures and abbreviations (wherein Ab is antibody and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4):



[0276] Exemplary antibody-drug conjugates where DM1 is linked through a BMPEO linker to a thiol group of the

antibody have the structure and abbreviation:



where Ab is antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.

[0277] Immunoconjugates containing maytansinoids, methods of making the same, and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020 and 5,416,064; US 2005/0276812 A1; and European Patent EP 0 425 235 B1. See also Liu et al. Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996); and Chari et al. Cancer Research 52:127-131 (1992).


[0278] In some embodiments, antibody-maytansinoid conjugates may be prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. See, e.g., U.S. Patent No. 5,208,020. In some embodiments, ADC with an average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody. In some instances, even one molecule of toxin/antibody is expected to enhance cytotoxicity over the use of naked antibody.


[0279] Exemplary linking groups for making antibody-maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Patent No. 5208020; EP Patent 0425 235 B1; Chari et al. Cancer Research 52:127-131 (1992); US 2005/0276812 A1; and US 2005/016993 A1.

35 (2) Auristatins and dolastatins

[0280] Drug moieties include dolastatins, auristatins, and analogs and derivatives thereof (US 5635483; US 5780588; US 5767237; US 6124431). Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by any particular theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al (2001) Antimicrob. Agents and Chemother. 45(12):3580-3584) and have anticancer (US 5663149) and antifungal activity (Pettit et al (1998) Antimicrob. Agents Chemother. 42:2961-2965). The dolastatin/auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172; Doronina et al (2003) Nature Biotechnology 21(7):778-784; Francisco et al (2003) Blood 102(4):1458-1465).

[0281] Exemplary auristatin embodiments include the N-terminus linked monomethylauristatin drug moieties D_E and D_F, disclosed in US 7498298 and US 7659241:





10 wherein the wavy line of D_E and D_F indicates the covalent attachment site to an antibody or antibody-linker component, and independently at each location:

R² is selected from H and C₁-C₈ alkyl;

15 R³ is selected from H, C₁-C₈ alkyl, C₃-C₈ carbocycle, aryl, C₁-C₈ alkyl-aryl, C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and C₁-C₈ alkyl-(C₃-C₈ heterocycle);

R⁴ is selected from H, C₁-C₈ alkyl, C₃-C₈ carbocycle, aryl, C₁-C₈ alkyl-aryl, C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and C₁-C₈ alkyl-(C₃-C₈ heterocycle);

R⁵ is selected from H and methyl;

20 or R⁴ and R⁵ jointly form a carbocyclic ring and have the formula -(CR^aR^b)_n- wherein R^a and R^b are independently selected from H, C₁-C₈ alkyl and C₃-C₈ carbocycle and n is selected from 2, 3, 4, 5 and 6;

R⁶ is selected from H and C₁-C₈ alkyl;

R⁷ is selected from H, C₁-C₈ alkyl, C₃-C₈ carbocycle, aryl, C₁-C₈ alkyl-aryl, C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and C₁-C₈ alkyl-(C₃-C₈ heterocycle);

25 each R⁸ is independently selected from H, OH, C₁-C₈ alkyl, C₃-C₈ carbocycle and O-(C₁-C₈ alkyl);

R⁹ is selected from H and C₁-C₈ alkyl;

R¹⁰ is selected from aryl or C₃-C₈ heterocycle;

Z is O, S, NH, or NR¹², wherein R¹² is C₁-C₈ alkyl;

R¹¹ is selected from H, C₁-C₂₀ alkyl, aryl, C₃-C₈ heterocycle, -(R¹³O)_m-R¹⁴, or -(R¹³O)_m-CH(R¹⁵)₂;

30 m is an integer ranging from 1-1000;

R¹³ is C₂-C₈ alkyl;

R¹⁴ is H or C₁-C₈ alkyl;

each occurrence of R¹⁵ is independently H, COOH, -(CH₂)_n-N(R¹⁶)₂, -(CH₂)_n-SO₃H, or -(CH₂)_n-SO₃-C₁-C₈ alkyl;

each occurrence of R¹⁶ is independently H, C₁-C₈ alkyl, or -(CH₂)_n-COOH;

35 R¹⁸ is selected from -C(R⁸)₂-C(R⁸)₂-aryl, -C(R⁸)₂-C(R⁸)₂-(C₃-C₈ heterocycle), and -C(R⁸)₂-C(R⁸)₂-(C₃-C₈ carbocycle); and

n is an integer ranging from 0 to 6.

[0282] In one embodiment, R³, R⁴ and R⁷ are independently isopropyl or sec-butyl and R⁵ is -H or methyl. In an exemplary embodiment, R³ and R⁴ are each isopropyl, R⁵ is -H, and R⁷ is sec-butyl.

40 [0283] In yet another embodiment, R² and R⁶ are each methyl, and R⁹ is -H.

[0284] In still another embodiment, each occurrence of R⁸ is -OCH₃.

[0285] In an exemplary embodiment, R³ and R⁴ are each isopropyl, R² and R⁶ are each methyl, R⁵ is -H, R⁷ is sec-butyl, each occurrence of R⁸ is -OCH₃, and R⁹ is -H.

[0286] In one embodiment, Z is -O- or -NH-.

45 [0287] In one embodiment, R¹⁰ is aryl.


[0288] In an exemplary embodiment, R¹⁰ is -phenyl.

[0289] In an exemplary embodiment, when Z is -O-, R¹¹ is -H, methyl or t-butyl.


[0290] In one embodiment, when Z is -NH, R¹¹ is -CH(R¹⁵)₂, wherein R¹⁵ is -(CH₂)_n-N(R¹⁶)₂, and R¹⁶ is -C₁-C₈ alkyl or -(CH₂)_n-COOH.

50 [0291] In another embodiment, when Z is -NH, R¹¹ is -CH(R¹⁵)₂, wherein R¹⁵ is - (CH₂)_n-SO₃H.

[0292] An exemplary auristatin embodiment of formula D_E is MMAE, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:




[0293] An exemplary auristatin embodiment of formula D_F is MMAF, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:




[0294] Other exemplary embodiments include monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008848) and monomethylvaline compounds having phenylalanine sidechain modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008603).


[0295] Nonlimiting exemplary embodiments of ADC of Formula I comprising MMAE or MMAF and various linker components have the following structures and abbreviations (wherein "Ab" is an antibody; p is 1 to about 8, "Val-Cit" is a valine-citrulline dipeptide; and "S" is a sulfur atom):




Ab-MC-vc-PAB-MMAF



Ab-MC-vc-PAB-MMAE



Ab-MC-MMAE



Ab-MC-MMAF

[0296] Nonlimiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components further include Ab-MC-PAB-MMAF and Ab-PAB-MMAF. Immunoconjugates comprising MMAF attached to an antibody by a linker that is not proteolytically cleavable have been shown to possess activity comparable to immunoconjugates comprising MMAF attached to an antibody by a proteolytically cleavable linker (Doronina et al. (2006) *Bioconjugate Chem.* 17:114-124). In some such embodiments, drug release is believed to be effected by antibody degradation in the cell.

[0297] Typically, peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (see, e.g., E. Schröder and K. Lübke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press). Auristatin/dolastatin drug moieties may, in some embodiments, be prepared according to the methods of: US 7498298; US 5635483; US 5780588; Pettit et al (1989) *J. Am. Chem. Soc.* 111:5463-5465; Pettit et al (1998) *Anti-Cancer Drug Design* 13:243-277; Pettit, G.R., et al. *Synthesis*, 1996, 719-725; Pettit et al (1996) *J. Chem. Soc. Perkin Trans. 1* 5:859-863; and Doronina (2003) *Nat. Biotechnol.* 21(7):778-784.

[0298] In some embodiments, auristatin/dolastatin drug moieties of formulas D_E such as MMAE, and D_F , such as MMAF, and drug-linker intermediates and derivatives thereof, such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE, may be prepared using methods described in US 7498298; Doronina et al. (2006) *Bioconjugate Chem.* 17:114-124; and Doronina et al. (2003) *Nat. Biotech.* 21:778-784 and then conjugated to an antibody of interest.

(3) *Calicheamicin*

[0299] In some embodiments, the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., (1993) *Cancer Research* 53:3336-3342; Lode et al., (1998) *Cancer Research* 58:2925-2928). Calicheamicin has intracellular sites of action but, in certain instances, does not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody-mediated internalization may, in some embodiments, greatly enhances their cytotoxic effects. Nonlimiting exemplary methods of preparing antibody-drug conjugates with a calicheamicin drug moiety are described, for example, in US 5712374; US 5714586; US 5739116; and US 5767285.


(4) *Pyrrolobenzodiazepines*

[0300] In some embodiments, an ADC comprises a pyrrolobenzodiazepine (PBD). In some embodiments, PDB dimers recognize and bind to specific DNA sequences. The natural product anthramycin, a PBD, was first reported in 1965 (Leimgruber, et al., (1965) *J. Am. Chem. Soc.*, 87:5793-5795; Leimgruber, et al., (1965) *J. Am. Chem. Soc.*, 87:5791-5793). Since then, a number of PBDs, both naturally-occurring and analogues, have been reported (Thurston, et al., (1994) *Chem. Rev.* 1994, 433-465 including dimers of the tricyclic PBD scaffold (US 6884799; US 7049311; US 7067511; US 7265105; US 7511032; US 7528126; US 7557099). Without intending to be bound by any particular theory, it is believed that the dimer structure imparts the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In *Antibiotics III*. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, (1986) *Acc. Chem. Res.*, 19:230-237). Dimeric PBD compounds bearing C2 aryl substituents have been shown to be useful as cytotoxic agents (Hartley et al (2010) *Cancer Res.* 70(17):6849-6858; Antonow (2010) *J. Med. Chem.* 53(7):2927-2941; Howard et al (2009) *Bioorganic and Med. Chem. Letters* 19(22):6463-6466).

[0301] In some embodiments, PBD compounds can be employed as prodrugs by protecting them at the N10 position with a nitrogen protecting group which is removable *in vivo* (WO 00/12507; WO 2005/023814).

[0302] PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties (US 2010/0203007). Nonlimiting exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598).

[0303] Nonlimiting exemplary PBD dimer components of ADCs are of Formula A:



and salts and solvates thereof, wherein:

the wavy line indicates the covalent attachment site to the linker;

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

15 R² is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo;

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

20 R⁷ is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

Q is independently selected from O, S and NH;

R¹¹ is either H, or R or, where Q is O, SO₃M, where M is a metal cation;

R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₁₋₁₂ alkyl, C₃₋₈ heterocycl, C₃₋₂₀ heterocycle, and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

25 R¹², R¹⁶, R¹⁹ and R¹⁷ are as defined for R², R⁶, R⁹ and R⁷ respectively;

R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; and X and X' are independently selected from O, S and N(H).

30 [0304] In some embodiments, R and R' are each independently selected from optionally substituted C₁₋₁₂ alkyl, C₃₋₂₀ heterocycl, and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring.

[0305] In some embodiments, R⁹ and R¹⁹ are H.

[0306] In some embodiments, R⁶ and R¹⁶ are H.

35 [0307] In some embodiments, R⁷ are R¹⁷ are both OR^{7A}, where R^{7A} is optionally substituted C₁₋₄ alkyl. In some embodiments, R^{7A} is Me. In some embodiments, R^{7A} is is Ch₂Ph, where Ph is a phenyl group.

[0308] In some embodiments, X is O.

[0309] In some embodiments, R¹¹ is H.


[0310] In some embodiments, there is a double bond between C2 and C3 in each monomer unit.

40 [0311] In some embodiments, R² and R¹² are independently selected from H and R. In some embodiments, R² and R¹² are independently R. In some embodiments, R² and R¹² are independently optionally substituted C₅₋₂₀ aryl or C₅₋₇ aryl or C₈₋₁₀ aryl. In some embodiments, R² and R¹² are independently optionally substituted phenyl, thiienyl, napthyl, pyridyl, quinolinyl, or isoquinolinyl. In some embodiments, R² and R¹² are independently selected from =O, =CH₂, =CH-R^D, and =C(R^D)₂. In some embodiments, R² and R¹² are each =CH₂. In some embodiments, R² and R¹² are each H.


45 In some embodiments, R² and R¹² are each =O. In some embodiments, R² and R¹² are each =CF₂. In some embodiments, R² and/or R¹² are independently =C(R^D)₂. In some embodiments, R² and/or R¹² are independently =CH-R^D.

[0312] In some embodiments, when R² and/or R¹² is =CH-R^D, each group may independently have either configuration shown below:

50



(I)



(II)


55

In some embodiments, a $=\text{CH}-\text{R}^{\text{D}}$ is in configuration (I).

[0313] In some embodiments, R" is a C₃ alkylene group or a C₅ alkylene group.

[0314] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(I):

5



A(I);


10

wherein n is 0 or 1.

15

[0315] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(II):

20




A(II);

25

wherein n is 0 or 1.

[0316] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(III):

30



A(III);

35

wherein R^E and R^{E"} are each independently selected from H or R^D, wherein R^D is defined as above; and wherein n is 0 or 1.


40

[0317] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, R^E and/or R^{E"} is H. In some embodiments, R^E and R^{E"} are H. In some embodiments, R^E and/or R^{E"} is R^D, wherein R^D is optionally substituted C₁₋₁₂ alkyl. In some embodiments, R^E and/or R^{E"} is R^D, wherein R^D is methyl.

[0318] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(IV):

45

50



A(IV);

55


wherein Ar¹ and Ar² are each independently optionally substituted C₅₋₂₀ aryl; wherein Ar¹ and Ar² may be the same or different; and

56

wherein n is 0 or 1.

[0319] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(V):

5




A(V);

10 wherein Ar¹ and Ar² are each independently optionally substituted C₅₋₂₀ aryl; wherein Ar¹ and Ar² may be the same or different; and
 wherein n is 0 or 1.

[0320] In some embodiments, Ar¹ and Ar² are each independently selected from optionally substituted phenyl, furanyl, thiophenyl and pyridyl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted phenyl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted thien-2-yl or thien-3-yl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted quinolinyl or isoquinolinyl. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position. For example, the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl. In some embodiments, the quinolinyl is selected from quinolin-3-yl and quinolin-6-yl. The isoquinolinyl may be isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. In some embodiments, the isoquinolinyl is selected from isoquinolin-3-yl and isoquinolin-6-yl.

[0321] Further nonlimiting exemplary PBD dimer components of ADCs are of Formula B:

25



30

and salts and solvates thereof, wherein:

35 the wavy line indicates the covalent attachment site to the linker;

the wavy line connected to the OH indicates the S or R configuration;

R^{V1} and R^{V2} are independently selected from H, methyl, ethyl and phenyl (which phenyl may be optionally substituted with fluoro, particularly in the 4 position) and C₅₋₆ heterocyclyl; wherein R^{V1} and R^{V2} may be the same or different; and n is 0 or 1.


40 [0322] In some embodiments, R^{V1} and R^{V2} are independently selected from H, phenyl, and 4-fluorophenyl.

[0323] In some embodiments, a linker may be attached at one of various sites of the PBD dimer drug moiety, including the N10 imine of the B ring, the C-2 endo/exo position of the C ring, or the tether unit linking the A rings (see structures C(I) and C(II) below).


[0324] Nonlimiting exemplary PBD dimer components of ADCs include Formulas C(I) and C(II):

45

50



55



10 [0325] Formulas C(I) and C(II) are shown in their N10-C11 imine form. Exemplary PBD drug moieties also include the carbinolamine and protected carbinolamine forms as well, as shown in the table below:

15

Imine	Carbinolamine	Protected Carbinolamine

20 wherein:

X is CH_2 ($n = 1$ to 5), N, or O;

Z and Z' are independently selected from OR and NR_2 , where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;

25 R_1 , R'_1 , R^2 and R'_2 are each independently selected from H, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_{5\text{-}20}$ aryl (including substituted aryls), $\text{C}_{5\text{-}20}$ heteroaryl groups, $-\text{NH}_2$, $-\text{NHMe}$, $-\text{OH}$, and $-\text{SH}$, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;

R_3 and R'_3 are independently selected from H, OR, NHR, and NR_2 , where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;

30 R_4 and R'_4 are independently selected from H, Me, and OMe;


R_5 is selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_{5\text{-}20}$ aryl (including aryls substituted by halo, nitro, cyano, alkoxy, alkyl, heterocyclyl) and $\text{C}_{5\text{-}20}$ heteroaryl groups, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;

35 R_{11} is H, $\text{C}_1\text{-C}_8$ alkyl, or a protecting group (such as acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citruline-PAB);

R_{12} is H, $\text{C}_1\text{-C}_8$ alkyl, or a protecting group;

wherein a hydrogen of one of R_1 , R'_1 , R_2 , R'_2 , R_5 , or R_{12} or a hydrogen of the $-\text{OCH}_2\text{CH}_2(\text{X})_n\text{CH}_2\text{CH}_2\text{O}-$ spacer between the A rings is replaced with a bond connected to the linker of the ADC.



40 [0326] Exemplary PDB dimer portions of ADC include, but are not limited to (the wavy line indicates the site of covalent attachment to the linker):



50

[0327] Nonlimiting exemplary embodiments of ADCs comprising PBD dimers have the following structures:

55



n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8. In some embodiments, n is selected from 4, 5, 6, 7, and 8.

[0328] The linkers of PBD dimer-val-cit-PAB-Ab and the PBD dimer-Phe-Lys-PAB-Ab are protease cleavable, while the linker of PBD dimer-maleimide-acetal is acid-labile.

[0329] PBD dimers and ADC comprising PBD dimers may be prepared according to methods known in the art. See, e.g., WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598.

(5) Anthracyclines


[0330] In some embodiments, an ADC comprising anthracycline. Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. While not intending to be bound by any particular theory, studies have indicated that anthracyclines may operate to kill cells by a number of different mechanisms, including: 1) intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; 2) production by the drug of free radicals which then react with cellular macromolecules to cause damage to the cells, and/or 3) interactions of the drug molecules with the cell membrane (see, e.g., C. Peterson et al., "Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia" in Anthracycline Antibiotics In Cancer Therapy; N.R. Bachur, "Free Radical Damage" id. at pp.97-102). Because of their cytotoxic potential anthracyclines have been used in the treatment of numerous cancers such as leukemia, breast carcinoma, lung carcinoma, ovarian adenocarcinoma and sarcomas (see e.g., P.H. Wiernik, in Anthra

cycline: Current Status And New Developments p 11).

[0331] Nonlimiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al (2006) Current Med. Chem. 13:477-523; Jeffrey et al (2006) Bioorganic & Med. Chem. Letters 16:358-362; Torgov et al (2005) Bioconj. Chem. 16:717-721; Nagy et al (2000) Proc. Natl. Acad. Sci. USA 97:829-834; Dubowchik et al (2002) Bioorg. & Med. Chem. Letters 12:1529-1532; King et al (2002) J. Med. Chem. 45:4336-4343; EP 0328147; US 6630579). The antibody-drug conjugate BR96-doxorubicin reacts specifically with the tumor-associated antigen Lewis-Y and has been evaluated in phase I and II studies (Saleh et al (2000) J. Clin. Oncology 18:2282-2292; Ajani et al (2000) Cancer Jour. 6:78-81; Tolcher et al (1999) J. Clin. Oncology 17:478-484).

[0332] PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri, et al. (2005) Clinical Cancer Research 11(4):1608-1617). Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin and has been under clinical evaluation (Grandi et al (1990) Cancer Treat. Rev. 17:133; Ripamonti et al (1992) Brit. J. Cancer 65:703;), including phase II/III trials for hepatocellular carcinoma (Sun et al (2003) Proceedings of the American Society for Clinical Oncology 22, Abs 1448; Quintieri (2003) Proceedings of the American Association of Cancer Research, 44:1st Ed, Abs 4649; Pacciarini et al (2006) Jour. Clin. Oncology 24:14116).

[0333] A nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula Ia:



wherein R₁ is hydrogen atom, hydroxy or methoxy group and R₂ is a C₁-C₅ alkoxy group, or a pharmaceutically acceptable salt thereof;


L₁ and Z together are a linker (L) as described herein;

T is an antibody (Ab) as described herein; and

m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.

[0334] In some embodiments, R₁ and R₂ are both methoxy (-OMe).

[0335] A further nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula Ib:





wherein R₁ is hydrogen atom, hydroxy or methoxy group and R₂ is a C₁-C₅ alkoxy group, or a pharmaceutically acceptable salt thereof;

L₂ and Z together are a linker (L) as described herein;

T is an antibody (Ab) as described herein; and
 m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.

5 [0336] In some embodiments, R₁ and R₂ are both methoxy (-OMe).


[0337] In some embodiments, the nemorubicin component of a nemorubicin-containing ADC is PNU-159682. In some such embodiments, the drug portion of the ADC may have one of the following structures:




wherein the wavy line indicates the attachment to the linker (L).

45 [0338] Anthracyclines, including PNU-159682, may be conjugated to antibodies through several linkage sites and a variety of linkers (US 2011/0076287; WO2009/099741; US 2010/0034837; WO 2010/009124), including the linkers described herein.


[0339] Exemplary ADCs comprising a nemorubicin and linker include, but are not limited to:




PNU-159682 maleimide acetal-Ab;



PNU-159682-val-cit-PAB-Ab;



PNU-159682-val-cit-PAB-spacer-Ab;



isotopes are available for the production of radioconjugated antibodies. Examples include At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu. In some embodiments, when an immunoconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc⁹⁹ or I¹²³, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as zirconium-89, iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Zirconium-89 may be complexed to various metal chelating agents and conjugated to antibodies, e.g., for PET imaging (WO 2011/056983).

[0344] The radio- or other labels may be incorporated in the immunoconjugate in known ways. For example, a peptide may be biosynthesized or chemically synthesized using suitable amino acid precursors comprising, for example, one or more fluorine-19 atoms in place of one or more hydrogens. In some embodiments, labels such as Tc⁹⁹, I¹²³, Re¹⁸⁶, Re¹⁸⁸ and In¹¹¹ can be attached via a cysteine residue in the antibody. In some embodiments, yttrium-90 can be attached via a lysine residue of the antibody. In some embodiments, the IODOGEN method (Fraker et al (1978) *Biochem. Biophys. Res. Commun.* 80: 49-57 can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.

[0345] In certain embodiments, an immunoconjugate may comprise an antibody conjugated to a prodrug-activating enzyme. In some such embodiments, a prodrug-activating enzyme converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO 81/01145) to an active drug, such as an anti-cancer drug. Such immunoconjugates are useful, in some embodiments, in antibody-dependent enzyme-mediated prodrug therapy ("ADEPT"). Enzymes that may be conjugated to an antibody include, but are not limited to, alkaline phosphatases, which are useful for converting phosphate-containing prodrugs into free drugs; arylsulfatases, which are useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase, which is useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), which are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, which are useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β -galactosidase and neuraminidase, which are useful for converting glycosylated prodrugs into free drugs; β -lactamase, which is useful for converting drugs derivatized with β -lactams into free drugs; and penicillin amidases, such as penicillin V amidase and penicillin G amidase, which are useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. In some embodiments, enzymes may be covalently bound to antibodies by recombinant DNA techniques well known in the art. See, e.g., Neuberger et al., *Nature* 312:604-608 (1984).

c) Drug Loading

[0346] Drug loading is represented by p, the average number of drug moieties per antibody in a molecule of Formula I. Drug loading may range from 1 to 20 drug moieties (D) per antibody. ADCs of Formula I include collections of antibodies conjugated with a range of drug moieties, from 1 to 20. The average number of drug moieties per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC. The quantitative distribution of ADC in terms of p may also be determined. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.

[0347] For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, where the attachment is a cysteine thiol, as in certain exemplary embodiments above, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. In certain embodiments, higher drug loading, e.g. p > 5, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates. In certain embodiments, the average drug loading for an ADC ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. Indeed, it has been shown that for certain ADCs, the optimal ratio of drug moieties per antibody may be less than 8, and may be about 2 to about 5 (US 7498298).

[0348] In certain embodiments, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, lysine residues that do not react with the drug-linker intermediate or linker reagent, as discussed below. Generally, antibodies do not contain many free and reactive cysteine thiol groups which may be linked to a drug moiety; indeed most cysteine thiol residues in antibodies exist as disulfide bridges. In certain embodiments, an antibody may be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP), under partial or total reducing conditions, to generate reactive cysteine thiol groups. In certain embodiments, an antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.

[0349] The loading (drug/antibody ratio) of an ADC may be controlled in different ways, and for example, by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction

time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.

[0350] It is to be understood that where more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, then the resulting product is a mixture of ADC compounds with a distribution of one or more drug moieties attached to an antibody. The average number of drugs per antibody may be calculated from the mixture by a dual ELISA antibody assay, which is specific for antibody and specific for the drug. Individual ADC molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography (see, e.g., McDonagh et al (2006) *Prot. Engr. Design & Selection* 19(7):299-307; Hamblett et al (2004) *Clin. Cancer Res.* 10:7063-7070; Hamblett, K.J., et al. "Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate," Abstract No. 624, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004; Alley, S.C., et al. "Controlling the location of drug attachment in antibody-drug conjugates," Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004). In certain embodiments, a homogeneous ADC with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography.

15 d) Certain Methods of Preparing Immunoconjugates

[0351] An ADC of Formula I may be prepared by several routes employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a nucleophilic group of an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety D; and (2) reaction of a nucleophilic group of a drug moiety with a bivalent linker reagent, to form D-L, via a covalent bond, followed by reaction with a nucleophilic group of an antibody. Exemplary methods for preparing an ADC of Formula I via the latter route are described in US 7498298.

[0352] Nucleophilic groups on antibodies include, but are not limited to: (i) N-terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP), such that the antibody is fully or partially reduced. Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol. Reactive thiol groups may also be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies comprising one or more non-native cysteine amino acid residues).

[0353] Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug. In another embodiment, the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties. The resulting imine Schiff base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug (Hermanson, *Bioconjugate Techniques*). In another embodiment, antibodies containing N-terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) *Bioconjugate Chem.* 3:138-146; US 5362852). Such an aldehyde can be reacted with a drug moiety or linker nucleophile.

[0354] Exemplary nucleophilic groups on a drug moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.

[0355] Nonlimiting exemplary cross-linker reagents that may be used to prepare ADC are described herein in the section titled "Exemplary Linkers." Methods of using such cross-linker reagents to link two moieties, including a proteinaceous moiety and a chemical moiety, are known in the art. In some embodiments, a fusion protein comprising an

antibody and a cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. A recombinant DNA molecule may comprise regions encoding the antibody and cytotoxic portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

[0356] In yet another embodiment, an antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a drug or radionucleotide).

E. Methods and Compositions for Diagnostics and Detection

[0357] In certain embodiments, any of the anti-B7-H4 antibodies provided herein is useful for detecting the presence of B7-H4 in a biological sample. The term "detecting" as used herein encompasses quantitative or qualitative detection. A "biological sample" comprises, e.g., a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous breast, endometrial, or ovarian tissue).

[0358] In one embodiment, an anti-B7-H4 antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of B7-H4 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-B7-H4 antibody as described herein under conditions permissive for binding of the anti-B7-H4 antibody to B7-H4, and detecting whether a complex is formed between the anti-B7-H4 antibody and B7-H4 in the biological sample. Such method may be an *in vitro* or *in vivo* method. In one embodiment, an anti-B7-H4 antibody is used to select subjects eligible for therapy with an anti-B7-H4 antibody, e.g. where B7-H4 is a biomarker for selection of patients. In a further embodiment, the biological sample is a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous breast, endometrial, or ovarian tissue).

[0359] In a further embodiment, an anti-B7-H4 antibody is used *in vivo* to detect, e.g., by *in vivo* imaging, an B7-H4-positive cancer in a subject, e.g., for the purposes of diagnosing, prognosing, or staging cancer, determining the appropriate course of therapy, or monitoring response of a cancer to therapy. One method known in the art for *in vivo* detection is immuno-positron emission tomography (immuno-PET), as described, e.g., in van Dongen et al., *The Oncologist* 12:1379-1389 (2007) and Verel et al., *J. Nucl. Med.* 44:1271-1281 (2003). In such embodiments, a method is provided for detecting an B7-H4-positive cancer in a subject, the method comprising administering a labeled anti-B7-H4 antibody to a subject having or suspected of having an B7-H4-positive cancer, and detecting the labeled anti-B7-H4 antibody in the subject, wherein detection of the labeled anti-B7-H4 antibody indicates an B7-H4-positive cancer in the subject. In certain of such embodiments, the labeled anti-B7-H4 antibody comprises an anti-B7-H4 antibody conjugated to a positron emitter, such as ⁶⁸Ga, ¹⁸F, ⁶⁴Cu, ⁸⁶Y, ⁷⁶Br, ⁸⁹Zr, and ¹²⁴I. In a particular embodiment, the positron emitter is ⁸⁹Zr.

[0360] In further embodiments, a method of diagnosis or detection comprises contacting a first anti-B7-H4 antibody immobilized to a substrate with a biological sample to be tested for the presence of B7-H4, exposing the substrate to a second anti-B7-H4 antibody, and detecting whether the second anti-B7-H4 is bound to a complex between the first anti-B7-H4 antibody and B7-H4 in the biological sample. A substrate may be any supportive medium, e.g., glass, metal, ceramic, polymeric beads, slides, chips, and other substrates. In certain embodiments, a biological sample comprises a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous breast, endometrial, or ovarian tissue). In certain embodiments, the first or second anti-B7-H4 antibody is any of the antibodies described herein.

[0361] Exemplary disorders that may be diagnosed or detected according to any of the above embodiments include B7-H4-positive cancers, such as B7-H4-positive breast cancer, B7-H4-positive ovarian cancer, and B7-H4-positive endometrial cancer. In some embodiments, an B7-H4-positive cancer is a cancer that receives an anti-B7-H4 immuno-histochemistry (IHC) or *in situ* hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B. In another embodiment, a B7-H4-positive cancer expresses B7-H4 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B. In some embodiments, a B7-H4-positive cancer is a cancer that expresses B7-H4 according to a reverse-transcriptase PCR (RT-PCR) assay that detects B7-H4mRNA. In some embodiments, the RT-PCR is quantitative RT-PCR.

[0362] In certain embodiments, labeled anti-B7-H4 antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes ³²P, ¹⁴C, ¹²⁵I, ³H, and ¹³¹I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like. In another embodiment, a label is a positron emitter. Positron emitters include

but are not limited to ^{68}Ga , ^{18}F , ^{64}Cu , ^{86}Y , ^{76}Br , ^{89}Zr , and ^{124}I . In a particular embodiment, a positron emitter is ^{89}Zr .

F. Pharmaceutical Formulations

5 [0363] Pharmaceutical formulations of an anti-B7-H4 antibody or immunoconjugate as described herein are prepared by mixing such antibody or immunoconjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

10 [0364] Exemplary lyophilized antibody or immunoconjugate formulations are described in US Patent No. 6,267,958. Aqueous antibody or immunoconjugate formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

15 [0365] The formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, in some instances, it may be desirable to further provide Avastin® (bevacizumab), e.g., for the treatment of B7-H4-positive cancer such as B7-H4-positive breast cancer, B7-H4-positive ovarian cancer or B7-H4-positive endometrial cancer.

20 [0366] Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

25 [0367] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or immunoconjugate, which matrices are in the form of shaped articles, e.g. films, or microcapsules.

30 [0368] The formulations to be used for *in vivo* administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.

35

G. Therapeutic Methods and Compositions

40 [0369] Any of the anti-B7-H4 antibodies or immunoconjugates provided herein may be used in methods, e.g., therapeutic methods.

45 [0370] In one aspect, an anti-B7-H4 antibody or immunoconjugate provided herein is used in a method of inhibiting proliferation of an B7-H4-positive cell, the method comprising exposing the cell to the anti-B7-H4 antibody or immunoconjugate under conditions permissive for binding of the anti-B7-H4 antibody or immunoconjugate to B7-H4 on the surface of the cell, thereby inhibiting the proliferation of the cell. In certain embodiments, the method is an *in vitro* or an *in vivo* method. In further embodiments, the cell is a breast, ovarian, or endometrial cell.

50 [0371] Inhibition of cell proliferation *in vitro* may be assayed using the CellTiter-Glo™ Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, WI). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. See Crouch et al. (1993) J. Immunol. Meth. 160:81-88, US Pat. No. 6602677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high-throughput screening (HTS). See Cree et al. (1995) AntiCancer Drugs 6:398-404. The assay procedure involves adding a single reagent (CellTiter-Glo® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction. The luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device. The luminescence output is expressed as relative light

units (RLU).

[0372] In another aspect, an anti-B7-H4 antibody or immunoconjugate for use as a medicament is provided. In further aspects, an anti-B7-H4 antibody or immunoconjugate for use in a method of treatment is provided. In certain embodiments, an anti-B7-H4 antibody or immunoconjugate for use in treating B7-H4-positive cancer is provided. In certain embodiments, the invention provides an anti-B7-H4 antibody or immunoconjugate for use in a method of treating an individual having a B7-H4-positive cancer, the method comprising administering to the individual an effective amount of the anti-B7-H4 antibody or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.

[0373] In a further aspect, the invention provides for the use of an anti-B7-H4 antibody or immunoconjugate in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of B7-H4-positive cancer. In a further embodiment, the medicament is for use in a method of treating B7-H4-positive cancer, the method comprising administering to an individual having B7-H4-positive cancer an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.

[0374] In a further aspect, the disclosure provides a method for treating B7-H4-positive cancer. In one embodiment, the method comprises administering to an individual having such B7-H4-positive cancer an effective amount of an anti-B7-H4 antibody or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.

[0375] An B7-H4-positive cancer according to any of the above embodiments may be, e.g., B7-H4-positive breast cancer, B7-H4-positive ovarian cancer, and B7-H4-positive endometrial cancer. In some embodiments, an B7-H4-positive cancer is a cancer that receives an anti-B7-H4 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B. In another embodiment, a B7-H4-positive cancer expresses B7-H4 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B. In some embodiments, a B7-H4-positive cancer is a cancer that expresses B7-H4 according to a reverse-transcriptase PCR (RT-PCR) assay that detects B7-H4 mRNA. In some embodiments, the RT-PCR is quantitative RT-PCR.

[0376] An "individual" according to any of the above embodiments may be a human.

[0377] In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-B7-H4 antibodies or immunoconjugate provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-B7-H4 antibodies or immunoconjugates provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-B7-H4 antibodies or immunoconjugates provided herein and at least one additional therapeutic agent, e.g., as described below.

[0378] Antibodies or immunoconjugates of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody or immunoconjugate of the invention may be co-administered with at least one additional therapeutic agent. In certain embodiments, an additional therapeutic agent is Avastin® (bevacizumab), e.g., for the treatment of B7-H4-positive cancer such as B7-H4-positive breast cancer. In certain embodiments, an additional therapeutic agent is Kadcyla® (Trastuzumab emtansine).

[0379] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody or immunoconjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant. Antibodies or immunoconjugates of the invention can also be used in combination with radiation therapy.

[0380] An antibody or immunoconjugate of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intraleisional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

[0381] Antibodies or immunoconjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody or immunoconjugate need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody or immunoconjugate present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described

herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

[0382] For the prevention or treatment of disease, the appropriate dosage of an antibody or immunoconjugate of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody or immunoconjugate, the severity and course of the disease, whether the antibody or immunoconjugate is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody or immunoconjugate, and the discretion of the attending physician. The antibody or immunoconjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μ g/kg to 15 mg/kg (e.g. 0.1mg/kg-10mg/kg) of antibody or immunoconjugate can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody or immunoconjugate would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0383] It is understood that any of the above formulations or therapeutic methods may be carried out using both an immunoconjugate of the invention and an anti-B7-H4 antibody.

H. Articles of Manufacture

[0384] In another aspect of the disclosure an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the disorder and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody or immunoconjugate of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody or immunoconjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

III. EXAMPLES

[0385] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

[0386] The scope of the invention is defined by the appended claims.

A. Human B7-H4 Gene Expression

[0387] Human B7-H4 gene expression was analyzed using a proprietary database containing gene expression information (GeneExpress®, Gene Logic Inc., Gaithersburg, MD). Graphical analysis of the GeneExpress® database was conducted using a microarray profile viewer. **Figure 1** is a graphic representation of human B7-H4 gene expression in various tissues. The scale on the y-axis indicates gene expression levels based on hybridization signal intensity. Dots appear both to the left and to the right of the line extending from the name of each listed tissue. The dots appearing to the left of the line represent gene expression in normal tissue, and the dots appearing to the right of the line represent gene expression in tumor and diseased tissue. **Figure 1** shows increased B7-H4 gene expression in certain tumor or diseased tissues relative to their normal counterparts. In particular, B7-H4 is substantially overexpressed in breast,

endometrial, and ovarian tumors. The highest normal mRNA levels of B7-H4 is observed in breast, kidney, pancreas and ovary. Human B7-H4 protein expression is much lower in normal tissues, with either no expression ~30 tested tissues (including PBMCs, bone marrow, tonsil, and spleen) or low levels of expression in normal breast, ovarian, kidney, pancreatic and placental tissues, consistent with the genelogic data (data not shown).

5

B. Prevalence of Human B7-H4 in Breast and Ovarian Carcinomas

[0388] To evaluate the expression of B7-H4 in breast carcinoma, 185 primary breast carcinomas were acquired from multiple sources. Tissue microarrays (TMAs) were assembled using duplicate cores as described in Bubendorf L, et al., J Pathol. 2001 Sep;195(1):72-9, and included normal breast samples from matched cases.

10

[0389] B7-H4 expression was determined by immunohistochemistry using the A57.1 antibody directed against human B7-H4 (diaDexus, South San Francisco, CAB7-H4 hybridization intensity was scored by a trained pathologist according to the scheme below, taking into account the intensity (silver grains) as well as breadth of staining.

15

- 0 (negative): very weak or no hybridization in >90% of tumor cells
- 1+ (mild): predominant hybridization pattern is weak
- 2+ (moderate): predominant hybridization pattern is moderately strong in the majority (> 50%) of neoplastic cells
- 3+ (strong): predominant hybridization pattern is strong in the majority (>50%) of neoplastic cells

20 The same A57.1 antibody was used to control for the specificity of hybridization in normal breast tissue.

[0390] **Figure 2** shows exemplary breast carcinoma sections with 0, 1+, 2+, and 3+ levels of staining. The deposition of silver grains in the images indicates hybridization of the antibody and expression of B7-H4 protein. ~68% (126/185) of breast carcinoma sections analyzed were B7-H4 positive, showing staining at the 1+, 2+, or 3+ levels, with 32% (59/185) showing 1+ staining, 22% (41/185) showing 2+ staining and 15% (26/185) showing 3+ staining, respectively.

25

Furthermore, approximately ~70% of the B7-H4 positive breast carcinomas showed greater than 80% of tumor cells staining based on TMA cores.

[0391] To evaluate the significance of B7-H4 expression and prevalence in different breast cancer subtypes, breast cancer samples were compiled and categorized in three subtypes based on the human epidermal growth factor receptor 2 (Her2), hormone receptor (HR) and triple negative (TN) status of the primary tumor. The percentage of tumors that expressed B7-H4 was performed and scored as described above.

30

[0392] As shown in **Figure 3A**, B7-H4 expression was prevalent in all breast cancer subtypes, with ~65% of all subtypes being positive (score 1-3). In particular, ~60% of Her2+ and HR+ breast cancer subtypes also expressed B7-H4 and ~80% of TN breast cancer were B7-H4 positive. **Figure 3B** shows the prevalence of 0, 1+, 2+, and 3+ levels of B7-H4 staining in the breast cancer subtypes, measured by immunohistochemistry. ~20% of Her2+ and HR+ breast cancer subtypes and ~25% of TN breast cancer subtype showed a 1+ level of staining for B7-H4. ~28% of Her2+ and TN breast cancer subtypes and ~18% of HR+ breast cancer subtype showed a 2+ level of staining for B7-H4. ~15%, ~20% and ~25% of Her2+, HR+ and TN breast cancer subtypes, respectively, showed a 3+ level of staining for B7-H4.

35

[0393] Western Blot analysis also suggested that overall expression of B7-H4 in breast tumors was ~70%, with substantial high expression in ~40% of those breast tumors, as shown in **Figure 3C**. MX-1 tumor model was used as the endogenous positive control and BT549, a tumor cell line negative for B7-H4, as the endogenous negative control, and 10 different breast tumor samples were evaluated for B7-H4 protein expression as compared to 4 normal breast tissues (normal defined as normal adjacent tissue to tumor). 293 wildtype cells and 293 cells transfected with human B7-H4 were also included as controls. B-actin levels were used to normalize loading inconsistencies.

40

[0394] B7-H4 is expressed in 82% of primary breast tumors (Xentech panel), as detected using the A57.1 antibody using Western blot analysis. As shown in **Figure 3D**, B7-H4 appears as an ~62Kd band in 23/28 primary breast tumors tested.

[0395] Western Blot analysis also suggested that overall expression of B7-H4 in ovarian tumors was ~80%, with substantial high expression in ~60% of those ovarian tumors, as shown in **Figure 3E**.

50

C. Mouse Monoclonal Antibody Generation

[0396] Monoclonal antibodies against human B7-H4 were generated using the following procedures. Two separate groups of Balb/C mice (Charles River Laboratories, Hollister, CA) were hyperimmunized with either 293 cells overexpressing recombinant human B7-H4 or a DNA expression construct of human B7-H4, and a third group of mouse B7-H4 KO BL/6N mice were immunized with a mouse B7-H4 extracellular domain (ECD; amino acids 29-258) with a C-terminal Fc expressed in murine myeloma expression system.

55

[0397] Balb/c mice (Charles River Laboratories International, Inc., Hollister, CA, USA) were injected with either 293 cells overexpressing human B7-H4 in PBS (5 million/dose via intraperitoneal) or huB7-H4 plasmid DNA in lactated

Ringer's solution (via tail vein) followed by a protein boost with recombinant human B7-H4ECD (4 µg/dose via intraperitoneal). Mouse B7-H4 KO BL/6N mice were injected with recombinant mouse B7-H4 ECD as described above (via rear footpads) in adjuvant containing metabolizable squalene (4% v/v), Tween 80 (0.2 % v/v), trehalose 6,6-dimycolate (0.05% w/v) and monophosphoryl lipid A (0.05% w/v; Sigma Aldrich, USA). Serum titers were evaluated by standard enzyme linked immunosorbant assay (ELISA) and FACS following 6-9 injections. Splenic B cells harvested from sera B7-H4 positive mice were fused with mouse myeloma cells (X63.Ag8.653; American Type Culture Collection, Manassas, VA, USA) by electrofusion (Hybrimune; Harvard Apparatus, Inc., Holliston, MA, USA). After 10-14 days, hybridoma supernatants were screened for antibody secretion by ELISA. All positive clones were then expanded and re-screened for binding to hubB7-H4 and muB7-H4 by ELISA and FACS. Four hybridoma clones were identified: 1D11 (identified from the mouse B7-H4 immunized mB7-H4 KO mice), 2.32D6 (identified from the DNA immunized mice with human B7-H4) and 9B9 and 3.22.C10 (identified from the cellular immunization with 293 cells overexpressing recombinant human B7-H4) reacted strongly by fluorescent activated cell sorting (FACs) with stable cell line expressing recombinant human-, cynomolgus- and mouse-B7-H4.

[0398] Figure 4A shows certain monoclonal antibodies generated, along with certain properties, some of which will be described in further detail below.

D. Cloning and Chimerization of Mouse Monoclonal Antibodies

[0399] Monoclonal antibodies 1D11, 32D6, 9B9 and 22C10 were cloned and chimerized as follows.

[0400] Total RNA was extracted from hybridoma cells producing murine 1D11, 32D6, 9B9 and 22C10 using standard methods. The variable light (VL) and variable heavy (VH) domains were amplified using RT-PCR with degenerate primers to the heavy and light chains. The forward primers were specific for the N-terminal amino acid sequence of the VL and VH regions. Respectively, the LC and HC reverse primers were designed to anneal to a region in the constant light (CL) and constant heavy domain 1 (CH1), which are highly conserved across species. The polynucleotide sequence of the inserts was determined using routine sequencing methods. The 1D11 VL and VH amino acid sequences are shown in SEQ ID NOs: 3 and 4. The 1D11 heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 5, 6, and 7, respectively. The 1D11 light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 8, 9, and 10, respectively. The 32D6 VL and VH amino acid sequences are shown in SEQ ID NOs: 11 and 12. The 32D6 heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 13, 14, and 15, respectively. The 32D6 light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 16, 17, and 18, respectively. The 9B9 VL and VH amino acid sequences are shown in SEQ ID NOs: 19 and 20. The 9B9 heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 21, 22, and 23, respectively. The 9B9 light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 24, 25, and 26, respectively. The 22C10 VL and VH amino acid sequences are shown in SEQ ID NOs: 27 and 28. The 22C10 heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 29, 30, and 31, respectively. The 22C10 light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 32, 33, and 34, respectively. An alignment of the light chain and heavy chain variable regions of antibodies 1D11, 32D6, 9B9 and 22C10 are shown in Figure 5.

[0401] Each antibody was chimerized by cloning the mouse heavy chain variable region onto a human IgG1 heavy chain constant region and cloning the light chain variable region onto a human kappa light chain constant region, except for 9B9 which was cloned onto a human lambda light chain constant region.

E. Humanization of 1D11 and 22C10

[0402] Monoclonal antibody 1D11 and 22C10 were humanized as described below. Residue numbers are according to Kabat et al., Sequences of proteins of immunological interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991).

Direct hypervariable region grafts onto the acceptor human consensus framework

[0403] Variants constructed during the humanization of 1D11 and 22C10 were assessed in the form of an IgG. The VL and VH domains from murine 1D11 and 22C10 were aligned with the human VL kappa I (VL_{KI}) and human VH subgroup I (VH_I) consensus sequences.

[0404] Hypervariable regions from the murine 1D11 (mu1D11) antibody were engineered into VL_{KI} and VH_I acceptor frameworks to generate humanized 1D11.v1 (h1D11.v1), 1D11.v2 (h1D11.v2), 1D11.v3 (h1D11.v3), 1D11.v4 (h1D11.v4), 1D11.v1.1 (h1D11.v1.1), 1D11.v1.2 (h1D11.v1.2), 1D11.v1.3 (h1D11.v1.3), 1D11.v1.4 (h1D11.v1.4), 1D11.v1.5 (h1D11.v1.5), 1D11.v1.6 (h1D11.v1.6), 1D11.v1.7 (h1D11.v1.7), 1D11.v1.8 (h1D11.v1.9) and 1D11.v1.9 (h1D11.v1.9). Specifically, from the mu1D11 VL domain, positions 24-34 (L1), 50-56 (L2) and 89-97 (L3) were grafted into VL_{KI}. From the mu1D11 VH domain, positions 26-35 (H1), 50-65 (H2) and 95-102 (H3) were grafted into VH_I.

[0405] In addition, certain residues were found to be part of the framework residues acting as "Vernier" zone, which may adjust CDR structure and fine-tune the antigen fit. See, e.g., Foote and Winter, J. Mol. Biol. 224: 487-499 (1992) (Figures 5 and 6). These CDR definitions include positions defined by their sequence hypervariability (Wu, T. T. & Kabat, E. A. (1970)), their structural location (Chothia, C. & Lesk, A. M. (1987)) and their involvement in antigen-antibody contacts (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)). For example, the following positions in the VH and VL were retained from the mouse sequence in the following humanized 1D11 variants:

5 h1D11.v1 -- positions 67, 69 and 71 in framework III of VH; position 49 in framework II of VL as well as positions 69 and 71 in framework III of VL
 10 h1D11.v2 -- positions 67, 69 and 71 in framework III of VH; position 49 in framework II of VL as well as position 71 in framework III of VL
 h1D11.v3 -- positions 67, 69, 71 and 73 in framework III of VH; position 49 in framework II of VL as well as positions 58,69 and 71 in framework III of VL
 15 h1D11.v4 -- positions 67, 69, 71, 73 and 75 in framework III of VH; position 49 in framework II of VL as well as positions 58,69 and 71 in framework III of VL
 h1D11.v1.1 -- positions 67, 69 and 71 in framework III of VH; positions 69 and 71 in framework III of VL
 h1D11.v1.2 -- positions 67, 69 and 71 in framework III of VH; position 49 in framework II of VL as well as position 71 in framework III of VL
 20 h1D11.v1.3 -- positions 67, 69 and 71 in framework III of VH; position 49 in framework II of VL as well as position 69 in framework III of VL
 h1D11.v1.4 -- positions 69 and 71 in framework III of VH; position 49 in framework II of VL as well as positions 69 and 71 in framework III of VL
 h1D11.v1.5 -- positions 67 and 71 in framework III of VH; position 49 in framework II of VL as well as positions 69 and 71 in framework III of VL
 25 h1D11.v1.6 -- positions 67 and 69 in framework III of VH; position 49 in framework II of VL as well as positions 69 and 71 in framework III of VL
 h1D11.v1.7 -- positions 67 and 69 in framework III of VH; positions 69 and 71 in framework III of VL
 h1D11.v1.8 -- position 67 in framework III of VH; positions 69 and 71 in framework III of VL
 hD11.v1.9 - no changes in VH; positions 69 and 71 in framework III of VL
 30

[0406] The light chain variable region sequence and heavy chain variable region sequence for the various humanized variants of 1D11 are shown in **Figures 6** and **7**, respectively.

[0407] Among all four h1D11 variants (h1D11.v1-4), h1D11.v1 was shown to retain the closest affinity by comparison with mouse 1D11 by FACS on 293 cells expressing human B7-H4. As a result, additional h1D11.v1 variants were generated by modifying different Vernier positions of both heavy and light chain variable regions, as described above.

[0408] Hypervariable regions from the murine 22C10 (mu22C10) antibody were engineered into VL_{KI} and VH_I acceptor frameworks to generate various humanized 22C10. Specifically, from the mu22C10 VL domain, positions 24-34 (L1), 50-56 (L2) and 89-97 (L3) were grafted into VL_{KI}. From the mu22C10 VH domain, positions 26-35 (H1), 50-65 (H2) and 95-102 (H3) were grafted into VH_I.

[0409] For example, the following positions in the VH and VL were retained from the mouse sequence in the following humanized 22C10 variants:

45 h22C10.v1 -- positions 67, 69, 71 and 93 in framework III of VH; positions 46 and 47 in framework II of VL as well as position 71 in framework III of VL
 h22C10.v2 -- positions 67, 69, 71 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v3 -- positions 67, 69, 71, 73 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v4 -- positions 67, 69, 71, 76 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v5 -- positions 67, 69, 71, 75, 76 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v2.1 -- positions 67, 69, 71 and 93 in framework III of VH; position 47 in framework II of VL
 50 h22C10.v2.2 -- positions 67, 69, 71 and 93 in framework III of VH; position 46 in framework II of VL
 h22C10.v2.3 -- positions 69, 71 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v2.4 -- positions 67, 71 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v2.5 -- positions 67, 69 and 93 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v2.6 -- positions 67, 69 and 71 in framework III of VH; positions 46 and 47 in framework II of VL
 h22C10.v2.7 - no changes in VH; positions 46 and 47 in framework II of VL
 h22C10.v2.8 - no changes in VH; position 46 in framework II of VL
 55

[0410] The light chain variable region sequence and heavy chain variable region sequence for the various humanized

variants of 22C10 are shown in **Figures 8** and **9**, respectively.

[0411] The humanized variants of 1D11 and 22C10 were generated by Kunkel mutagenesis using a separate oligonucleotide for each hypervariable region. Correct clones were identified by DNA sequencing.

5 Assessment of variants

[0412] For screening purposes, IgG variants were initially produced in 293 cells. Vectors coding for VL and VH were transfected into 293 cells. IgG was purified from cell culture media by protein A affinity chromatography.

10 **[0413]** The small-scale preps were initially screened by FACS and Scatchard Analyses to determine species-specificity and affinity (Kd) to recombinant and endogenous B7-H4. Initial EC₅₀ and species specificity were determined by incubating different concentrations (0-10 µg/ml) of the humanized variants with 293 cells overexpressing recombinant human-, cynomolgus-, or mouse-B7-H4, and the tumor cell line, MX-1, expressing endogenous human B7-H4, at 4°C for 40 minutes followed by a wash and staining with a secondary goat-anti-human IgG antibody conjugated to Dylight-650 for 20 minutes at 4°C. The fluorescent signal was acquired with a BD FACS Calibur and EC₅₀ values were determined with 15 the Graph Pad program Prism 4.

1. Species Cross-Reactivity

20 **[0414]** Monoclonal antibodies were tested to determine if they cross-react with B7-H4 from species other than human.

Figure 10 shows an alignment between human (SEQ ID NO: 73), chimp (SEQ ID NO: 81), cynomolgus monkey (SEQ ID NO: 75), rat (SEQ ID NO: 77) and mouse (SEQ ID NO: 79) B7-H4. Residues that are identical among all five species are indicated by grouping within the red box. Residues that are different are indicated by a red dot. The B7-H4 orthologs have very high sequence identity: human B7-H4 100%; chimp B7-H4 96.09%; cynomolgus monkey B7-H4 98.6%, rat B7-H4 86.87%, and mouse B7-H4 87.63%). In particular, rat B7-H4 is 97.17% identical to mouse B7-H4. The B7-H4 orthologs also have very high sequence similarity: human B7-H4 100%; chimp B7-H4 97.42%; cynomolgus monkey B7-H4 98.8%, rat B7-H4 89.3%, and mouse B7-H4 90.12%).

25 **[0415]** Binding to each species of B7-H4 was determined by FACS analysis of 293 cells stably transfected with B7-H4 (human, chimp, cynomolgus monkey, rat, or mouse B7-H4); stained Dylight-650 conjugated goat anti-human antibody. Untransfected 293 cells do not normally express B7-H4.

30 **[0416]** As shown in **Figure 11**, representative FACS screen data shows hu1D11v1.7-9 and hu 22C10v2.7-8 binding to recombinant human, cynomolgus, and mouse B7-H4 with EC50 in the range of the parent chimeric antibody.

2. Antibody Affinities

35 **[0417]** Scatchard analysis was performed following standard procedures (Holmes et al., *Science* 256:1205-1210 (1992)) to determine the relative binding affinities of ch1D11, ch9B9, ch2210 and ch32D6 antibodies.

40 **[0418]** Anti-B7-H4 antibodies were [¹²⁵I] labeled using the indirect Iodogen method. The [¹²⁵I] labeled anti-B7-H4 antibodies were purified from free ¹²⁵I-Na by gel filtration using a NAP-5 column (GE Healthcare); the purified iodinated anti-B7-H4 antibodies had a range of specific activities of 8-10 µCi/µg. Competition assay mixtures of 50 µL volume containing a fixed concentration of [¹²⁵I] labeled antibody and decreasing concentrations of serially diluted, unlabeled antibody were placed into 96-well plates. 293 cells stably expressing human, cyno, rat, or mouse B7-H4 or MX-1 tumor cells were cultured in growth media at 37°C in 5% CO₂. Cells were detached from the flask using Sigma Cell Dissociation Solution and were washed with binding buffer, which consisted of Dulbecco's Modified Eagle Medium (DMEM) with 1% bovine serum albumin (BSA), 300 mM human IgG and 0.1% sodium azide. The washed cells were added to the 96 well plates at a density of 100,000 cells in 0.2 mL of binding buffer. The final concentration of the [¹²⁵I] labeled antibody in each well was ~250 pM. The final concentration of the unlabeled antibody in the competition assay ranged from 1000 nM through ten 2-fold dilution steps to a 0 nM buffer-only assay. Competition assays were carried out in triplicate. Competition assays were incubated for 2 hours at room temperature. After the 2-hour incubation, the competition assays were transferred to a Millipore Multiscreen filter plate (Billerica, MA) and washed 4 times with binding buffer to separate the free from bound [¹²⁵I] labeled antibody. The filters were counted on a Wallac Wizard 1470 gamma counter (PerkinElmer Life and Analytical Sciences Inc.; Wellesley, MA). The binding data was evaluated using NewLigand software (Genentech), which uses the fitting algorithm of Munson and Robard to determine the binding affinity of the antibody (Munson and Robard 1980).

45 **[0419]** As shown in **Figure 4A**, ch1D11 bound to human B7-H4, cyno B7-H4, mouse B7-H4, and rat B7-H4 expressed on stably transfected 293 cells with affinities of 6.1 nM, 4.1 nM, 9.4 nM and 4.1 nM, respectively. ch22C10 bound to human B7-H4, cyno B7-H4, mouse B7-H4, and rat B7-H4 expressed on stably transfected 293 cells with affinities of 6.6 nM, 4.6 nM, 18.3 nM and 5.7 nM, respectively. ch9B9 bound to human B7-H4, cyno B7-H4, mouse B7-H4, and rat B7-H4 expressed on stably transfected 293 cells with affinities of 6.6 nM, 5.2 nM, 13.7 nM and 4.7 nM, respectively. ch32D6

bound to human B7-H4 and cyno B7-H4 expressed on stably transfected 293 cells with affinities of 4.8 nM and 3.1 nM, respectively.

[0420] The affinities of the various humanized anti-B7-H4 antibodies were also evaluated using Scatchard analysis as described above. MX-1 tumor cells stably expressing human B7-H4 were cultured in growth media at 37°C in 5% CO₂. As shown in **Figure 12**, hu1D11.v1.7, hu1D11.v1.8 and hu1D11.v1.9 bound to human B7-H4 with affinities of 8.3 nM, 8.7 nM and 7.8 nM, respectively (compared to 7.8 nM for the parental 1D11 antibody). Hu22C10.v2.7 and hu22C10.v2.8 bound to human B7-H4 with affinities of 6.3 nM and 10 nM, respectively (compared to 4.9 nM for the parental 22C10 antibody).

10 F. Monoclonal Antibody Epitope Grouping

[0421] To determine the epitope grouping of the monoclonal antibodies, FACS analysis was performed to assess whether other antibodies could displace a reference antibody..

[0422] Epitope grouping was determined using a cell-based competition binding FACS assay. 293 cells expressing recombinant human B7-H4 were incubated with a Dylight-488-labeled tracer antibody (0.3-1 μ g/ml) in the presence of unlabeled antibody (0, 0.05, 0.5, 5, 50 μ g/ml). When the tracer is displaced by unlabeled antibody, competition has occurred indicating that the antibody binds to the same or similar region on B7-H4 - this should occur when the same antibody is used as tracer and competitor. When there is no displacement of tracer by a different unlabeled antibody, the unlabeled antibody is binding to a different region in B7-H4.

[0423] To determine whether the B7-H4 antibodies bind to either the Ig-V or Ig-C domain of B7-H4, chimeric Ig domain molecules were engineered that contain either a B7-H4 (IgV; G28-F150 including spacer S151-V157)-irrelevant (Ig-C) (construct-88) or an irrelevant (Ig-V)-B7-H4 (Ig-C; D158-G236 including TM/CD D237-K282) (construct-88B) membrane protein using standard molecular cloning methods. N-terminal or cytoplasmic tags were attached to confirm that 293 cells transfected with these constructs express protein on the cell membrane (data not shown). Briefly, 293 cells were transiently transfected with constructs 88 & 88B using polyfect. After 48 hours, the cells were stained with 10 μ g/ml of Dylight-488 or - 650 labeled ch9B9, ch1D11, ch22C10 or ch32D6 for 30-40 minutes at 4°C, washed and analyzed on a BD FACS calibur.

[0424] In addition, the results were independently confirmed with an engineered soluble B7-H4 (Ig-V; G28-V157)-Fc fusion protein. When incubated at concentrations of 3-300 fold of a dye-labeled tracer antibody, binding of the tracer was blocked to 293-huB7-H4 cells as determined by FACS.

[0425] The B7-H4 (Ig-V) domain contains a single N-linked glycosylation site (N112-S114), and to determine whether glycosylation influences binding of the antibodies to B7-H4, S114 was substituted with alanine using standard site-specific mutagenesis to prevent glycosylation in the full-length human B7-H4 membrane construct. The mutated S114A human B7-H4 constructs were transfected into 293 cells with polyfect, and 48 hours later analyzed along with the 293-huB7-H4 stable cell line for antibody binding by FACS.

[0426] **Figure 4A** summarizes those results in the column titled "epitope group." As shown in Figure 4, antibodies 1D11 and 9B9 both bind to an epitope grouped under "A" while antibody 22.C10 binds to an epitope grouped under "B" and antibody 32D6 binds to an epitope grouped under "C".

[0427] It was further confirmed that three monoclonal antibodies definitely bound to the B7-H4 Ig-V domain with ch22C10 possibly binding an epitope comprising both Ig-V/Ig-C and that such binding was glycosylation independent - all 4 antibodies bound 100-fold more than the isotype control. Representative data for ch1D11 and ch22C10 are shown in Figure 4B. The version of ch1D11 used was a slightly modified version of ch1D11 in which the 1D11 mAb light chain contained a substituted at C43G. No binding was detected by any of the monoclonal antibodies to the B7-H4 Ig-C domain.

45 G. Internalization of anti-B7-H4 Antibody

[0428] One desirable attribute of an ADC target is the ability to internalize the antibody into a degradative compartment in the cell. To determine whether anti-B7-H4 antibody gets internalized upon binding, SKBR3 adenocarcinoma cells were seeded in cell culture treated 4-well chamber slides (Nalge Nunc International), and incubated for 2 hours at 4°C with either Dylight 594 conjugated anti-B7-H4 9B9 mAb (10 μ g/mL) or anti-EGF-Alexa 488 (3 μ g/mL) as membrane staining controls. For internalization, both were added and incubated for 2 hours at 4°C. Cells were then washed and subjected to a 16 hour chase in the presence of lysosomal protease inhibitors pepstatin (5 μ g/mL)/leupeptin (10 μ g/mL). All treatment groups were followed by fixation in 3% Para formaldehyde (Polysciences, Inc.) for 20 min. at room temperature and washed with 50 mM ammonium chloride and PBS, and subsequent nuclear staining with DAPI. Leica SP5 confocal microscope (Leica Microsystems) was used for image analyses.

[0429] As shown in **Figure 13**, considerable overlap of 9B9 and EGF (used as a lysosomal marker) staining was apparent within the cells. These results predict that an anti-B7-H4 ADC should effectively internalize, undergo degradation and release drug to kill cancer cells.

[0430] In order to demonstrate that anti-B7-H4 antibodies reach lysosomes, ch1D11 and ch22C10 anti-B7-H4 antibodies labeled with a dye conjugate were incubated with MX-1 carcinoma cells and fluorescence resonance energy transfer (FRET) was used to track the intracellular location of the antibodies. FRET is a mechanism of energy transfer between two chromophores - in this case a donor and an acceptor dye. Briefly, either ch1D11 or ch22C10 were conjugated to two dyes, FAM and TAMRA, held together by a peptide spacer containing a cathepsin cleavage site. In the uncleaved state, the green dye (donor) is quenched due to the close proximity of the red dye (acceptor), so membrane and cytosolic staining appears red. When the antibody conjugate enters the lysosome, the lysosomal enzyme Cathepsin cleaves the peptide spacer increasing the distance of the donor from the acceptor, thus preventing the energy transfer to the red dye and allowing the green dye to be visible. To accomplish this, cells were incubated with 2 μ g/ml of antibody-conjugate on ice for 30 minutes. The cells were immediately imaged to show membrane staining (T0) and with a Leica SP5 confocal microscope with time-lapsed photography over a 10 hour period at 37°C. As shown in **Figure 14**, both ch1D11 and ch22C10 are localized in the lysosome - merged images of intact (red) and cleaved (green) conjugate show yellow regions where both conjugates have co-localized in the lysosome.

15 H. Production of Anti-B7-H4 Antibody Drug Conjugates

[0431] For larger scale antibody production, antibodies were produced in CHO cells. Vectors coding for VL and VH were transfected into CHO cells and IgG was purified from cell culture media by protein A affinity chromatography.

[0432] Anti-B7-H4 antibody-drug conjugates (ADCs) were produced by conjugating 1D11, 22C10 and 9B9 to the drug-linker moiety MC-vc-PAB-MMAE, which is depicted herein. For convenience, the drug-linker moiety MC-vc-PAB-MMAE is sometimes referred to in these Examples and in the Figures as "vcMMAE" or "VCE." Prior to conjugation, the antibodies were partially reduced with TCEP using standard methods in accordance with the methodology described in WO 2004/010957 A2. The partially reduced antibodies were conjugated to the drug-linker moiety using standard methods in accordance with the methodology described, e.g., in Doronina et al. (2003) Nat. Biotechnol. 21:778-784 and US 2005/0238649 A1. Briefly, the partially reduced antibodies were combined with the drug-linker moiety to allow conjugation of the drug-linker moiety to reduced cysteine residues of the antibody. The conjugation reactions were quenched, and the ADCs were purified. The drug load (average number of drug moieties per antibody) for each ADC was determined and was between 3.5-3.9 (auristatin) and 1.6-1.9 (nemorubicin) for the anti-B7-H4 antibodies.

[0433] Alternatively, anti-B7-H4 antibody-drug conjugates (ADCs) were produced by conjugating 1D11 to the drug-linker moiety PNU-159682 maleimide with acetal linker (PNU-159682 maleimide acetal linker), which is depicted herein.

I. Efficacy of anti-B7-H4 Antibody Drug Conjugates in MX-1 Human Breast Cancer Cell Line Xenograft

[0434] The efficacy of the anti-B7-H4 ADCs was investigated using a MX-1 human breast cancer xenograft model. The MX-1 cell line is a triple negative (TN; ER(-) / PR(-) / Her2(-)) breast ductal carcinoma cell line. B7-H4 is highly expressed in MX-1 cells, and was confirmed IHC, FACS, IF and confocal microscopy and Western blot. MX-1 tumor fragments (1 mm³) (B7-H4-positive by FACS using 9B9) were implanted subcutaneously into the dorsal flank of 10 mice/group and when implants reached 100-150 mm³ post-inoculation, mice were given a single intravenous injection of 3 mg/kg or 10 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate, 3 mg/kg or 10 mg/kg ch9B9-vcMMAE antibody-drug conjugate, ch22C10-vcMMAE antibody-drug conjugate, ch1D11-vcMMAE antibody-drug conjugate, or 10 mg/kg ch9B9 naked antibody; or with vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds at 1, 7 and 14 days post injection.

[0435] As shown in **Figure 15**, substantial tumor growth inhibition was achieved with all three anti-B7-H4 antibody-drug conjugates at both concentrations tested.

45 J. Efficacy of anti-B7-H4 Antibody Drug Conjugates in HBCX-24 Breast Cancer Cell Line Xenograft

[0436] The efficacy of the anti-B7-H4 ADCs was investigated using a HBCX-24 breast cancer xenograft model. HBCX-24 cell line is a triple negative (TN; ER(-)/PR(-)/Her2(-)) breast carcinoma cell line. B7-H4 is highly expressed in HBCX-24 breast cancer cells, and was confirmed by IHC, FACS, IF and confocal microscopy and Western blot. There was a prevalence of 1+ and 2+ levels of B7-H4 staining in the HBCX-24 breast cancer cells, measured by immunohistochemistry. HBCX-24 tumor fragments (20 mm³) were implanted subcutaneously into the dorsal flank of 5-10 mice/group and when implant reached 75-200 mm³ post-inoculation, mice were given a single intravenous injection of 6 mg/kg or 10 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate, 3 mg/kg, 6 mg/kg or 10 mg/kg ch9B9-vcMMAE antibody-drug conjugate, or 10 mg/kg ch9B9 naked antibody; or with vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds 1, 7 and 14 days post injection.

[0437] As shown in **Figure 16**, substantial tumor growth inhibition was achieved with ch9B9 anti-B7-H4 antibody-drug conjugates at all concentrations tested.

K. Efficacy of anti-B7-H4 Antibody Drug Conjugates in MX-1 Breast Cancer Cell Xenograft

[0438] The efficacy of anti-B7-H4 ADCs produced by conjugating 1D11 to the drug-linker moiety PNU-159682 maleimide with acetal linker was investigated using a MX-1 breast cancer xenograft model. MX-1 tumor fragments (1 mm³) were implanted subcutaneously into the dorsal flank of 10 mice/group and when implants reached 100-150 mm³ post-inoculation, mice were given a single intravenous injection of 0.1 mg/kg, 0.5 mg/kg or 2.5 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate, or 0.1 mg/kg, 0.5 mg/kg or 2.5 mg/kg ch1D11-PNU-159682 maleimide with acetal linker; or with vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds at 1, 7, and 14 days post injection.

[0439] As shown in **Figure 17**, the 2.5 mg/kg dose of ch1D11 ADC was found to retard tumor growth, while the lower doses of 0.1 mg/kg and 0.5 mg/kg had no appreciable effect on tumor growth.

L. Efficacy of anti-B7-H4 Antibody Drug Conjugates in MX-1 Breast Cancer Cell Xenograft

[0440] The efficacy of anti-B7-H4 ADCs of hu22C10v2.7 was investigated using the MX-1 xenograft model as described in Example K. Mice were segregated into groups of 10, and administered a single intravenous dose of hu22C10v2.7 naked antibody at 12 mg/kg; hu22C10v2.7-vc-PAB-MMAE at 0.5 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, 12 mg/kg; human anti-gD-5B6-vc-PAB-MMAE at 6 or 12 mg/kg; or vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds. Tumor growth inhibition (TGI) was calculated as percent area under the fitted tumor volume-time curve (AUC) per day for each treatment group in relation to the vehicle, using the following formula:

$$\% \text{TGI} = 100 \cdot (1 - \frac{\text{AUC}_{\text{treatment/Day}}}{\text{AUC}_{\text{vehicle/Day}}})$$

A TGI value of 100% indicates tumor stasis, a TGI of > 1% but < 100% indicates tumor growth delay, and a TGI of > 100% indicates tumor regression.

[0441] As shown in **Figure 18**, hu22C10v2.7-vc-PAB-MMAE showed significant tumor growth inhibition of 91%, 106% and 108% for the 6, 9, and 12 mg/kg doses, respectively; with 38% partial response (PR) and 62% complete response (CR) at the 9 mg/kg dose. No response was observed with either the vehicle or control ADC.

M. Efficacy of anti-B7-H4 Antibody Drug Conjugates in HCC-1569x2 Breast Cancer Cell Xenograft

[0442] The efficacy of anti-B7-H4 ADCs of hu22C10v2.7 was investigated using the HCC-1569x2 (Her2⁺/ER⁻) breast cancer cell xenograft model. B7-H4 is highly expressed in HCC-1569x2 xenografts, and was confirmed by IHC and FACS (**Figure 19A**). SCID beige mice were inoculated with HCC-1569x2 cells (5x10⁶ in matrigel) into their mammary fat pad and monitored until tumor volumes reached 250-375 mm³. Mice were segregated into groups of 10, and administered a single intravenous dose of ch22C10-vc-PAB-MMAE at 5 mg/kg, or hu22C10v2.7-vc-PAB-MMAE at 3mg/kg or 5 mg/kg, or human anti-gD-5B6-vc-PAB-MMAE at 5 mg/kg, or vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds.

[0443] As shown in **Figure 19B**, ch22C10-vc-PAB-MMAE and hu22C10v2.7-vc-PAB-MMAE showed tumor growth inhibition (TGI) of 107% and 105%, respectively, at the 5 mg/kg dose. There was no significant difference in efficacy between the chimeric or humanized 22C10 antibody drug conjugates. The lower 3 mg/kg dose of hu22C10v2.7-vc-PAB-MMAE showed tumor growth inhibition (TGI) of 94% compared to either the vehicle or control ADC.

[0444] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention.

Table of Sequences

SEQ ID NO	Description	Sequence
1	huk ₁	DIQMTQSPSS LSASVGDRVT ITCRASQGIS SYLAWYQQKP GKAPKLLIYA ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSYYPFTFGQ GTKVEIKR
2	huVH ₁	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYIHWVRQA PGQGLEWIGW INPGSGNTNY AQKFQGRVTI TRDTSTSTAY LELSSLRSED TAVYYCARFD YWGQGTLVTV SS

(continued)

SEQ ID NO	Description	Sequence
5	3 mu1D11 light chain variable region	DIQMTQSPSS LSASLGGKVT ITCKASQGFN KYVAWYQHKP GQCPRLLIHY TSTLQPGIPA RFSGSGSGRD YSFSISNLEP EDSATYFCLQ YGNLLYAFGG GTKLEIKR
10	4 mu1D11 heavy chain variable region	QVQLQQSGAE LVRPGTSVKM SCKASGYTFT SYWIGWAKQR PGHGFEWIGD IYPGGGYTNY NEKFKGKATL TADKSSSTAY MQFSSLTSED SAIYYCARLD GSSYRGAMDS WGQGTSITVS S
15	5 mu1D11 HVR H1	GYTFTSYYIH
20	6 mu1D11 HVR H2	DIYPGGGYTN YNEKFKG
25	7 mu1D11 HVR H3	LDGSSYRGAM DS
30	8 mu1D11 HVR L1	KASQGFNKYV A
35	9 mu1D11 1 HVR L2	YTSTLQP
40	10 mu1D11 1 HVR L3	LQYGNLLYA
45	11 mu32D6 light chain variable region	DIVMTQSPSS LIVTAGEKVT MSCRSSQSLF DSGSQRNYLT WFHQKPGRPP KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQTEDLA VYFCQNDYSF PFTFGSGTKL EEK
50	12 mu32D6 heavy chain variable region	EVQLQQSGPD LVKPGASVKI SCKASGYSFT GYYIHWMKQS HGKSLEWIGR VNPNNNGDPIY NQKFRGKAIL TVDQSSNTAY MELRSLTSEA SAVYYCARVL FYYGSPFAYW GQGTLVTVSA
55	13 mu32D6 HVR H1	GYSFTGYYIH
60	14 mu32D6 HVR H2	RVNPNNGDPIYNQKFRG
65	15 mu32D6 HVR H3	VLFYYGSPFAY
70	16 mu32D6 HVR L1	RSSQSLFDGSQQRNYLT
75	17 mu32D6 HVR L2	WASTRES
80	18 mu32D6 HVR L3	QNDYSFPFT
85	19 mu9B9 light chain variable region	QAVVTQESAL TTSPGDTVTL TCRSSTGAVT TSNYANWQE KPDHLFTGLI GGTNNRVPGV PARFSGSLIG DKAALTITGA QTEDEAMYFC ALWYNNHWVF GGGTKLE
90	20 mu9B9 heavy chain variable region	QVQLQQSGAE LMKPGASVKM SCKATGYTFS SYWIEWVKQR PGHGLEWIGE ILPGTSITTY NAKFKVKATF TADTSSNTAY MQLSSLTSED SAVYFCARYY FGSSSFYFDY WGQGTSLTVS S
95	21 mu9B9 HVR H1	GYTFSSYIWIE
100	22 mu9B9 HVR H2	EILPGTSITTYNAKFKV
105	23 mu9B9 HVR H3	ARYYFGSSSFYFDY
110	24 mu9B9 HVR L1	RSSTGAVTTSNYAN
115	25 mu9B9 HVR L2	GTNNRVP
120	26 mu9B9 HVR L3	ALWYNNHWVV
125	27 mu22C10 light chain variable region	QIVLTQSPTI MSASPGEKVT LTCSATSSIS YMHWYQQKPG TSPKGWIYDT SKLAHGVPAR FSGSGSGTSY SLTISSMEAE DAATYYCHQR RSYPFTFGSG TKLEIKR

(continued)

SEQ ID NO	Description	Sequence
5	28	mu22C10 heavy chain variable region QVQLQQPGAE LVKPGTSVKL SCKASGYTFT NFWIHWVIQR PGQGLEWIGE IDPSDSYTNY NQFKKGKATL TVDKSSNTAY MQLSSLTSED SAVYYCSREI TTVDYWGQGT TLTVSS
10	29	mu22C10 HVR H1 GYTFTNFWIH
30	30	mu22C10 HVR H2 EIDPSDSYTNYNQKFKG
31	31	mu22C10 HVR H3 EITTVDY
32	32	mu22C10 HVR L1 SATSSISYMH
33	33	mu22C10 HVR L2 DTSKLAH
34	34	mu22C10 HVR L3 HQRRSYPFT
35	35	hu1D1 1.v1.7 light chain variable region; hu1D1 1.v1.8 light chain variable region; hu1D1 1.v1.9 light chain variable region DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIYY TSTLQPGVPS RFSGSGSGRD YTLTISSLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
36	36	hu1D11.v1.6 heavy chain variable region; hu1D11.v1.7 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKGRATL TRDTSTSTAY LELSSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
37	37	hu1D11.v1.8 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKGRATI TRDTSTSTAY LELSSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
38	38	hu1D11.v1.9 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKGRVTI TRDTSTSTAY LELSSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
39	39	hu1D11.v1 HVR H1 hu1D11.v2 HVR H1 hu1D11.v3 HVR H1 hu1D11.v4 HVR H1 hu1D11.v1.1 HVR H1 hu1D11.v1.2 HVR H1 hu1D11.v1.3 HVR H1 hu1D11.v1.4 HVR H1 hu1D11.v1.5 HVR H1 hu1D11.v1.6 HVR H1 hu1D11.v1.7 HVR H1 hu1D11.v1.8 HVR H1 hu1D11.v1.9 HVR H1 GYTFTSYWIG

(continued)

SEQ ID NO	Description	Sequence
5		
40	hu1D11.v1 HVR H2 hu1D1 1.v2 HVR H2 hu1D1 1.v3 HVR H2 hu1D1 1.v4 HVR H2 hu1D1 1.v1.1 HVR H2 hu1D1 1.v1.2 HVR H2 hu1D1 1.v1.3 HVR H2 hu1D1 1.v1.4 HVR H2 hu1D11.v1.5 HVR H1 hu1D1 1.v1.6 HVR H2 hu1D1 1.v1.7 HVR H2 hu1D1 1.v1.8 HVR H2 hu1D1 1.v1.9 HVR H2	DIYPGGGYTNYNEKFKG
10		
15		
20	41 hu1D11.v1 HVR H3 hu1D11.v2 HVR H3 hu1D11.v3 HVR H3 hu1D11.v4 HVR H3 hu1D11.v1.1 HVR H3 hu1D11.v1.2 HVR H3 hu1D11.v1.3 HVR H3 hu1D11.v1.4 HVR H3 hu1D11.v1.5 HVR H3 hu1D11.v1.6 HVR H3 hu1D11.v1.7 HVR H3 hu1D11.v1.8 HVR H3 hu1D11.v1.9 HVR H3	LDGSSYRGAMDS
25		
30		
35	42 hu1D1 1.v1 HVR L1 hu1D1 1.v2 HVR L1 hu1D1 1.v3 HVR L1 hu1D1 1.v4 HVR L1 hu1D11.v1.1 HVR L1 hu1D1 1.v1.2 HVR L1 hu1D1 1.v1.3 HVR L1 hu1D1 1.v1.4 HVR L1 hu1D11.v1.5 HVR L1 hu1D1 1.v1.6 HVR L1 hu1D1 1.v1.7 HVR L1 hu1D1 1.v1.8 HVR L1 hu1D1 1.v1.9 HVR L1	KASQGFNKYVA
40		
45		

(continued)

SEQ ID NO	Description	Sequence	
5	43	hu1D11.1 HVR L2 hu1D11.v2 HVR L2 hu1D11.v3 HVR L2 hu1D11.v4 HVR L2 hu1D11.v1.1 HVR L2 hu1D11.v1.2 HVR L2 hu1D11.v1.3 HVR L2 hu1D11.v1.4 HVR L2 hu1D11.v1.5 HVR L2 hu1D11.v1.6 HVR L2 hu1D11.v1.7 HVR L2 hu1D11.v1.8 HVR L2 hu1D11.v1.9 HVR L2	YTSTLQP
10			
15			
20	44	hu1D1 1.v1 HVR L3 hu1D1 1.v2 HVR L3 hu1D1 1.v3 HVR L3 hu1D1 1.v4 HVR L3 hu1D1 1.v1.1 HVR L3 hu1D1 1.v1.2 HVR L3 hu1D1 1.v1.3 HVR L3 hu1D1 1.v1.4 HVR L3 hu1D11.v1.5 HVR L3 hu1D1 1.v1.6 HVR L3 hu1D1 1.v1.7 HVR L3 hu1D1 1.v1.8 HVR L3 hu1D1 1.v1.9 HVR L3	LQYGNLLYA
25			
30			
35	45	hu1D11.v1 light chain (LC) framework 1 (FR1) hu1D11.v2 LC FR1 hu1D11.v3 LC FR1 hu1D11.v4 LC FR1 hu1D11.v1.1 LC FR1 hu1D11.v1.2 LC FR1 hu1D11.v1.3 LC FR1 hu1D11.v1.4 LC FR1 hu1D11.v1.5 LC FR1 hu1D11.v1.6 LC FR1 hu1D11.v1.7 LC FR1 hu1D11.v1.8 LC FR1 hu1D11.v1.9 LC FR1	DIQMTQSPSS LSASVGDRVT ITC
40			
45			
50	46	hu1D1 1.v1.1 LC FR2 hu1D1 1.v1.7 LC FR2 hu1D1 1.v1.8 LC FR2 hu1D1 1.v1.9 LC FR2	WYQQKPGKAP KLLIY
55			

(continued)

SEQ ID NO	Description	Sequence
5	47	GVPSRFSGSG SGRDYTLTIS SLQPEDFATY YC
10		hu1D1 1.v1 LC FR3
		hu1D1 1.v1.4 LC FR3
		hu1D11.v1.5 LC FR3
		hu1D1 1.v1.6 LC FR3
		hu1D1 1.v1.7 LC FR3
		hu1D1 1.v1.8 LC FR3
		hu1D1 1.v1.9 LC FR3
15	48	FGQGTKVEIK R
20		hu1D1 1.v1 LC FR4
		hu1D1 1.v2 LC FR4
		hu1D1 1.v3 LC FR4
		hu1D1 1.v4 LC FR4
		hu1D1 1.v1.1 LC FR4
		hu1D1 1.v1.2 LC FR4
		hu1D1 1.v1.3 LC FR4
		hu1D1 1.v1.4 LC FR4
		hu1D11.v1.5 LC FR4
		hu1D1 1.v1.6 LC FR4
		hu1D1 1.v1.7 LC FR4
		hu1D1 1.v1.8 LC FR4
		hu1D1 1.v1.9 LC FR4
30	49	EVQLVQSGAE VKKPGASVKV SCKAS
35		hu1D1 1.v1 heavy chain (HC)
		framework 1 (FR1)
		hu1D1 1.v2 HC FR1
		hu1D1 1.v3 HC FR1
		hu1D1 1.v4 HC FR1
		hu1D1 1.v1.1 HC FR1
		hu1D1 1.v1.2 HC FR1
		hu1D1 1.v1.3 HC FR1
		hu1D1 1.v1.4 HC FR1
		hu1D11.v1.5 HC FR1
		hu1D1 1.v1.6 HC FR1
		hu1D1 1.v1.7 HC
		FR1hu1D1.v1.8 HC FR1
		hu1D1 1.v1.9 HC FR1
45	50	WVRQAPGQGL EWIG
50		hu1D1 1.v1 HC FR2
		hu1D1 1.v2 HC FR2
		hu1D1 1.v3 HC FR2
		hu1D1 1.v4 HC FR2
		hu1D1 1.v1.1 HC FR2
		hu1D1 1.v1.2 HC FR2
		hu1D1 1.v1.3 HC FR2
		hu1D1 1.v1.4 HC FR2
		hu1D11.v1.5 HC FR2
		hu1D1 1.v1.6 HC FR2
		hu1D1 1.v1.7 HC FR2
		hu1D1 1.v1.8 HC FR2
		hu1D1 1.v1.9 HC FR2
55		

(continued)

SEQ ID NO	Description	Sequence
5	51 hu1D1 1.v1.6 HC FR3 hu1D1 1.v1.7 HC FR3	RATLTRDTST STAYLELSSL RSEDTAVYYC AR
10	52 hu1D1 1.v1.8 HC FR3	RATITRDTST STAYLELSSL RSEDTAVYYC AR
15	53 hu1D1 1.v1.9 HC FR3	RVTITRDTST STAYLELSSL RSEDTAVYYC AR
20	54 hu1D1 1.v1 HC FR4 hu1D1 1.v2 HC FR4 hu1D1 1.v3 HC FR4 hu1D1 1.v4 HC FR4 hu1D1 1.v1.1 HC FR4 hu1D1 1.v1.2 HC FR4 hu1D1 1.v1.3 HC FR4 hu1D1 1.v1.4 HC FR4 hu1D11.v1.5 HC FR4 hu1D1 1.v1.6 HC FR4 hu1D1 1.v1.7 HC FR4 hu1D1 1.v1.8 HC FR4 hu1D1 1.v1.9 HC FR4	WGQGTLTVS S
25	55 hu22C10.v2 light chain variable region hu22C10.v3 light chain variable region hu22C10.v4 light chain variable region hu22C10.v5 light chain variable region hu22C10.v2.3 light chain variable region hu22C10.v2.4 light chain variable region hu22C10.v2.5 light chain variable region hu22C10.v2.6 light chain variable region hu22C10.v2.7 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCSATSSIS YMHWYQQKPG KAPKGWIYDT SKLAHGVPSR FSGSGSGTDF TLTISSLQPE DFATYYCHQR RSYPFTFGQG TKVEIK
30	56 hu22C10.v2.7 heavy chain variable region; hu22C10.v2.8 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRVTI TRDTSTSTAY LELESSLRSED TAVYYCAREI TTVDYWGQGT LTVSS
35		
40	57 hu22C10.v2.8 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCSATSSIS YMHWYQQKPG KAPKGWIYDT SKLAHGVPSR FSGSGSGTDF TLTISSLQPE DFATYYCHQR RSYPFTFGQG TKVEIK
45		
50		

(continued)

SEQ ID NO	Description	Sequence	
5	58	hu22C10.v1 HVR H1 hu22C10.v2 HVR H1 hu22C10.v3 HVR H1 hu22C10.v4 HVR H1 hu22C10.v5 HVR H1 hu22C10.v2.1 HVR H1 hu22C10.v2.2 HVR H1 hu22C10.v2.3 HVR H1 hu22C10.v2.4 HVR H1 hu22C10.v2.5 HVR H1 hu22C10.v2.6 HVR H1 hu22C10.v2.7 HVR H1 hu22C10.v2.8 HVR H1	GYTFTNFWIH
10	59	hu22C10.v1 HVR H2 hu22C10.v2 HVR H2 hu22C10.v3 HVR H2 hu22C10.v4 HVR H2 hu22C10.v5 HVR H2 hu22C10.v2.1 HVR H2 hu22C10.v2.2 HVR H2 hu22C10.v2.3 HVR H2 hu22C10.v2.4 HVR H2 hu22C10.v2.5 HVR H2 hu22C10.v2.6 HVR H2 hu22C10.v2.7 HVR H2 hu22C10.v2.8 HVR H2	EIDPSDSYTNYNQKFKG
15	60	hu22C10.v1 HVR H3 hu22C10.v2 HVR H3 hu22C10.v3 HVR H3 hu22C10.v4 HVR H3 hu22C10.v5 HVR H3 hu22C10.v2.1 HVR H3 hu22C10.v2.2 HVR H3 hu22C10.v2.3 HVR H3 hu22C10.v2.4 HVR H3 hu22C10.v2.5 HVR H3 hu22C10.v2.6 HVR H3 hu22C10.v2.7 HVR H3 hu22C10.v2.8 HVR H3	EITTVDY
20	61	hu22C10.v1 HVR L1 hu22C10.v2 HVR L1 hu22C10.v3 HVR L1 hu22C10.v4 HVR L1 hu22C10.v5 HVR L1 hu22C10.v2.1 HVR L1 hu22C10.v2.2 HVR L1	SATSSISYMH
25			
30			
35			
40			
45			
50			
55			

(continued)

SEQ ID NO	Description	Sequence
5	hu22C10.v2.3 HVR L1 hu22C10.v2.4 HVR L1 hu22C10.v2.5 HVR L1 hu22C10.v2.6 HVR L1 hu22C10.v2.7 HVR L1 hu22C10.v2.8 HVR L1	
10		
15		
20		
25		
30		
35		
40		
45		
50		
55		
62	hu22C10.v1 HVR L2 hu22C10.v2 HVR L2 hu22C10.v3 HVR L2 hu22C10.v4 HVR L2 hu22C10.v5 HVR L2 hu22C10.v2.1 HVR L2 hu22C10.v2.2 HVR L2 hu22C10.v2.3 HVR L2 hu22C10.v2.4 HVR L2 hu22C10.v2.5 HVR L2 hu22C10.v2.6 HVR L2 hu22C10.v2.7 HVR L2 hu22C10.v2.8 HVR L2	DTSKLAH
63	hu22C10.v1 HVR L3 hu22C10.v2 HVR L3 hu22C10.v3 HVR L3 hu22C10.v4 HVR L3 hu22C10.v5 HVR L3 hu22C10.v2.1 HVR L3 hu22C10.v2.2 HVR L3 hu22C10.v2.3 HVR L3 hu22C10.v2.4 HVR L3 hu22C10.v2.5 HVR L3 hu22C10.v2.6 HVR L3 hu22C10.v2.7 HVR L3 hu22C10.v2.8 HVR L3	HQRRSYPFT
64	hu22C10.v1 LC FR1 hu22C10.v2 LC FR1 hu22C10.v3 LC FR1 hu22C10.v4 LC FR1 hu22C10.v5 LC FR1 hu22C10.v2.1 LC FR1 hu22C10.v2.2 LC FR1 hu22C10.v2.3 LC FR1 hu22C10.v2.4 LC FR1 hu22C10.v2.5 LC FR1 hu22C10.v2.6 LC FR1 hu22C10.v2.7 LC FR1 hu22C10.v2.8 LC FR1	DIQMTQSPSSLSASVGDRVITIC

(continued)

SEQ ID NO	Description	Sequence	
5	65	hu22C10.v1 LC FR2 hu22C10.v2 LC FR2 hu22C10.v3 LC FR2 hu22C10.v4 LC FR2 hu22C10.v5 LC FR2 hu22C10.v2.3 LC FR2 hu22C10.v2.4 LC FR2 hu22C10.v2.5 LC FR2 hu22C10.v2.6 LC FR2 hu22C10.v2.7 LC FR2	WYQQKPGKAPKGWIY
10	66	hu22C10.v2.8 LC FR2	WYQQKPGKAPKGIIY
15	67	hu22C10.v2 LC FR3 hu22C10.v3 LC FR3 hu22C10.v4 LC FR3 hu22C10.v5 LC FR3 hu22C10.v2.1 LC FR3 hu22C10.v2.2 LC FR3 hu22C10.v2.3 LC FR3 hu22C10.v2.4 LC FR3 hu22C10.v2.5 LC FR3 hu22C10.v2.6 LC FR3 hu22C10.v2.7 LC FR3 hu22C10.v2.8 LC FR3	GVPSRFSGSGSGTDFTLTSSLQPEDFATYYC
20	68	hu22C10.v1 LC FR4 hu22C10.v2 LC FR4 hu22C10.v3 LC FR4 hu22C10.v4 LC FR4 hu22C10.v5 LC FR4 hu22C10.v2.1 LC FR4 hu22C10.v2.2 LC FR4 hu22C10.v2.3 LC FR4 hu22C10.v2.4 LC FR4 hu22C10.v2.5 LC FR4 hu22C10.v2.6 LC FR4 hu22C10.v2.7 LC FR4 hu22C10.v2.8 LC FR4	FGQGTKVEIKR
25			
30			
35			
40			
45			

(continued)

SEQ ID NO	Description	Sequence
5		
69	hu22C10.v1 HC FR1 hu22C10.v2 HC FR1 hu22C10.v3 HC FR1 hu22C10.v4 HC FR1 hu22C10.v5 HC FR1 hu22C10.v2.1 HC FR1 hu22C10.v2.2 HC FR1 hu22C10.v2.3 HC FR1 hu22C10.v2.4 HC FR1 hu22C10.v2.5 HC FR1 hu22C10.v2.6 HC FR1 hu22C10.v2.7 HC FR1 hu22C10.v2.8 HC FR1	EVQLVQSGAEV KKPGASVKVS CKAS
10		
20	70	WVRQAPGQGLEWIG
25		
30		
35	71	RTVI TRDTSTSTAY LELSSLRSED TAVYYCAR
40		
45		
50		
55	72	WGQGT LTVSS
60		
65		
70		
73	Human B7_H4 precursor; signal sequence = amino acids 1-28	MASLGQILFW SIISIIIL A GAI ALI IIGFG ISGRHSITVT TVASAGNIGE DGILSCTFEP DIKLSDIVIQ WLKEGVVLGV

(continued)

SEQ ID NO	Description	Sequence
5		HEFKEGKDEL SEQDEMFRGR TAVFADQVIV GNASLRLKNV QLTDAGTYKC YIITSKGKGN ANLEYKTGAF SMPEVNVDYN ASSETLRCEA PRWFPPQPTVV WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV TESEIKRRSH LQLLNSKASL CVSSFFAISW ALLPLSPYLM LK
10	74 Human B7-H4 mature, without signal sequence; amino acids 29 to 282	FGISGRHSIT VTTVASAGNI GEDGILSCTF EPDIKLSDIV IQWLKEGVLG LVHEFKEGKD ELSEQDEMFR GRTAVFADQV IVGNASLRLK NVQLTDAGTY KCYIITSKGK GNANLEYKTG AFSMPEVNVD YNASSETLRC EAPRWFPPQPT VVWASQVDQG ANFSEVSNTS FELNSENVTM KVVSVLYNVT INNTYSCMIE NDIAKATGDI KVTESEIKRR SHLQLLNSKA SLCVSSFFAI SWALLPLSPY LMLK
15	75 Cynomolgus monkey B7-H4 precursor; signal sequence = amino acids 1-28	MASLGQILFW SIISIIFILA GAIALIIGFG ISGRHSITVT TVASAGNIGE DGILSCTFEP DIKLSDIVIQ WLKEGVIGLV HEFKEGKDEL SEQDEMFRGR TAVFADQVIV GNASLRLKNV QLTDAGTYKC YIITSKGKGN ANLEYKTGAF SMPEVNVDYN ASSETLRCEA PRWFPPQPTVV WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV TESEIKRRSH LQLLNSKASL CVSSFLAISW ALLPLAPYLM LK
20	76 Cynomolgus monkey B7-H4 mature, without signal sequence; amino acids 29-282	FGISGRHSIT VTTVASAGNI GEDGILSCTF EPDIKLSDIV IQWLKEGVIG LVHEFKEGKD ELSEQDEMFR GRTAVFADQV IVGNASLRLK NVQLTDAGTY KCYIITSKGK GNANLEYKTG AFSMPEVNVD YNASSETLRC EAPRWFPPQPT VVWASQVDQG ANFSEVSNTS FELNSENVTM KVVSVLYNVT INNTYSCMIE NDIAKATGDI KVTESEIKRR SHLQLLNSKA SLCVSSFLAI SWALLPLAPY LMLK
25	77 Rat B7-H4 precursor; signal sequence = amino acids 1-28	MASLGQIIFW SIINVIIILA GAIVLIIGFG ISGKHFITVT TFTSAGNIGE DGTLSCTFEP DIKLNIGIVIQ WLKEGIKGLV HEFKEGKDDL SQQHEMFRGR TAVFADQVIV GNASLRLKNV QLTDAGTYTC YIHTSKGKGN ANLEYKTGAF SMPEINVVDYN ASSESLRCEA PRWFPPQPTVA WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV TDSEVKRRSQ LELLNSGPSP CVSSVSAAGW ALLSLSCCLM LR
30	78 Rat B7-H4 mature, without signal sequence; amino acids 29-282	FGISGKHFIT VTTFTSAGNI GEDGTLSCTF EPDIKLNIV IQWLKEGIKG LVHEFKEGKD DLSQQHEMFR GRTAVFADQV VVGNASLRLK NVQLTDAGTY TCYIHTSKGK GNANLEYKTG AFSMPEINVYD YNASSESLRC EAPRWFPPQPT VAWASQVDQG ANFSEVSNTS FELNSENVTM KVVSVLYNVT INNTYSCMIE NDIAKATGDI KVTDSEVKRR SQLELLNSGP SPCVSSVSAAG GWALLSLSCC LMLR
35	79 Mouse B7-H4 precursor; signal sequence = amino acids 1-28	MASLGQIIFW SIINIIILA GAIALIIGFG ISGKHFITVT TFTSAGNIGE DGTLSCTFEP DIKLNIGIVIQ WLKEGIKGLV HEFKEGKDDL SQQHEMFRGR TAVFADQVIV GNASLRLKNV QLTDAGTYTC YIRTSKGKGN ANLEYKTGAF SMPEINVVDYN ASSESLRCEA PRWFPPQPTVA WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV TDSEVKRRSQ LQLLNSGPSP CVFSSAFAAG WALLSLSCCL MLR
40		
45		
50		
55		

(continued)

SEQ ID NO	Description	Sequence
5	80	Mouse B7-H4 mature, without signal sequence; amino acids 29 to 283 FGISGKHFIT VTTFTSAGNI GEDGTLSTF EPDIKLN GIV IQLKEGIKG LVHEFKEGKD DLSQQHEMFR GRTAVFADQV VVGNASLRK NVQLTDAGTY TCYIRTSKGK GNANLEYKTG AFSMPEINVD YNASSESLRC EAPRWFPQPT VAWASQVDQG ANFSEVSNTS FELNSEVNTM KVVSVLYNVT INNTYSCMIE NDIAKATGDI KVTDSEVKRR SQLQLLNSGP SPCVFSSAFA AGWALLSLSC CLMLR
10	81	Chimp B7-H4 precursor; signal sequence = amino acids 1-24 MKPLTSRIIS IIIILAGAIR LIIGFGISGR HSITVTTVAS AGNIGEDGIL SCTFEPDIKL SDIVIQWLKE GVLGLVHEFK EGKDELSEQD EMFRGRTAVF ADQVIVGNAS LRLKNVQLTD AGTYKCYIIT SKGKGNNLE YKTGAFSMPE VNVDYNASSE TLRCEAPRWF PQPTVVWASQ IDQGANFSEV SNTSFELNSE NVTMKVVSVL YNATINNTYS CMIENDIKA TGDIKVTESE IKRRSHLQLL NSKASLCVSS FFAISWALLP LSPYLMNK
15	82	Chimp B7-H4 mature, without signal sequence; amino acids 25 to 278 FGISGRHSIT VTTVASAGNI GEDGILSCTF EPDIKLSDIV IQLKEGVLG LVHEFKEGKD ELSEQDEMFR GRTAVFADQV IVGNASLRK NVQLTDAGTY KCYIITSKGK GNANLEYKTG AFSMPEVNVD YNASSETLRC EAPRWFPQPT VVWASQIDQG ANFSEVSNTS FELNSEVNTM KVVSVLYNAT INNTYSCMIE NDIAKATGDI KVTESEIKRR SHLQLLNSKA SLCVSSFFAI SWALLPLSPY LMLK
20	83	hu1D11.v1 LC FR2 hu1D1 1.v2 LC FR2 hu1D1 1.v3 LC FR2 hu1D1 1.v4 LC FR2 hu1D1 1.v1.2 LC FR2 hu1D1 1.v1.3 LC FR2 hu1D1 1.v1.4 LC FR2 hu1D11.v1.5 LC FR2 hu1D1 1.v1.6 LC FR2 WYQQKPGKAP KLLIH
25	84	hu1D1 1.v2 LC FR3 GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YC
30	85	hu1D11.v3 LC FR3 hu1D11.v4 LC FR3 GIPSRFSGSG SGRDYTLTIS SLQPEDFATY YC
35	86	hu1D1 1.v1.2 LC FR3 GVPSRFSGSG SGTDYTLTIS SLQPEDFATY YC
40	87	hu1D1 1.v1.3 LC FR3 GVPSRFSGSG SGRDFTLTIS SLQPEDFATY YC
45	88	hu1D11.v1 HC FR3 hu1D11.v.2 HC FR3 hu1D11.v.1.1 HC FR3 hu1D11.v.1.2 HC FR3 hu1D11.v.1.3 HC FR3 RATLTADTST STAYLELSSL RSEDTAVYYC AR
50	89	hu1D1 1.v3 HC FR3 RATLTADKST STAYLELSSL RSEDTAVYYC AR
55	90	hu1D1 1.v4 HC FR3 RATLTADKSS STAYLELSSL RSEDTAVYYC AR
	91	hu1D1 1.v1.4 HC FR3 RVTLTADTST STAYLELSSL RSEDTAVYYC AR
	92	hu1D11.v1.5 HC FR3 RATITADTST STAYLELSSL RSEDTAVYYC AR

(continued)

SEQ ID NO	Description	Sequence
5	93 hu1D1 1.v1 light chain variable region; hu1D1 1.v1.4 light chain variable region; hu1D11.v1.5 light chain variable region; hu1D1 1.v1.6 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIHY TSTLQPGVPS RFSGSGSGRD YTTLTISSLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
10	94 hu1D11.v1.3 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIHY TSTLQPGVPS RFSGSGSGRD FTLTISLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
15	95 hu1D1 1.v1.2 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIHY TSTLQPGVPS RFSGSGSGTD YTTLTISSLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
20	96 hu1D1 1.v1.1 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIYY TSTLQPGVPS RFSGSGSGRD YTTLTISSLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
25	97 hu1D11.v2 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIHY TSTLQPGVPS RFSGSGSGTD FTLTISLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
30	98 hu1D11.v3 light chain variable region; hu1D11.v4 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKASQGFN KYVAWYQQKP GKAPKLLIHY TSTLQPGIPS RFSGSGSGRD YTTLTISSLQP EDFATYYCLQ YGNLLYAFGQ GTKVEIKR
35	99 hu1D11.v1.5 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKKGRATI TADTSTSTAY LELESSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
40	100 hu1D11.v1.4 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKKGRVTL TADTSTSTAY LELESSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
45	101 hu1D11.v1 heavy chain variable region; hu1D11.v2 heavy chain variable region; hu1D11.v1.1 heavy chain variable region; hu1D1 1.v1.2 heavy chain variable region; hu1D11.v1.3 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKKGRATL TADTSTSTAY LELESSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
50	102 hu1D11.v3 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKKGRATL TADKSTSTAY LELESSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S
55	103 hu1D11.v4 heavy chain variable region	EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWIGWVRQA PGQGLEWIGD IYPGGGYTNY NEFKKGRATL TADKSSSTAY LELESSLRSED TAVYYCARLD GSSYRGAMDS WGQGTLVTVS S

(continued)

SEQ ID NO	Description	Sequence
5	104	hu22C10.v1 light chain variable region DIQMTQSPSS LSASVGDRVT ITCSATSSIS YMHWYQQKPG KAPKGWIYDT SKLAHGVPSPR FSGSGSGTDX TLTISSLQPE DFATYYCHQR RSYPFTFGQG TKVEIK
10	105	hu22C10.v2.1 light chain variable region DIQMTQSPSS LSASVGDRVT ITCSATSSIS YMHWYQQKPG KAPKLWIYDT SKLAHGVPSPR FSGSGSGTDF TLTISSLQPE DFATYYCHQR RSYPFTFGQG TKVEIK
15	106	hu22C10.v2.2 light chain variable region; hu22C10.v2.8 light chain variable region DIQMTQSPSS LSASVGDRVT ITCSATSSIS YMHWYQQKPG KAPKGLIYDT SKLAHGVPSPR FSGSGSGTDF TLTISSLQPE DFATYYCHQR RSYPFTFGQG TKVEIK
20	107	hu22C10.v2.6 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TVDTSTSTAY LELOSSLRSED TAVYYCAREI TTVDYWGQGT LTVSS
25	108	hu22C10.v2.5 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TRDTSTSTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
30	109	hu22C10.v2.4 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATI TVDTSTSTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
35	110	hu22C10.v2.3 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRVTL TVDTSTSTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
40	111	hu22C10.v1 heavy chain variable region; hu22C10.v2 heavy chain variable region hu22C10.v2.1 heavy chain variable region; hu22C10.v2.2 heavy chain variable region EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TVDTSTSTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
45	112	hu22C10.v3 heavy chain variable region; EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TVDKSTSTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
50	113	hu22C10.v4 heavy chain variable region; EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TVDKSTNTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
55	114	hu22C10.v5 heavy chain variable region; EVQLVQSGAE VKKPGASVKV SCKASGYTFT NFWIHWVRQA PGQGLEWIGE IDPSDSYTNY NQKFKGRATL TVDKSSNTAY LELOSSLRSED TAVYYCSREI TTVDYWGQGT LTVSS
	115	hu22C10.v2.1 LC FR2 WYQQKPGKAPKLWY
	116	hu22C10.v2.2 LC FR2 WYQQKPGKAPKGLIY
	117	hu22C10.v1 LC FR3 GVPSRFSGSGSGTDX TLTISSLQPEDFATYYC
	118	hu22C10.v2.6 HC FR3 RATL TVDTSTSTAY LELOSSLRSED TAVYYCAR
	119	hu22C10.v2.5 HC FR3 RATL TRDTSTSTAY LELOSSLRSED TAVYYCSR
	120	hu22C10.v2.4 HC FR3 RATI TVDTSTSTAY LELOSSLRSED TAVYYCSR
	121	hu22C10.v2.3 HC FR3 RVTL TVDTSTSTAY LELOSSLRSED TAVYYCSR

(continued)

SEQ ID NO	Description	Sequence	
5	122	hu22C10.v1 HC FR3 hu22C10.v2 HC FR3 hu22C10.v2.1 HC FR3 hu22C10.v2.2 HC FR3	RATL TVDTSTSTAY LELOSSLRSED TAVYYCSR
10	123	hu22C10.v3 HC FR3	RATL TVDKSTSTAY LELOSSLRSED TAVYYCSR
	124	hu22C10.v4 HC FR3	RATL TVDKSTNTAY LELOSSLRSED TAVYYCSR
	125	hu22C10.v5 HC FR3	RATL TVDKSSNTAY LELOSSLRSED TAVYYCSR

15 SEQUENCE LISTING

[0445]

20 <110> GENENTECH, INC.

<120> ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES

<130> SJK/FP7320997

25 <140> Divisional of EPA 14717318.1
<141> 2014-03-13

<150> PCT/US2014/025285
<151> 2014-03-13

30 <150> US 61/784,877
<151> 2013-03-14

<150> US 61/785,811
<151> 2013-03-14

35 <150> US 61/874,175
<151> 2013-09-05

40 <160> 125

<170> PatentIn version 3.5

<210> 1
<211> 108
<212> PRT
<213> Homo sapiens

45 <400> 1

50

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr
 20 25 30

10 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

20 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Phe
 85 90 95

25 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 2

<211> 112

<212> PRT

30 <213> Homo sapiens

<400> 2

35 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

40 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

45 Gly Trp Ile Asn Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

50 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

55 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 100 105 110

<210> 3
 <211> 108
 <212> PRT
 <213> Mus musculus

5

<400> 3

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

10

Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

15

Val Ala Trp Tyr Gln His Lys Pro Gly Gln Cys Pro Arg Leu Leu Ile
 35 40 45

20

His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

25

Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro
 65 70 75 80

30

Glu Asp Ser Ala Thr Tyr Phe Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

35

Ala Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
 100 105

<210> 4
 <211> 121
 <212> PRT
 <213> Mus musculus

<400> 4

40

45

50

55

1 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr
 5 10 15

5 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

10 Trp Ile Gly Trp Ala Lys Gln Arg Pro Gly His Gly Phe Glu Trp Ile
 35 40 45

15 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

20 Met Gln Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys
 85 90 95

25 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

30 Gln Gly Thr Ser Ile Thr Val Ser Ser
 115 120

35 <210> 5
 <211> 10
 <212> PRT
 <213> Mus musculus

40 <400> 5

45 Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His
 1 5 10

50 <210> 6
 <211> 17
 <212> PRT
 <213> Mus musculus

55 <400> 6

Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

50 Gly

55 <210> 7
 <211> 12
 <212> PRT
 <213> Mus musculus

<400> 7

	Leu	Asp	Gly	Ser	Ser	Tyr	Arg	Gly	Ala	Met	Asp	Ser
1					5						10	

5

<210> 8

<211> 11

<212> PRT

<213> Mus musculus

10

<400> 8

	Lys	Ala	Ser	Gln	Gly	Phe	Asn	Lys	Tyr	Val	Ala
1					5					10	

15

<210> 9

<211> 7

<212> PRT

<213> Mus musculus

20

<400> 9

	Tyr	Thr	Ser	Thr	Leu	Gln	Pro
1					5		

25

<210> 10

<211> 9

<212> PRT

<213> Mus musculus

30

<400> 10

	Leu	Gln	Tyr	Gly	Asn	Leu	Leu	Tyr	Ala
1					5				

35

<210> 11

<211> 113

<212> PRT

<213> Mus musculus

40

<400> 11

	Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ile	Val	Thr	Ala	Gly
1					5						10			15		

45

50

55

Glu Lys Val Thr Met Ser Cys Arg Ser Ser Gln Ser Leu Phe Asp Ser
 20 25 30

5 Gly Ser Gln Arg Asn Tyr Leu Thr Trp Phe His Gln Lys Pro Gly Arg
 35 40 45

10 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

15 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Val Gln Thr Glu Asp Leu Ala Val Tyr Phe Cys Gln Asn
 85 90 95

20 Asp Tyr Ser Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Glu
 100 105 110

Lys

25 <210> 12
 <211> 120
 <212> PRT
 <213> Mus musculus
 30 <400> 12

35 Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala
 1 5 10 15

40 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30

Tyr Ile His Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45

45 Gly Arg Val Asn Pro Asn Asn Gly Asp Pro Ile Tyr Asn Gln Lys Phe
 50 55 60

50 Arg Gly Lys Ala Ile Leu Thr Val Asp Gln Ser Ser Asn Thr Ala Tyr
 65 70 75 80

55 Met Glu Leu Arg Ser Leu Thr Ser Glu Ala Ser Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Val Leu Phe Tyr Tyr Gly Ser Pro Phe Ala Tyr Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ala
115 120

5 <210> 13
<211> 10
<212> PRT
<213> Mus musculus

10 <400> 13

Gly Tyr Ser Phe Thr Gly Tyr Tyr Ile His
1 5 10

15 <210> 14
<211> 17
<212> PRT
<213> Mus musculus

20 <400> 14

Arg Val Asn Pro Asn Asn Gly Asp Pro Ile Tyr Asn Gln Lys Phe Arg
1 5 10 15

25 Gly

30 <210> 15
<211> 11
<212> PRT
<213> Mus musculus

35 <400> 15

Val Leu Phe Tyr Tyr Gly Ser Pro Phe Ala Tyr
1 5 10

40 <210> 16
<211> 17
<212> PRT
<213> Mus musculus

45 <400> 16

Arg Ser Ser Gln Ser Leu Phe Asp Ser Gly Ser Gln Arg Asn Tyr Leu
1 5 10 15

50 Thr

55 <210> 17
<211> 7
<212> PRT
<213> Mus musculus

<400> 17

Trp Ala Ser Thr Arg Glu Ser
1 5

<210> 18
 <211> 9
 <212> PRT
 <213> Mus musculus

5

<400> 18

Gln Asn Asp Tyr Ser Phe Pro Phe Thr
 1 5

10

<210> 19
 <211> 107
 <212> PRT
 <213> Mus musculus

15

<400> 19

Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser Pro Gly Asp
 1 5 10 15

20

Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser
 20 25 30

25

Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly
 35 40 45

Leu Ile Gly Gly Thr Asn Asn Arg Val Pro Gly Val Pro Ala Arg Phe
 50 55 60

Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala
 65 70 75 80

35

Gln Thr Glu Asp Glu Ala Met Tyr Phe Cys Ala Leu Trp Tyr Asn Asn
 85 90 95

40

His Trp Val Phe Gly Gly Thr Lys Leu Glu
 100 105

45

<210> 20
 <211> 121
 <212> PRT
 <213> Mus musculus

<400> 20

50

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Tyr
 20 25 30

Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile
 35 40 45

5 Gly Glu Ile Leu Pro Gly Thr Ser Ile Thr Thr Tyr Asn Ala Lys Phe
 50 55 60

10 Lys Val Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
 65 70 75 80

15 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Tyr Tyr Phe Gly Ser Ser Phe Tyr Phe Asp Tyr Trp Gly
 100 105 110

20 Gln Gly Thr Ser Leu Thr Val Ser Ser
 115 120

<210> 21

<211> 10

25 <212> PRT

<213> Mus musculus

<400> 21

30 Gly Tyr Thr Phe Ser Ser Tyr Trp Ile Glu
 1 5 10

<210> 22

<211> 17

35 <212> PRT

<213> Mus musculus

<400> 22

40 Glu Ile Leu Pro Gly Thr Ser Ile Thr Thr Tyr Asn Ala Lys Phe Lys
 1 5 10 15

45 Val

<210> 23

<211> 14

<212> PRT

50 <213> Mus musculus

<400> 23

55 Ala Arg Tyr Tyr Phe Gly Ser Ser Phe Tyr Phe Asp Tyr
 1 5 10

<210> 24

<211> 14

<212> PRT

<213> *Mus musculus*

<400> 24

5 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn
1 5 10

<210> 25

<211> 7

10 <212> PRT

<213> *Mus musculus*

<400> 25

15 Gly Thr Asn Asn Arg Val Pro
1 5

<210> 26

<211> 9

20 <212> PRT

<213> *Mus musculus*

<400> 26

25 Ala Leu Trp Tyr Asn Asn His Trp Val
1 5

<210> 27

<211> 106

30 <212> PRT

<213> *Mus musculus*

<400> 27

35 Gln Ile Val Leu Thr Gln Ser Pro Thr Ile Met Ser Ala Ser Pro Gly
1 5 10 15

His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Gly Trp Ile Tyr
35 40 45

45

Asp Thr Ser Lys Leu Ala His Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60

50 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 55 85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 28
 <211> 116
 <212> PRT
 <213> Mus musculus

5

<400> 28

10 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Thr
 1 5 10 15

15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

Trp Ile His Trp Val Ile Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

20 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

25 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr
 65 70 75 80

30 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95

Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Thr Leu
 100 105 110

35 Thr Val Ser Ser
 115

<210> 29
 <211> 10
 <212> PRT
 <213> Mus musculus

<400> 29

45 Gly Tyr Thr Phe Thr Asn Phe Trp Ile His
 1 5 10

<210> 30
 <211> 17
 <212> PRT
 <213> Mus musculus

<400> 30

55 Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys

1

5

10

15

Gly

5

<210> 31
 <211> 7
 <212> PRT
 <213> Mus musculus
 10
 <400> 31

Glu Ile Thr Thr Val Asp Tyr
 1 5

15

<210> 32
 <211> 10
 <212> PRT
 <213> Mus musculus
 20
 <400> 32

Ser Ala Thr Ser Ser Ile Ser Tyr Met His
 1 5 10

25

<210> 33
 <211> 7
 <212> PRT
 <213> Mus musculus
 30
 <400> 33

Asp Thr Ser Lys Leu Ala His
 1 5

35

<210> 34
 <211> 9
 <212> PRT
 <213> Mus musculus
 40
 <400> 34

His Gln Arg Arg Ser Tyr Pro Phe Thr
 1 5

45

<210> 35
 <211> 108
 <212> PRT
 <213> Artificial sequence
 50
 <220>
 <223> Synthetic
 55
 <400> 35

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

5 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

10 Tyr Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

15 Ser Gly Ser Gly Arg Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

20 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

25 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 36

<211> 121

25 <212> PRT

<213> Artificial sequence

30 <220>

<223> Synthetic

35 <400> 36

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

35 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

40 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

45 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

50 Lys Gly Arg Ala Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

55 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

55 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

5 <210> 37
 <211> 121
 <212> PRT
 <213> Artificial sequence

10 <220>
 <223> Synthetic

<400> 37

15 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

20 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

25 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

30 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

35 Lys Gly Arg Ala Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

40 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

45 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

50 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

55 <210> 38
 <211> 121
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic

<400> 38

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

10 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

15 Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

30 <210> 39
 <211> 10
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic

<400> 39

40 Gly Tyr Thr Phe Thr Ser Tyr Trp Ile Gly
 1 5 10

45 <210> 40
 <211> 17
 <212> PRT
 <213> Artificial sequence

50 <220>
 <223> Synthetic

<400> 40

55 Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 41
 <211> 12
 <212> PRT
 <213> Artificial sequence

5
 <220>
 <223> Synthetic

<400> 41

10
 Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser
 1 5 10

<210> 42
 <211> 11
 <212> PRT
 <213> Artificial sequence

15
 <220>
 <223> Synthetic

<400> 42

20
 Lys Ala Ser Gln Gly Phe Asn Lys Tyr Val Ala
 1 5 10

<210> 43
 <211> 7
 <212> PRT
 <213> Artificial sequence

25
 <220>
 <223> Synthetic

35 <400> 43

Tyr Thr Ser Thr Leu Gln Pro
 1 5

40 <210> 44
 <211> 9
 <212> PRT
 <213> Artificial sequence

45 <220>
 <223> Synthetic

<400> 44

50 Leu Gln Tyr Gly Asn Leu Leu Tyr Ala
 1 5

<210> 45
 <211> 23
 <212> PRT
 <213> Artificial sequence

<220>

<223> Synthetic

<400> 45

5 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys
 20

10

<210> 46

<211> 15

<212> PRT

<213> Artificial sequence

15

<220>

<223> Synthetic

<400> 46

20

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 1 5 10 15

<210> 47

<211> 32

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

<400> 47

35

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Thr
 1 5 10 15

40

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 20 25 30

45

<210> 48

<211> 11

<212> PRT

<213> Artificial sequence

50

<220>

<223> Synthetic

<400> 48

55

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 1 5 10

<210> 49

<211> 25

<212> PRT

<213> Artificial sequence

<220>
<223> Synthetic

5 <400> 49

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

10 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser
20 25

15 <210> 50
<211> 14
<212> PRT
<213> Artificial sequence

20 <220>
<223> Synthetic

<400> 50

25 Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly
1 5 10

<210> 51
<211> 32
30 <212> PRT
<213> Artificial sequence

35 <220>
<223> Synthetic

<400> 51

40 Arg Ala Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

45 <210> 52
<211> 32
<212> PRT
<213> Artificial sequence

50 <220>
<223> Synthetic

<400> 52

55

Arg Ala Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
 1 5 10 15

5 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

<210> 53

<211> 32

10 <212> PRT

<213> Artificial sequence

15 <220>

<223> Synthetic

<400> 53

Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
 1 5 10 15

20 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

25 <210> 54

<211> 11

<212> PRT

<213> Artificial sequence

30 <220>

<223> Synthetic

<400> 54

35 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1 5 10

<210> 55

<211> 106

40 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

45 <400> 55

50

55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Ser Ala Thr Ser Ser Ile Ser Tyr Met
 20 25 30

10 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Trp Ile Tyr
 35 40 45

15 Asp Thr Ser Lys Leu Ala His Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
 65 70 75 80

20 Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 85 90 95

25 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 56

<211> 116

<212> PRT

30 <213> Artificial sequence

<220>

<223> Synthetic

35 <400> 56

40

45

50

55

1 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 10 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 15 35 40 45

15 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 20 50 55 60

20 Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 25 65 70 75 80

25 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 30 85 90 95

30 Ala Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 35 100 105 110

35 Thr Val Ser Ser
 40 115

40 <210> 57

45 <211> 106

50 <212> PRT

55 <213> Artificial sequence

60 <220>

65 <223> Synthetic

70 <400> 57

75 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 80 1 5 10 15

85 Asp Arg Val Thr Ile Thr Cys Ser Ala Thr Ser Ser Ile Ser Tyr Met
 90 20 25 30

95 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr
 100 35 40 45

Asp Thr Ser Lys Leu Ala His Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

5 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
 65 70 75 80

10 Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 85 90 95

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

15 <210> 58

<211> 10

<212> PRT

<213> Artificial sequence

20 <220>

<223> Synthetic

25 <400> 58

Gly Tyr Thr Phe Thr Asn Phe Trp Ile His
 1 5 10

30 <210> 59

<211> 17

<212> PRT

<213> Artificial sequence

35 <220>

<223> Synthetic

<400> 59

40 Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys
 1 5 10 15

Gly

45 <210> 60

<211> 7

<212> PRT

<213> Artificial sequence

50 <220>

<223> Synthetic

<400> 60

55 Glu Ile Thr Thr Val Asp Tyr
 1 5

<210> 61

<211> 10
 <212> PRT
 <213> Artificial sequence

5 <220>
 <223> Synthetic

<400> 61

10 Ser Ala Thr Ser Ser Ile Ser Tyr Met His
 1 5 10

<210> 62

<211> 7

15 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic

20 <400> 62

Asp Thr Ser Lys Leu Ala His
 1 5

25 <210> 63
 <211> 9
 <212> PRT
 <213> Artificial sequence

30 <220>
 <223> Synthetic

<400> 63

35 His Gln Arg Arg Ser Tyr Pro Phe Thr
 1 5

40 <210> 64
 <211> 23
 <212> PRT
 <213> Artificial sequence

45 <220>
 <223> Synthetic

<400> 64

50 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys
 20

55 <210> 65
 <211> 15
 <212> PRT

5 <213> Artificial sequence

10 <220>
 5 <223> Synthetic

15 <400> 65

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Trp Ile Tyr
 1 5 10 15

20 <210> 66
 15 <211> 15
 <212> PRT
 <213> Artificial sequence

25 <220>
 <223> Synthetic

30 <400> 66

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr
 1 5 10 15

35 <210> 67
 25 <211> 32
 <212> PRT
 <213> Artificial sequence

40 <220>
 <223> Synthetic

45 <400> 67

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 20 25 30

50 <210> 68
 40 <211> 11
 <212> PRT
 <213> Artificial sequence

45 <220>
 <223> Synthetic

55 <400> 68

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 1 5 10

55 <210> 69
 <211> 25
 <212> PRT
 <213> Artificial sequence

<220>
<223> Synthetic

<400> 69

5

Gl u Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

10 Ser Val Lys Val Ser Cys Lys Ala Ser
20 25

<210> 70

<211> 14

15 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

20

<400> 70

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly
1 5 10

25

<210> 71

<211> 32

<212> PRT

<213> Artificial sequence

30

<220>

<223> Synthetic

35

<400> 71

Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

40

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 72

<211> 11

45 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

50

<400> 72

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

55

<210> 73

<211> 282

<212> PRT

<213> Homo sapiens

<400> 73

5

10

15

20

25

30

35

40

45

50

55

Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
 1 5 10 15

5 Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
 20 25 30

10 Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile
 35 40 45

15 Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
 50 55 60

20 Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val
 65 70 75 80

25 His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met
 85 90 95

30 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn
 100 105 110

35 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
 115 120 125

40 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
 130 135 140

45 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn
 145 150 155 160

50 Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
 165 170 175

55 Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
 180 185 190

Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
 195 200 205

Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
 210 215 220

Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
 225 230 235 240

Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
 245 250 255

5 Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu
 260 265 270

10 Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
 275 280

<210> 74

<211> 254

<212> PRT

15 <213> Homo sapiens

<400> 74

20 Phe Gly Ile Ser Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser
 1 5 10 15

25 Ala Gly Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro
 20 25 30

Asp Ile Lys Leu Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val
 35 40 45

30 Leu Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu
 50 55 60

35 Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val
 65 70 75 80

40 Ile Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp
 85 90 95

45 Ala Gly Thr Tyr Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn
 100 105 110

50 Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg
 130 135 140

55 Trp Phe Pro Gln Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly
 145 150 155 160

Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu
 165 170 175

Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn
 180 185 190

5 Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly
 195 200 205

10 Asp Ile Lys Val Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln
 210 215 220

Leu Leu Asn Ser Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile
 225 230 235 240

15 Ser Trp Ala Leu Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
 245 250

20 <210> 75
 <211> 282
 <212> PRT
 <213> Macaca fascicularis

25 <400> 75
 Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
 1 5 10 15

30 Phe Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
 20 25 30

35 Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile
 35 40 45

40 Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
 50 55 60

45 Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Ile Gly Leu Val
 65 70 75 80

50 His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met
 85 90 95

55 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn
 100 105 110

60 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
 115 120 125

65 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
 130 135 140

Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn
 145 150 155 160

5 Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
 165 170 175

10 Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
 180 185 190

Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
 195 200 205

15 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
 210 215 220

20 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
 225 230 235 240

25 Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
 245 250 255

Lys Ala Ser Leu Cys Val Ser Ser Phe Leu Ala Ile Ser Trp Ala Leu
 260 265 270

30 Leu Pro Leu Ala Pro Tyr Leu Met Leu Lys
 275 280

35 <210> 76
 <211> 254
 <212> PRT
 <213> Macaca fascicularis

40 <400> 76

Phe Gly Ile Ser Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser
 1 5 10 15

45 Ala Gly Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro
 20 25 30

50 Asp Ile Lys Leu Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val
 35 40 45

55 Ile Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu
 50 55 60

Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val
 65 70 75 80

Ile Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp
 85 90 95

5 Ala Gly Thr Tyr Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn
 100 105 110

10 Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn
 115 120 125

15 Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg
 130 135 140

Trp Phe Pro Gln Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly
 145 150 155 160

20 Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu
 165 170 175

25 Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn
 180 185 190

Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly
 195 200 205

30 Asp Ile Lys Val Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln
 210 215 220

35 Leu Leu Asn Ser Lys Ala Ser Leu Cys Val Ser Ser Phe Leu Ala Ile
 225 230 235 240

40 Ser Trp Ala Leu Leu Pro Leu Ala Pro Tyr Leu Met Leu Lys
 245 250

<210> 77
 <211> 282
 <212> PRT
 45 <213> Rattus norvegicus
 <400> 77

50 Met Ala Ser Leu Gly Gln Ile Ile Phe Trp Ser Ile Ile Asn Val Ile
 1 5 10 15

Ile Ile Leu Ala Gly Ala Ile Val Leu Ile Ile Gly Phe Gly Ile Ser
 20 25 30

55 Gly Lys His Phe Ile Thr Val Thr Phe Thr Ser Ala Gly Asn Ile
 35 40 45

Gly Glu Asp Gly Thr Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
 50 55 60

5 Asn Gly Ile Val Ile Gln Trp Leu Lys Glu Gly Ile Lys Gly Leu Val
 65 70 75 80

10 His Glu Phe Lys Glu Gly Lys Asp Asp Leu Ser Gln Gln His Glu Met
 85 90 95

15 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Val Val Gly Asn
 100 105 110

Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
 115 120 125

20 Thr Cys Tyr Ile His Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
 130 135 140

25 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Ile Asn Val Asp Tyr Asn
 145 150 155 160

30 Ala Ser Ser Glu Ser Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
 165 170 175

Pro Thr Val Ala Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
 180 185 190

35 Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
 195 200 205

40 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
 210 215 220

Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
 225 230 235 240

45 Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Glu Leu Leu Asn Ser
 245 250 255

50 Gly Pro Ser Pro Cys Val Ser Ser Val Ser Ala Ala Gly Trp Ala Leu
 260 265 270

55 Leu Ser Leu Ser Cys Cys Leu Met Leu Arg
 275 280

<210> 78
 <211> 254

EP 3 299 391 B1

<212> PRT

<213> *Rattus norvegicus*

<400> 78

5

10

15

20

25

30

35

40

45

50

55

Phe Gly Ile Ser Gly Lys His Phe Ile Thr Val Thr Thr Phe Thr Ser
 1 5 10 15

5 Ala Gly Asn Ile Gly Glu Asp Gly Thr Leu Ser Cys Thr Phe Glu Pro
 20 25 30

10 Asp Ile Lys Leu Asn Gly Ile Val Ile Gln Trp Leu Lys Glu Gly Ile
 35 40 45

15 Lys Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Asp Leu Ser Gln
 50 55 60

20 Gln His Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val
 65 70 75 80

25 Val Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp
 85 90 95

30 Ala Gly Thr Tyr Thr Cys Tyr Ile His Thr Ser Lys Gly Lys Gly Asn
 100 105 110

35 Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Ile Asn
 115 120 125

40 Val Asp Tyr Asn Ala Ser Ser Glu Ser Leu Arg Cys Glu Ala Pro Arg
 130 135 140

45 Trp Phe Pro Gln Pro Thr Val Ala Trp Ala Ser Gln Val Asp Gln Gly
 145 150 155 160

50 Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu
 165 170 175

55 Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn
 180 185 190

Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly
 195 200 205

60 Asp Ile Lys Val Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Glu
 210 215 220

65 Leu Leu Asn Ser Gly Pro Ser Pro Cys Val Ser Ser Val Ser Ala Ala
 225 230 235 240

Gly Trp Ala Leu Leu Ser Leu Ser Cys Cys Leu Met Leu Arg
 245 250

<210> 79
 <211> 283
 <212> PRT
 <213> Mus musculus

5

<400> 79

10

Met	Ala	Ser	Leu	Gly	Gln	Ile	Ile	Phe	Trp	Ser	Ile	Ile	Asn	Ile	Ile
1															15

5

10

15

Ile	Ile	Leu	Ala	Gly	Ala	Ile	Ala	Leu	Ile	Ile	Gly	Phe	Gly	Ile	Ser
															30

20

25

30

15

Gly	Lys	His	Phe	Ile	Thr	Val	Thr	Thr	Phe	Thr	Ser	Ala	Gly	Asn	Ile
															45

35

40

20

Gly	Glu	Asp	Gly	Thr	Leu	Ser	Cys	Thr	Phe	Glu	Pro	Asp	Ile	Lys	Leu
															60

50

55

60

25

Asn	Gly	Ile	Val	Ile	Gln	Trp	Leu	Lys	Glu	Gly	Ile	Lys	Gly	Leu	Val
															80

65

70

75

30

His	Glu	Phe	Lys	Glu	Gly	Lys	Asp	Asp	Leu	Ser	Gln	Gln	His	Glu	Met
															95

85

90

95

25

Phe	Arg	Gly	Arg	Thr	Ala	Val	Phe	Ala	Asp	Gln	Val	Val	Val	Gly	Asn
															110

100

105

110

35

Ala	Ser	Leu	Arg	Leu	Lys	Asn	Val	Gln	Leu	Thr	Asp	Ala	Gly	Thr	Tyr
															125

115

120

125

40

Thr	Cys	Tyr	Ile	Arg	Thr	Ser	Lys	Gly	Lys	Gly	Asn	Ala	Asn	Leu	Glu
															140

130

135

140

45

Tyr	Lys	Thr	Gly	Ala	Phe	Ser	Met	Pro	Glu	Ile	Asn	Val	Asp	Tyr	Asn
															160

145

150

155

50

Ala	Ser	Ser	Glu	Ser	Leu	Arg	Cys	Glu	Ala	Pro	Arg	Trp	Phe	Pro	Gln
															175

165

170

175

55

Pro	Thr	Val	Ala	Trp	Ala	Ser	Gln	Val	Asp	Gln	Gly	Ala	Asn	Phe	Ser
															190

180

185

190

Glu	Val	Ser	Asn	Thr	Ser	Phe	Glu	Leu	Asn	Ser	Glu	Asn	Val	Thr	Met
															205

195

200

205

55

Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
 210 215 220

5 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
 225 230 235 240

10 Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Gln Leu Leu Asn Ser
 245 250 255

15 Gly Pro Ser Pro Cys Val Phe Ser Ser Ala Phe Ala Ala Gly Trp Ala
 260 265 270

15 Leu Leu Ser Leu Ser Cys Cys Leu Met Leu Arg
 275 280

<210> 80

<211> 255

<212> PRT

<213> Mus musculus

<400> 80

25 Phe Gly Ile Ser Gly Lys His Phe Ile Thr Val Thr Thr Phe Thr Ser
 1 5 10 15

30 Ala Gly Asn Ile Gly Glu Asp Gly Thr Leu Ser Cys Thr Phe Glu Pro
 20 25 30

35 Asp Ile Lys Leu Asn Gly Ile Val Ile Gln Trp Leu Lys Glu Gly Ile
 35 40 45

40 Lys Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Asp Leu Ser Gln
 50 55 60

45 Gln His Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val
 65 70 75 80

50 Val Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp
 85 90 95

55 Ala Gly Thr Tyr Thr Cys Tyr Ile Arg Thr Ser Lys Gly Lys Gly Asn
 100 105 110

60 Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Ile Asn
 115 120 125

65 Val Asp Tyr Asn Ala Ser Ser Glu Ser Leu Arg Cys Glu Ala Pro Arg
 130 135 140

Trp Phe Pro Gln Pro Thr Val Ala Trp Ala Ser Gln Val Asp Gln Gly
 145 150 155 160

5 Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu
 165 170 175

10 Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn
 180 185 190

15 Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly
 195 200 205

Asp Ile Lys Val Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Gln
 210 215 220

20 Leu Leu Asn Ser Gly Pro Ser Pro Cys Val Phe Ser Ser Ala Phe Ala
 225 230 235 240

25 Ala Gly Trp Ala Leu Leu Ser Leu Ser Cys Cys Leu Met Leu Arg
 245 250 255

<210> 81

<211> 278

<212> PRT

30 <213> Pan troglodytes

<400> 81

35 Met Lys Pro Leu Thr Ser Arg Ile Ile Ser Ile Ile Ile Ile Leu Ala
 1 5 10 15

40 Gly Ala Ile Arg Leu Ile Ile Gly Phe Gly Ile Ser Gly Arg His Ser
 20 25 30

Ile Thr Val Thr Val Ala Ser Ala Gly Asn Ile Gly Glu Asp Gly
 35 40 45

45 Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu Ser Asp Ile Val
 50 55 60

50 Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val His Glu Phe Lys
 65 70 75 80

55 Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met Phe Arg Gly Arg
 85 90 95

Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn Ala Ser Leu Arg
 100 105 110

Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys Tyr Ile
 115 120 125

5 Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly
 130 135 140

10 Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu
 145 150 155 160

15 Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val
 165 170 175

Trp Ala Ser Gln Ile Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn
 180 185 190

20 Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met Lys Val Val Ser
 195 200 205

25 Val Leu Tyr Asn Ala Thr Ile Asn Asn Thr Tyr Ser Cys Met Ile Glu
 210 215 220

Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val Thr Glu Ser Glu
 225 230 235 240

30 Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser Lys Ala Ser Leu
 245 250 255

35 Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro Leu Ser
 260 265 270

40 Pro Tyr Leu Met Leu Lys
 275

<210> 82
 <211> 254
 <212> PRT
 45 <213> Pan troglodytes

<400> 82

50 Phe Gly Ile Ser Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser
 1 5 10 15

55 Ala Gly Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro
 20 25 30

Asp Ile Lys Leu Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val
 35 40 45

Leu Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu
 50 55 60

5 Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val
 65 70 75 80

10 Ile Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp
 85 90 95

15 Ala Gly Thr Tyr Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn
 100 105 110

Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn
 115 120 125

20 Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg
 130 135 140

25 Trp Phe Pro Gln Pro Thr Val Val Trp Ala Ser Gln Ile Asp Gln Gly
 145 150 155 160

Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu
 165 170 175

30 Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn Ala Thr Ile Asn
 180 185 190

35 Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly
 195 200 205

40 Asp Ile Lys Val Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln
 210 215 220

Leu Leu Asn Ser Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile
 225 230 235 240

45 Ser Trp Ala Leu Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
 245 250

50 <210> 83
 <211> 15
 <212> PRT
 <213> Artificial sequence

55 <220>
 <223> Synthetic

<400> 83

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile His
 1 5 10 15

5 <210> 84
 <211> 32
 <212> PRT
 <213> Artificial sequence

10 <220>
 <223> Synthetic

<400> 84

15 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 1 5 10 15

20 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 20 25 30

25 <210> 85
 <211> 32
 <212> PRT
 <213> Artificial sequence

30 <220>
 <223> Synthetic

<400> 85

35 Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Thr
 1 5 10 15

40 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 20 25 30

45 <210> 86
 <211> 32
 <212> PRT
 <213> Artificial sequence

50 <220>
 <223> Synthetic

<400> 86

55 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
 1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 20 25 30

55 <210> 87
 <211> 32
 <212> PRT
 <213> Artificial sequence

<220>
<223> Synthetic

5 <400> 87

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Phe Thr
1 5 10 15

10 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 88
<211> 32
15 <212> PRT
<213> Artificial sequence

<220>
<223> Synthetic
20 <400> 88

Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

25 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

30 <210> 89
<211> 32
<212> PRT
<213> Artificial sequence

35 <220>
<223> Synthetic
<400> 89

40 Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

45 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

50 <210> 90
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic
55 <400> 90

Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Leu Glu
1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

5 <210> 91
 <211> 32
 <212> PRT
 <213> Artificial sequence

10 <220>
 <223> Synthetic

<400> 91

15 Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
 1 5 10 15

20 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

25 <210> 92
 <211> 32
 <212> PRT
 <213> Artificial sequence

30 <220>
 <223> Synthetic

<400> 92

35 Arg Ala Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
 1 5 10 15

40 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

45 <210> 93
 <211> 108
 <212> PRT
 <213> Artificial sequence

50 <220>
 <223> Synthetic

<400> 93

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

10 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 15 50 55 60

20 Ser Gly Ser Gly Arg Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

25 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

30 <210> 94
 <211> 108
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic

<400> 94

40

45

50

55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

10 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Arg Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

20 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

25 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 95

<211> 108

<212> PRT

30 <213> Artificial sequence

<220>

<223> Synthetic

35 <400> 95

40

45

50

55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

10 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

20 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

25 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 96

<211> 108

<212> PRT

30 <213> Artificial sequence

<220>

<223> Synthetic

35 <400> 96

40

45

50

55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

10 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 Tyr Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Arg Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

20 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

25 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

30 <210> 97
 <211> 108
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic

<400> 97

40

45

50

55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

10 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

20 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

25 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

30 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 98

<211> 108

<212> PRT

35 <213> Artificial sequence

<220>

<223> Synthetic

35 <400> 98

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

40 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Gly Phe Asn Lys Tyr
 20 25 30

45 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

50

55

His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60

5 Ser Gly Ser Gly Arg Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

10 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Leu Tyr
 85 90 95

15 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

15 <210> 99

<211> 121

<212> PRT

<213> Artificial sequence

20 <220>
 <223> Synthetic

25 <400> 99

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

35 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

40 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

45 Lys Gly Arg Ala Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

50 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

55 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

55 <210> 100
 <211> 121
 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

5

<400> 100

10	Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
	1				5					10					15	

15	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
					20				25					30		

20	Trp	Ile	Gly	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Ieu	Glu	Trp	Ile
					35				40					45		

25	Gly	Asp	Ile	Tyr	Pro	Gly	Gly	Gly	Tyr	Thr	Asn	Tyr	Asn	Glu	Lys	Phe
					50			55			60					

30	Lys	Gly	Arg	Val	Thr	Leu	Thr	Ala	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr
					65		70			75					80	

35	Leu	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85				90					95		

40	Ala	Arg	Leu	Asp	Gly	Ser	Ser	Tyr	Arg	Gly	Ala	Met	Asp	Ser	Trp	Gly
					100				105					110		

45	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser							
					115			120								

<210> 101

<211> 121

40 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

45 <400> 101

50

55

1 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 10 20 25 30

10 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 15 35 40 45

15 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 20 50 55 60

20 Lys Gly Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 25 65 70 75 80

25 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 30 85 90 95

30 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 35 100 105 110

35 Gln Gly Thr Leu Val Thr Val Ser Ser
 40 115 120

40 <210> 102

45 <211> 121

50 <212> PRT

55 <213> Artificial sequence

55 <220>

60 <223> Synthetic

65 <400> 102

70

75

80

85

1 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

10 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

15 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

30 <210> 103

<211> 121

<212> PRT

<213> Artificial sequence

35 <220>

<223> Synthetic

40 <400> 103

45

50

55

1 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

10 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

15 Gly Asp Ile Tyr Pro Gly Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ala Arg Leu Asp Gly Ser Ser Tyr Arg Gly Ala Met Asp Ser Trp Gly
 100 105 110

30 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

35 <210> 104

<211> 106

<212> PRT

<213> Artificial sequence

40 <220>

<223> Synthetic

<400> 104

45 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

50 Asp Arg Val Thr Ile Thr Cys Ser Ala Thr Ser Ser Ile Ser Tyr Met
 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Trp Ile Tyr
 35 40 45

55 Asp Thr Ser Lys Leu Ala His Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

55

Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
 65 70 75 80

5 Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 85 90 95

10 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 105

<211> 106

<212> PRT

15 <213> Artificial sequence

<220>

<223> Synthetic

20 <400> 105

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

25 Asp Arg Val Thr Ile Thr Cys Ser Ala Thr Ser Ser Ile Ser Tyr Met
 20 25 30

30 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp Ile Tyr
 35 40 45

35 Asp Thr Ser Lys Leu Ala His Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

40 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
 65 70 75 80

45 Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 85 90 95

50 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 106

<211> 106

<212> PRT

55 <213> Artificial sequence

<220>

<223> Synthetic

<400> 106

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Ser Ala Thr Ser Ser Ile Ser Tyr Met
 20 25 30

10 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr
 35 40 45

15 Asp Thr Ser Lys Leu Ala His Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

20 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
 65 70 75 80

25 Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Arg Ser Tyr Pro Phe Thr
 85 90 95

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

30 <210> 107
 <211> 116
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic

<400> 107

40

45

50

55

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

15 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

20 Lys Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

25 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

30 Ala Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

35 <210> 108
 <211> 116
 <212> PRT
 <213> Artificial sequence

40 <220>
 <223> Synthetic

<400> 108

45

50

55

1 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

15 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Arg Ala Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

30 Thr Val Ser Ser
 115

35 <210> 109
 <211> 116
 <212> PRT
 <213> Artificial sequence

40 <220>
 <223> Synthetic

<400> 109

45 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

50 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

55

Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

5 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

10 Lys Gly Arg Ala Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

15 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

20 Thr Val Ser Ser
 115

<210> 110

<211> 116

25 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

30 <400> 110

35 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

40 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

45 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

50 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

55 Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

55 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
115

5 <210> 111
<211> 116
<212> PRT
<213> Artificial sequence

10 <220>
<223> Synthetic

<400> 111

15 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

20 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
20 25 30

25 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

30 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

35 Lys Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

40 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

45 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

50 Thr Val Ser Ser
115

55 <210> 112
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic

<400> 112

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

15 Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

30 <210> 113
 <211> 116
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic

<400> 113

40

45

50

55

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Ile Glu Trp Ile
 35 40 45

15 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

20 Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Asn Thr Ala Tyr
 65 70 75 80

25 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

30 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

35 <210> 114
 <211> 116
 <212> PRT
 <213> Artificial sequence

40 <220>
 <223> Synthetic

<400> 114

45

50

55

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe
 20 25 30

10 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

15 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr
 65 70 75 80

20 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

25 Ser Arg Glu Ile Thr Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

30 Thr Val Ser Ser
 115

35 <210> 115
 <211> 15
 <212> PRT
 <213> Artificial sequence

40 <220>
 <223> Synthetic

45 <400> 115

50 Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp Ile Tyr
 1 5 10 15

55 <210> 116
 <211> 15
 <212> PRT
 <213> Artificial sequence

60 <220>
 <223> Synthetic

65 <400> 116

70 Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr
 1 5 10 15

75 <210> 117
 <211> 32

<212> PRT

<213> Artificial sequence

<220>

5 <223> Synthetic

<400> 117

10 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
1 5 10 1515 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 118

<211> 32

<212> PRT

<213> Artificial sequence

20

<220>

<223> Synthetic

<400> 118

25

Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 1530 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 119

<211> 32

35 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

40

<400> 119

Arg Ala Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

45

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
20 25 30

50

<210> 120

<211> 32

<212> PRT

<213> Artificial sequence

55

<220>

<223> Synthetic

<400> 120

EP 3 299 391 B1

Arg Ala Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

5 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
20 25 30

<210> 121

<211> 32

10 <212> PRT

<213> Artificial sequence

15 <220>

<223> Synthetic

<400> 121

Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

20 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
25 30

25 <210> 122

<211> 32

<212> PRT

<213> Artificial sequence

30 <220>

<223> Synthetic

<400> 122

35 Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

40 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
20 25 30

<210> 123

<211> 32

45 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

50 <400> 123

Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Leu Glu
1 5 10 15

55 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
20 25 30

<210> 124
 <211> 32
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic

<400> 124

10

Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Asn Thr Ala Tyr Leu Glu
 1 5 10 15

15 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
 20 25 30

<210> 125
 <211> 32
 <212> PRT
 <213> Artificial sequence

20

<220>
 <223> Synthetic

25

<400> 125

Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Leu Glu
 1 5 10 15

30

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg
 20 25 30

35

Claims

1. An isolated monoclonal antibody that binds to B7-H4, wherein the antibody comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

40

2. The antibody of claim 1, which is a humanized or chimeric antibody.

45

3. The antibody of claim 1, which is an antibody fragment that binds B7-H4.

50

4. The antibody of claim 1, further comprising a heavy chain framework FR3 sequence of SEQ ID NO: 51, 52, or 53.

5. The antibody of claim 1, wherein the antibody comprises

- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36, 37, or 38;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 35; or
- (c) a VH sequence as in (a) and a VL sequence as in (b); or
- (d) a VH sequence of SEQ ID NO: 36 and a VL sequence of SEQ ID NO: 35; or
- (e) a VH sequence of SEQ ID NO: 37 and a VL sequence of SEQ ID NO: 35; or
- (f) VH sequence of SEQ ID NO: 38 and a VL sequence of SEQ ID NO: 35; or.

6. The antibody of any one of claims 1 to 5, which is an IgG1, IgG2a or IgG2b antibody.

7. Isolated nucleic acid encoding the antibody of any one of claims 1 to 6.

5 8. A host cell comprising the nucleic acid of claim 7.

9. An immunoconjugate comprising the antibody of any one of claims 1 to 6 and a cytotoxic agent.

10 10. The immunoconjugate of claim 9 having the formula Ab-(L-D)p, wherein:

10 (a) Ab is the antibody;


(b) L is a linker;

(c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a
15 nemorubicin derivative; and


(d) p ranges from 1-8.

11. The immunoconjugate of claim 10, wherein D

20 (i) has formula D_E



30 and wherein R^2 and R^6 are each methyl, R^3 and R^4 are each isopropyl, R^5 is H, R^7 is sec-butyl, each R^8 is independently selected from CH_3 , $O-CH_3$, OH, and H; R^9 is H; and R^{18} is $-C(R^8)_2-C(R^8)_2-aryl$; or
(ii) is a pyrrolobenzodiazepine of Formula A:



45 wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R^2 is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo;

46 R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo; R^7 is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

47 Q is independently selected from O, S and NH;

50 R^{11} is either H, or R or, where Q is O, SO₃M, where M is a metal cation;

51 R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₃₋₈ heterocycl and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

52 R^{12} , R^{16} , R^{19} and R^{17} are as defined for R^2 , R^6 , R^9 and R^7 respectively;

53 R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and

54 X and X' are independently selected from O, S and N(H); or

55 (iii) has a structure selected from:


5

10

15

20


and



25

30

35



12. The immunoconjugate of claim 11(i), wherein the drug is MMAE.

13. The immunoconjugate of claim 11(ii), wherein D has the structure:

40

45




50

wherein n is 0 or 1.

55

14. The immunoconjugate of any one of claims 10 to 13, wherein the linker is (i) cleavable by a protease, and optionally, wherein the linker comprises valine-citrulline dipeptide, an N-methyl-valine-citrulline dipeptide, an alanine-phenylalanine dipeptide, a phenylalanine-lysine dipeptide, or a phenylalanine-homolysine dipeptide, or (ii) acid-labile, and optionally, wherein the linker comprises hydrazone.



15. The immunoconjugate of claim 10 having a formula selected from:




45

50

55





ID No. 40, (iii) HVR-H3, umfassend die Aminosäuresequenz von SEQ ID No. 41; (iv) HVR-L1, umfassend die Aminosäuresequenz von SEQ ID No. 42, (v) HVR-L2, umfassend die Aminosäuresequenz von SEQ ID No. 43 und (vi) HVR-L3, umfassend die Aminosäuresequenz von SEQ ID No. 44.

5 2. Antikörper nach Anspruch 1, der ein humanisierter oder chimärer Antikörper ist.

10 3. Antikörper nach Anspruch 1, der ein Antikörperfragment ist, das an B7-H4 bindet.

15 4. Antikörper nach Anspruch 1, der außerdem eine Schwerkettengerüst-FR3-Sequenz von SEQ ID No. 51, 52 oder 53 umfasst.

20 5. Antikörper nach Anspruch 1, wobei der Antikörper Folgendes umfasst:

(a) eine VH-Sequenz mit zumindest 95 % Sequenzidentität in Bezug auf die Aminosäuresequenz von SEQ ID No. 36, 37 oder 38;

(b) eine VL-Sequenz mit zumindest 95 % Sequenzidentität in Bezug auf die Aminosäuresequenz von SEQ ID No. 35; oder

(c) eine VH-Sequenz wie in (a) und eine VL-Sequenz wie in (b); oder

(d) eine VH-Sequenz von SEQ ID No. 36 und eine VL-Sequenz von SEQ ID No. 35; oder

(e) eine VH-Sequenz von SEQ ID No. 37 und eine VL-Sequenz von SEQ ID No. 35; oder

(f) eine VH-Sequenz von SEQ ID No. 38 und eine VL-Sequenz von SEQ ID No. 35.

25 6. Antikörper nach einem der Ansprüche 1 bis 5, der ein IgG1-, IgG2a- oder IgG2b-Antikörper ist.

30 7. Isolierte Nucleinsäure, die für einen Antikörper nach einem der Ansprüche 1 bis 6 kodiert.

35 8. Wirtszelle, die eine Nucleinsäure nach Anspruch 7 umfasst.

40 9. Immunkonjugat, das einen Antikörper nach einem der Ansprüche 1 bis 6 und ein zytotoxisches Mittel umfasst.

45 10. Immunkonjugat nach Anspruch 9 mit der Formel $Ab-(L-D)_p$, worin:

(a) Ab ein Antikörper ist;


(b) L ein Linker ist;

(c) D ein aus einem Maytansinoid, einem Auristatin, einem Calicheamicin, einem Pyrrolobenzodiazepin und einem Neorubicinderivat ausgewähltes Arzneimittel ist; und

(d) p im Bereich von 1 bis 8 liegt.


50 11. Immunkonjugat nach Anspruch 10, worin D

(i) die Formel D_E aufweist:



worin R² und R⁶ jeweils Methyl sind, R³ und R⁴ jeweils Isopropyl sind, R⁵ H ist, R⁷ sec-Butyl ist, die R⁸ jeweils unabhängig aus CH₃, O-CH₃, OH und H ausgewählt sind; R⁹ H ist und R¹⁸ -C(R⁸)₂-C(R⁸)₂-Aryl ist; oder

(ii) ein Pyrrolobenzodiazepin der Formel A ist:



worin die gestrichelten Linien das optionale Vorliegen einer Doppelbindung zwischen C1 und C2 oder C2 und C3 anzeigen;

R² jeweils unabhängig aus H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R und COR ausgewählt ist und gegebenenfalls weiters aus Halogen oder Dihalogen ausgewählt ist, worin R^D jeweils unabhängig aus R, CO₂R, COR, CHO, CO₂H und Halogen ausgewählt ist;

R⁶ und R⁹ jeweils unabhängig aus H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn und Halogen ausgewählt sind;

R⁷ jeweils unabhängig aus H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn und Halogen ausgewählt ist; Q jeweils unabhängig aus O, S und NH ausgewählt ist;

R¹¹ entweder H oder R ist oder, wenn Q O ist, SO₃M ist, worin M ein Metallkation ist;


R und R' jeweils unabhängig aus gegebenenfalls substituierten C₁₋₈-Alkyl-, C₃₋₈-Heterocyclyl- und C₅₋₂₀-Arylgruppen ausgewählt sind und gegebenenfalls in Bezug auf die Gruppe NRR' zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen gegebenenfalls substituierten 4-, 5-, 6- oder 7-gliedrigen heterozyklischen Ring bilden;

R¹², R¹⁶, R¹⁹ und R¹⁷ jeweils wie R², R⁶, R⁹ bzw. R⁷ definiert sind;

R" eine C₃₋₁₂-Alkylengruppe ist, wobei die Kette gegebenenfalls durch ein oder mehrere Heteroatome und/oder aromatische Ringe, die gegebenenfalls substituiert sind, unterbrochen ist; und


X und X' jeweils unabhängig aus O, S und N(H) ausgewählt sind; oder

(iii) eine Struktur aufweist, die ausgewählt ist aus:



und

5



10

15


12. Immunkonjugat nach Anspruch 11(i), wobei das Arzneimittel MMAE ist.

20

13. Immunkonjugat nach Anspruch 11(ii), worin D die folgende Struktur aufweist:

25

30




worin $n = 0$ oder 1 ist.

35 14. Immunkonjugat nach einem der Ansprüche 10 bis 13, wobei der Linker (i) durch eine Protease spaltbar ist und gegebenenfalls Folgendes umfasst: ein Valin-Citrullin-Dipeptid, ein N-Methyl-Valin-Citrullin-Dipeptid, ein Alanin-Phenylalanin-Dipeptid, ein Phenylalanin-Lysin-Dipeptid oder ein Phenylalanin-Homolysin-Dipeptid oder (ii) säure-labil ist, und wobei der Linker gegebenenfalls Hydrazon umfasst.

40




15. Immunkonjugat nach Anspruch 10, das eine aus den folgenden ausgewählte Formel aufweist:


45




50

55







16. Pharmazeutische Formulierung, die ein Immunkonjugat nach einem der Ansprüche 10 bis 15 und einen pharmazeutisch annehmbaren Träger umfasst.

17. Immunkonjugat nach einem der Ansprüche 10 bis 15 zur Verwendung in einem Verfahren zur Behandlung eines Individuums mit einem B7-H4-positiven Krebs, wobei das Verfahren das Verabreichen einer wirksamen Menge des Immunkonjugats an das Individuum umfasst.

18. Immunkonjugat zur Verwendung nach Anspruch 17, wobei der B7-H4-positive Krebs aus Brustkrebs, Eierstockkrebs und Endometriumkrebs ausgewählt ist.

Revendications

1. Anticorps monoclonal isolé qui se lie à B7-H4, où l'anticorps comprend (i) une HVR-H1 comprenant la séquence d'acides aminés de SEQ ID NO: 39, (ii) une HVR-H2 comprenant la séquence d'acides aminés de SEQ ID NO: 40, (iii) une HVR-H3 comprenant la séquence d'acides aminés de SEQ ID NO: 41 ; (iv) une HVR-L1 comprenant la séquence d'acides aminés de SEQ ID NO: 42, (v) une HVR-L2 comprenant la séquence d'acides aminés de SEQ ID NO: 43, et (vi) une HVR-L3 comprenant la séquence d'acides aminés de SEQ ID NO: 44.

2. Anticorps selon la revendication 1, qui est un anticorps humanisé ou chimérique.

3. Anticorps selon la revendication 1, qui est un fragment d'anticorps qui se lie à B7-H4.

4. Anticorps selon la revendication 1, comprenant en outre une séquence FR3 de charpente de chaîne lourde de SEQ ID NO: 51, 52, ou 53.

5. Anticorps selon la revendication 1, où l'anticorps comprend

(a) une séquence VH présentant au moins 95 % d'identité de séquence avec la séquence d'acides aminés de SEQ ID NO: 36, 37, ou 38 ;

(b) une séquence VL présentant au moins 95 % d'identité de séquence avec la séquence d'acides aminés de SEQ ID NO: 35 ; ou

(c) une séquence VH telle que en (a) et une séquence VL telle que en (b) ; ou

(d) une séquence VH de SEQ ID NO: 36 et une séquence VL de SEQ ID NO: 35 ; ou

(e) une séquence VH de SEQ ID NO: 37 et une séquence VL de SEQ ID NO: 35 ; ou

(f) une séquence VH de SEQ ID NO: 38 et une séquence VL de SEQ ID NO: 35.

6. Anticorps selon l'une quelconque des revendications 1 à 5, qui est un anticorps IgG1, IgG2a ou IgG2b.

7. Acide nucléique isolé codant pour l'anticorps selon l'une quelconque des revendications 1 à 6.

8. Cellule hôte comprenant l'acide nucléique selon la revendication 7.


9. Immunoconjugué comprenant l'anticorps selon l'une quelconque des revendications 1 à 6 et un agent cytotoxique.

5 10. Immunoconjugué selon la revendication 9 possédant la formule Ab-(L-D)p, dans laquelle :

(a) Ab est l'anticorps ;
 (b) L est un segment de liaison ;
 (c) D est un médicament sélectionné parmi un maytansinoïde, une auristatine, une calichéamicine, une pyrrolobenzodiazépine, et un dérivé de némorubicine ; et
 10 (d) p est compris entre 1 et 8.


11. Immunoconjugué selon la revendication 10, dans lequel D

15 (i) possède la formule D_E



et dans laquelle R² et R⁶ sont chacun méthyle, R³ et R⁴ sont chacun isopropyle, R⁵ est H, R⁷ est sec-butyle, chaque R⁸ est indépendamment sélectionné parmi CH₃, O-CH₃, OH, et H ; R⁹ est H ; et R¹⁸ est -C(R⁸)₂-C(R⁸)₂-aryle ; ou

30 (ii) est une pyrrolobenzodiazépine de Formule A :



45 dans laquelle les lignes en pointillés indiquent la présence facultative d'une double liaison entre C1 et C2 ou C2 et C3 ;

R² est indépendamment sélectionné parmi H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R et COR, et facultativement en outre sélectionné parmi halo ou dihalo, où R^D est indépendamment sélectionné parmi R, CO₂R, COR, CHO, CO₂H, et halo ;

R⁶ et R⁹ sont indépendamment sélectionnés parmi H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn et halo ; R⁷ est indépendamment sélectionné parmi H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn et halo ; Q est indépendamment sélectionné parmi O, S et NH ;

50 R¹¹ est soit H, soit R ou, lorsque Q est O, SO₃M, où M est un cation métallique ;

R et R' sont chacun indépendamment sélectionnés parmi des groupes alkyle en C₁₋₈, hétérocyclyle en C₃₋₈ et aryle en C₅₋₂₀ facultativement substitués, et facultativement par rapport au groupe NRR', R et R' conjointement avec l'atome d'azote auquel ils sont attachés forment un cycle hétérocyclique à 4, 5, 6 ou 7 chaînons facultativement substitué ;

55 R¹², R¹⁶, R¹⁹ et R¹⁷ sont tels que définis pour R², R⁶, R⁹ et R⁷ respectivement ;

R" est un groupe alkylène en C₃₋₁₂, dont la chaîne peut être interrompue par un ou plusieurs hétéroatomes et/ou cycles aromatiques qui sont facultativement substitués ; et

X et X' sont indépendamment sélectionnés parmi O, S et N(H) ; ou

(iii) possède une structure sélectionnée parmi :

5


10

15

20

25

et



30

35


40

50

55

45 12. Immunoconjugué selon la revendication 11(i), dans lequel le médicament est la MMAE.

13. Immunoconjugué selon la revendication 11(ii), dans lequel D possède la structure :








dans laquelle n est 0 ou 1.



15 14. Immunoconjugué selon l'une quelconque des revendications 10 à 13, dans lequel le segment de liaison est (i) clivable par une protéase, et facultativement, dans lequel le segment de liaison comprend un dipeptide valine-citrulline, un dipeptide N-méthyl-valine-citrulline, un dipeptide alanine-phénylalanine, un dipeptide phénylalanine-lysine, ou un dipeptide phénylalanine-homolysine, ou (ii) labile en milieu acide, et facultativement, dans lequel le segment de liaison comprend une hydrazone.

20

15. Immunoconjugué selon la revendication 10, possédant une formule sélectionnée parmi :







16. Formulation pharmaceutique comprenant l'immunoconjugué selon l'une quelconque des revendications 10 à 15 et un véhicule pharmaceutiquement acceptable.

17. Immunoconjugué selon l'une quelconque des revendications 10 à 15 destiné à être utilisé dans un procédé de traitement d'un individu souffrant d'un cancer positif pour B7-H4, le procédé comprenant l'administration à l'individu d'une quantité efficace dudit immunoconjugué.

18. Immunoconjugué destiné à être utilisé selon la revendication 17, dans lequel le cancer positif pour B7-H4 est sélectionné parmi le cancer du sein, le cancer de l'ovaire, et le cancer de l'endomètre.

FIGURE 1





FIGURE 2

Breast Carcinomas



Normal Breast






FIGURE 3**(A)****(B)**

FIGURE 3




FIGURE 3

(D)




FIGURE 3

(E)




FIGURE 4

(A) Antibody	Affinity ⁽¹⁾	Epitope Group ⁽²⁾	Domain ⁽³⁾	Comments
1D11	H - 6.1nM C - 4.1nM M - 9.4nM R - 4.1nM	A	Ig-V	Protein immunization (mB7-H4:Fc) mB7-H4 (-) mouse
9B9	H - 6.6nM C - 5.2nM M - 13.7nM R - 4.7nM	A	Ig-V	Cellular immunization 293-hB7-H4 cells
3.22.C10	H - 6.6nM C - 4.6nM M - 18.3nM R - 5.7nM	B	Ig-V/IgC	Cellular immunization 293-hB7-H4 cells
2.32D6	H - 4.8nM C - 3.1nM M - NB R - NB	C	Ig-V	DNA immunization & hB7-H4:Fc boost

¹ Scatchard on stable cell line expressing recombinant B7-H4

² Determined by FACS competition

³ FACS (chimeric Ig domains)





FIGURE 5

xB7H4 Hybridoma Clones VL SEQ Alignment

xB7H4	Hybrideroma	Clones	CDR-L1	CDR-L2
m22C10	Q I V L T Q S P T I M S A S P G E K V T L T C S A T	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	S S I S Y M H W Y Q Q K P G T S P K G W I Y D T S K L A H G V P	50 51 52 53 54 55 56 57 58 59
m32D6	D I V M T Q S P S S L I V T A G E K V T M S C R S S Q S L F D S G S Q R N Y L T W H Q K P G R P P K L L I Y W A S T R E S G V P	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34		
m989	Q A V V T Q E S A . L T T S P G D T V T L T C R S S T G A V	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	T T S S N Y A N W V Q E K P D H L F T G L I G G T N N R V P G V P	
m1D11	D I Q M T Q S P S S L S A S L G G K V T I T C K A S Q	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	G F N K Y V A W Y Q H K P G Q C P R L L I H Y T S T L Q P G I P	
xB7H4	Hybrideroma	Clones	CDR-L3	
m22C10	A R F S G S G S G T S Y S L T I S S M E A F D A A T Y Y H C Q R R S Y P F T F G S G T K L E	60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105		
m32D6	D R F T G S G S G T D F T L T I S S V Q T E D L A V Y F C Q N D Y S F P F T F G S G T K L E	60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105		
m989	A R F S G S G S L I G D K A A L T I T G A Q T E D E A M Y F C A L W Y N N H W V F G G G T K L E	60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105		
m1D11	A R F S G S G S G R D Y S F S I S N L E P E D S A T Y F C L Q Y G N L L Y A F G G G T K L E	60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105		

xB7H4 Hybridoma Clones VH SEQ Alignment

xB7H4		Hybridoma												CDR-H1												CDR-H2																																																																																																																												
Clones	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150
m22C10	Q	V	Q	L	Q	P	Q	G	A	E	L	V	K	P	G	T	S	V	K	L	S	C	K	A	S	G	Y	T	F	T	N	F	W	I	H	W	V	I	Q	R	P	G	G	L	E	W	I	G	E	I	D	P	S	D	S	Y	T	N	Y	N	Q	K	F	K	G																																																																																					
m32D6	E	V	Q	L	Q	Q	S	G	P	D	L	V	K	P	G	A	S	V	K	I	S	C	K	A	S	G	Y	F	T	G	Y	Y	I	H	W	M	K	Q	S	H	G	K	S	L	E	W	I	G	R	V	N	P	N	G	D	P	I	Y	N	Q	K	F	R	G																																																																																						
m9B9	Q	V	Q	L	Q	Q	S	G	A	E	L	M	K	P	G	A	S	V	K	M	S	C	K	A	S	G	Y	T	F	S	S	Y	W	I	E	V	W	K	Q	R	P	G	H	G	L	E	W	I	G	E	I	L	P	G	T	S	I	T	T	Y	N	A	K	F	K	V																																																																																				
mlD11	Q	V	Q	L	Q	Q	S	G	A	E	L	V	R	P	G	T	S	V	K	M	S	C	K	A	S	G	Y	T	F	T	S	Y	W	I	G	W	A	K	Q	R	P	G	H	F	E	W	I	G	D	I	Y	P	G	G	G	Y	T	N	Y	N	E	K	F	K	G																																																																																					

FIGURE 6

Light Chain Variable Domain Sequence Alignment of xB7H4 m1D11 & h1D11.v1-4 with HuKI

Highlight framework difference by comparison m1D11 and h1D11.v1-4 to consensus human VL kappa 1

FIGURE 6 (continued)

Light Chain Variable Domain Sequence
Alignment of xB7H4 m1D11 & h1D11.v1.1-1.9 with HuKI

Kabat#	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42						
													Kabat - CDR L1				Chothia - CDR L1				Contact - CDR L1																											
huKI	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	S	S	Y	L	A	W	Y	Q	K	P	G	K							
m1D11	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	G	█	█	█	█	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K						
h1D11.v1.1	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.2	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.3	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.4	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.5	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.6	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.7	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.8	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
h1D11.v1.9	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	K	A	S	Q	G	F	N	K	Y	V	A	W	Y	Q	K	P	G	K							
*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*		
Kabat#	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84						
												Kabat - CDR L2				Chothia - CDR L2				Contact - CDR L2																												
huKI	A	P	K	L	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A						
m1D11	█	█	P	L	L	I	█	Y	T	S	T	L	Q	P	G	█	█	P	█	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	█	A							
h1D11.v1.1	A	P	K	L	L	I	Y	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.2	A	P	K	L	L	I	█	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.3	A	P	K	L	L	I	█	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.4	A	P	K	L	L	I	█	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.5	A	P	K	L	L	I	█	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.6	A	P	K	L	L	I	█	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.7	A	P	K	L	L	I	Y	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.8	A	P	K	L	L	I	Y	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
h1D11.v1.9	A	P	K	L	L	I	Y	Y	T	S	T	L	Q	P	G	V	P	S	R	F	S	G	S	G	S	G	D	█	█	█	I	S	█	L	█	P	E	D	F	A								
*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*		
Kabat#	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124								
												Kabat - CDR L3				Chothia - CDR L3				Contact - CDR L3																												
huKI	T	Y	Y	C	Q	Q	Y	Y	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																								
m1D11	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	█	G	T	K	█	█	E	I	K	R																							
h1D11.v1.1	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.2	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.3	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.4	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.5	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.6	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.7	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.8	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
h1D11.v1.9	T	Y	Y	C	L	Q	Y	G	N	L	L	Y	A	F	G	Q	G	T	K	V	E	I	K	R																								
*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

 **Highlight framework difference by comparison m1D11 and h1D11.v1.1-1.9 to consensus human VL kappa 1**

FIGURE 7

**Heavy Chain Variable Domain Sequence
Alignment of xB7H4 m1D11 & h1D11.v1-4 with HuVH1**




FIGURE 7

Highlight framework difference by comparison m1D11 and h1D11.v1-4 to consensus human VH subgroup 1

FIGURE 7 (continued)

Heavy Chain Variable Domain Sequence Alignment of xB7H4 m1D11 & h1D11.v1.1-1.9 with HuVH1

Highlight framework difference by comparison m1D11 and h1D11.v1.1-1.9 to consensus human VH subgroup 1

FIGURE 8

Light Chain Variable Domain Sequence Alignment of xB7H4 m22C10 & h22C10.v1-5 with HuKI

Highlight framework difference by comparison m22C10 and h22C10.v1-5 to consensus human VL kappa 1


FIGURE 8 (continued)

**Light Chain Variable Domain Sequence
Alignment of xB7H4 m22C10 & h22C10.v2.1-2.8 with HuKI**

Kabat8		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42									
Kabat - CDR L1 Chothia - CDR L1 Contact - CDR L1																																																				
huKI	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	S	S	Y	L	A	W	Y	Q	Q	K	P	G	K										
m22C10	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█				
h22C10.v2.1	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.2	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.3	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.4	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.5	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.6	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.7	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
h22C10.v2.8	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	T	-	S	S	I	S	Y	M	H	W	Y	Q	Q	K	P	G	K										
	*	*																																																		
Kabat8		43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84									
Kabat - CDR L2 Chothia - CDR L2 Contact - CDR L2																																																				
huKI	A	P	K	L	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A											
m22C10	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█	█				
h22C10.v2.1	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.2	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.3	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.4	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.5	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.6	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.7	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
h22C10.v2.8	A	P	K	L	L	I	Y	D	T	S	K	L	A	H	G	V	P	S	R	F	S	G	S	G	G	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A										
	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*				
Kabat8		85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108																											
Kabat - CDR L3 Chothia - CDR L3 Contact - CDR L3																																																				
huKI	T	Y	Y	C	Q	Q	Y	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																													
m22C10	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.1	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.2	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.3	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.4	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.5	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.6	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.7	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
h22C10.v2.8	T	Y	Y	C	H	Q	R	R	S	Y	P	F	T	F	G	Q	G	T	K	V	E	I	K	R																												
	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Highlight framework difference by comparison m22C10 and h22C10.v2.1-2.8 to consensus human VL kappa 1

FIGURE 9



 **Highlight framework difference by comparison m22C10 and h22C10.v1-5 to consensus human VH subgroup 1**

FIGURE 9 (continued)

Heavy Chain Variable Domain Sequence Alignment of xB7H4 m22C10 & h22C10.v2.1-2.8 with HuVH1

Highlight framework difference by comparison m22C10 and h22C10.v2.1-2.8 to consensus human VH subgroup 1

FIGURE 10

	Human	Chimp	Cyno	Mouse	Rat
Identity %	100	96.09	98.6	87.63	86.87
Similarity %	100	97.42	98.8	90.12	89.3

Rat B7-H4 is 97.17
Identical to Mouse B7-H4

Sequence alignment of B7-H4 across species. The alignment shows high conservation of the protein structure across humans, chimpanzees, cynomolgus monkeys, mice, and rats. The sequence is presented in blocks, with gaps indicated by dashes. Amino acid positions are indicated on the left. Conserved residues are highlighted with black boxes, and identical residues are marked with dots. The alignment shows a highly conserved N-terminal domain and a C-terminal domain with a transmembrane region.

Residues highlighted in black boxes are conserved across all species. Identical residues are marked with dots.

Key regions highlighted in black boxes include:

- Residues 1-50: N-terminal domain, including a signal peptide-like sequence.
- Residues 51-100: A domain with a conserved sequence motif.
- Residues 101-150: A domain with a conserved sequence motif.
- Residues 151-200: A domain with a conserved sequence motif.
- Residues 201-250: A domain with a conserved sequence motif, including a transmembrane region.

FIGURE 11




FIGURE 12

Antibody	Affinity (MX-1)	Affinity of parent antibody (MX-1)	Fold to Parent mAb	Epitope	Mouse Framework Residues
1D11hv1.7	8.3 nM	7.8 nM	0.94	A	LC – R69, Y71 HC – A67, L69
1D11hv1.8	8.7 nM	7.8 nM	0.89	A	LC – R69, Y71 HC – A67
1D11hv1.9	7.8 nM	7.8 nM	1	A	LC – R69, Y71 HC – None
22C10hv2.7	6.3 nM	4.9nM	0.78	C	LC - G46, W47 HC - None
22C10hv2.8	10 nM	4.9nM	.49	C	LC - G46 HC - None

FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16

HBCX-24 Triple negative breast cancer primary transplant model




FIGURE 17




FIGURE 18






FIGURE 19

A



B



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2009073533 A [0004]
- WO 2008067283 A [0004]
- WO 2004101756 A [0004]
- WO 2006053110 A [0004]
- WO 2013025779 A [0004]
- US 20090208489 A [0004]
- WO 9316185 A [0187]
- US 5571894 A [0187]
- US 5587458 A [0187]
- US 5869046 A [0187]
- EP 404097 A [0188]
- WO 199301161 A [0188]
- US 6248516 B1 [0189]
- US 4816567 A [0191] [0229]
- US 5821337 A [0193] [0202]
- US 7527791 B [0193]
- US 6982321 B [0193]
- US 7087409 B [0193]
- US 6075181 A [0196]
- US 6150584 A [0196]
- US 5770429 A [0196]
- US 7041870 B [0196]
- US 20070061900 A [0196]
- US 7189826 B [0197]
- US 5750373 A [0200]
- US 20050079574 A [0200]
- US 20050119455 A [0200]
- US 20050266000 A [0200]
- US 20070117126 A [0200]
- US 20070160598 A [0200]
- US 20070237764 A [0200]
- US 20070292936 A [0200]
- US 20090002360 A [0200]
- WO 9308829 A [0203]
- US 5731168 A [0203]
- WO 2009089004 A1 [0203]
- US 4676980 A [0203]
- US 20060025576 A1 [0204]
- US 20080069820 A [0205]
- WO 2008077546 A [0216]
- US 20030157108 A [0216]
- US 20040093621 A [0216]
- WO 200061739 A [0216]
- WO 200129246 A [0216]
- US 20030115614 A [0216]
- US 20020164328 A [0216]
- US 20040132140 A [0216]
- US 20040110704 A [0216]
- US 20040110282 A [0216]
- US 20040109865 A [0216]
- WO 2003085119 A [0216]
- WO 2003084570 A [0216]
- WO 2005035586 A [0216]
- WO 2005035778 A [0216]
- WO 2005053742 A [0216]
- WO 2002031140 A [0216]
- US 20030157108 A1 [0216]
- WO 2004056312 A1 [0216]
- WO 2003085107 A [0216]
- WO 2003011878 A, Jean-Mairet [0217]
- US 6602684 B, Umana [0217]
- US 20050123546 A, Umana [0217]
- WO 199730087 A, Patel [0217]
- WO 199858964 A, Raju, S. [0217]
- WO 199922764 A, Raju, S. [0217]
- US 5500362 A [0219]
- WO 5821337 A [0219]
- WO 2006029879 A [0219]
- WO 2005100402 A [0219]
- US 6737056 B [0220] [0221]
- US 7332581 B [0220]
- WO 2004056312 A [0221]
- US 6194551 B [0223]
- WO 9951642 A [0223]
- US 20050014934 A1, Hinton [0224]
- US 7371826 B [0224]
- US 5648260 A [0225]
- US 5624821 A [0225]
- WO 9429351 A [0225]
- US 7521541 B [0226]
- US 5648237 A [0231]
- US 5789199 A [0231]
- US 5840523 A [0231]
- US 5959177 A [0234]
- US 6040498 A [0234]
- US 6420548 B [0234]
- US 7125978 B [0234]
- US 6417429 B [0234]
- US 5208020 A [0251] [0272] [0273] [0277] [0278] [0279]
- US 7498298 B [0252] [0281] [0297] [0298] [0347] [0351]
- US 7375078 B [0257]
- US 6214345 B [0264]
- WO 02088172 A [0264] [0280]
- US 2003130189 A [0264]
- US 2003096743 A [0264]
- WO 03026577 A [0264]

- WO 03043583 A [0264]
- WO 04032828 A [0264]
- WO 9411026 A [0265]
- US 3896111 A [0266]
- US 4151042 A [0266]
- US 4137230 A [0266]
- US 4248870 A [0266]
- US 4256746 A [0266] [0269]
- US 4260608 A [0266]
- US 4265814 A [0266]
- US 4294757 A [0266] [0269]
- US 4307016 A [0266] [0269]
- US 4308268 A [0266]
- US 4308269 A [0266]
- US 4309428 A [0266]
- US 4313946 A [0266] [0270]
- US 4315929 A [0266] [0270]
- US 4317821 A [0266]
- US 4322348 A [0266] [0270]
- US 4331598 A [0266] [0270]
- US 4361650 A [0266] [0269]
- US 4364866 A [0266] [0270]
- US 4424219 A [0266] [0270]
- US 4450254 A [0266] [0270]
- US 4362663 A [0266] [0270]
- US 4371533 A [0266] [0270]
- US 633410 A [0272] [0273]
- US 7276497 B [0273]
- US 6913748 B [0273]
- US 6441163 B [0273]
- US RE39151 E [0273]
- US 5416064 A [0277]
- US 20050276812 A1 [0277] [0279]
- EP 0425235 B1 [0277] [0279]
- US 2005016993 A1 [0279]
- US 5635483 A [0280] [0297]
- US 5780588 A [0280] [0297]
- US 5767237 A [0280]
- US 6124431 A [0280]
- US 5663149 A [0280]
- US 7659241 B [0281]
- WO 2007008848 A [0294]
- WO 2007008603 A [0294]
- US 5712374 A [0299]
- US 5714586 A [0299]
- US 5739116 A [0299]
- US 5767285 A [0299]
- US 6884799 B [0300]
- US 7049311 B [0300]
- US 7067511 B [0300]
- US 7265105 B [0300]
- US 7511032 B [0300]
- US 7528126 B [0300]
- US 7557099 B [0300]
- WO 0012507 A [0301]
- WO 2005023814 A [0301]
- US 20100203007 A [0302]
- WO 2009016516 A [0302] [0329]
- US 2009304710 A [0302] [0329]
- US 2010047257 A [0302] [0329]
- US 2009036431 A [0302] [0329]
- US 20110256157 A [0302] [0329]
- WO 2011130598 A [0302] [0329]
- EP 0328147 A [0331]
- US 6630579 B [0331]
- US 20110076287 A [0338]
- WO 2009099741 A [0338]
- US 20100034837 A [0338]
- WO 2010009124 A [0338]
- WO 9321232 A [0341]
- WO 2011056983 A [0343]
- WO 8101145 A [0345]
- US 5362852 A [0353]
- US 4737456 A [0362]
- US 20050260186 A [0363]
- US 20060104968 A [0363]
- US 6267958 B [0364]
- US 6171586 B [0364]
- WO 2006044908 A [0364]
- US 6602677 B [0371]
- WO 2004010957 A2 [0432]
- US 20050238649 A1 [0432]
- EP 14717318 A [0445]
- US 2014025285 W [0445]
- US 61784877 B [0445]
- US 61785811 B [0445]
- US 61874175 B [0445]

Non-patent literature cited in the description

- **ZHU et al.** *Blood*, 2009, vol. 113 (8), 1759-1767 [0002]
- **SUH et al.** *Molecular and Cellular Biology*, 2006, vol. 26 (17), 6403-6411 [0002]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. Public Health Service, National Institutes of Health, 1991 [0044] [0052]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. NIH Publication, 1991, vol. 1-3, 91-3242 [0050]
- **CHOTHIA ; LESK.** *J. Mol. Biol.*, 1987, vol. 196, 901-917 [0052]
- **ALMAGRO ; FRANSSON.** *Front. Biosci.*, 2008, vol. 13, 1619-1633 [0052] [0193] [0194]
- **FLATMAN et al.** *J. Chromatogr. B*, 2007, vol. 848, 79-87 [0055]
- **KINDT et al.** Kuby Immunology. W.H. Freeman and Co, 2007, 91 [0070]
- **PORTOLANO et al.** *J. Immunol.*, 1993, vol. 150, 880-887 [0070]

- CLARKSON et al. *Nature*, 1991, vol. 352, 624-628 [0070]
- PAQUETTE, LEO A. *Principles of Modern Heterocyclic Chemistry*. W.A. Benjamin, 1968 [0091]
- The Chemistry of Heterocyclic Compounds, A series of Monographs. John Wiley & Sons, 1950, vol. 13, 14, 16, 19, 28 [0091]
- *J. Am. Chem. Soc.*, 1960, vol. 82, 5566 [0091]
- McGraw-Hill Dictionary of Chemical Terms. McGraw-Hill Book Company, 1984 [0107]
- ELIEL, E. ; WILEN, S. *Stereochemistry of Organic Compounds*. John Wiley & Sons, Inc, 1994 [0107]
- T. W. GREENE. *Protective Groups in Organic Synthesis*. John Wiley & Sons, 1991 [0109]
- CHEN et al. *J. Mol. Biol.*, 1999, vol. 293, 865-881 [0185] [0186]
- PRESTA et al. *Cancer Res.*, 1997, vol. 57, 4593-4599 [0185]
- HUDSON et al. *Nat. Med.*, 2003, vol. 9, 129-134 [0187] [0188]
- PLUCKTHÜN. *The Pharmacology of Monoclonal Antibodies*. Springer-Verlag, 1994, vol. 113, 269-315 [0187]
- HOLLINGER et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0188] [0203]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851-6855 [0191]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323-329 [0193]
- QUEEN et al. *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 10029-10033 [0193]
- KASHMIRI et al. *Methods*, 2005, vol. 36, 25-34 [0193]
- PADLAN. *Mol. Immunol.*, 1991, vol. 28, 489-498 [0193]
- DALL'ACQUA et al. *Methods*, 2005, vol. 36, 43-60 [0193]
- OSBOURN et al. *Methods*, 2005, vol. 36, 61-68 [0193]
- KLIMKA et al. *Br. J. Cancer*, 2000, vol. 83, 252-260 [0193]
- SIMS et al. *J. Immunol.*, 1993, vol. 151, 2296 [0194]
- CARTER et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285 [0194]
- PRESTA et al. *J. Immunol.*, 1993, vol. 151, 2623 [0194]
- BACA et al. *J. Biol. Chem.*, 1997, vol. 272, 10678-10684 [0194]
- ROSOK et al. *J. Biol. Chem.*, 1996, vol. 271, 22611-22618 [0194]
- VAN DIJK ; VAN DE WINKEL. *Curr. Opin. Pharmacol.*, 2001, vol. 5, 368-74 [0195]
- LONBERG. *Curr. Opin. Immunol.*, 2008, vol. 20, 450-459 [0195]
- LONBERG. *Nat. Biotech.*, 2005, vol. 23, 1117-1125 [0196]
- KOZBOR. *J. Immunol.*, 1984, vol. 133, 3001 [0197]
- BRODEUR et al. *Monoclonal Antibody Production Techniques and Applications*. Marcel Dekker, Inc, 1987, 51-63 [0197]
- BOERNER et al. *J. Immunol.*, 1991, vol. 147, 86 [0197]
- LI et al. *Proc. Natl. Acad. Sci. USA*, 2006, vol. 103, 3557-3562 [0197]
- NI. *Xiandai Mianyixue*, 2006, vol. 26 (4), 265-268 [0197]
- VOLLMERS ; BRANDLEIN. *Histology and Histopathology*, 2005, vol. 20 (3), 927-937 [0197]
- VOLLMERS ; BRANDLEIN. *Methods and Findings in Experimental and Clinical Pharmacology*, 2005, vol. 27 (3), 185-91 [0197]
- HOOGENBOOM et al. *Methods in Molecular Biology*. Human Press, 2001, vol. 178, 1-37 [0199] [0210]
- MCCAFFERTY et al. *Nature*, vol. 348, 552-554 [0199]
- CLACKSON et al. *Nature*, 1991, vol. 352, 624-628 [0199]
- MARKS et al. *J. Mol. Biol.*, 1992, vol. 222, 581-597 [0199]
- MARKS ; BRADBURY. *Methods in Molecular Biology*. Human Press, 2003, vol. 248, 161-175 [0199]
- SIDHU et al. *J. Mol. Biol.*, 2004, vol. 338 (2), 299-310 [0199]
- LEE et al. *J. Mol. Biol.*, 2004, vol. 340 (5), 1073-1093 [0199]
- FELLOUSE. *Proc. Natl. Acad. Sci. USA*, 2004, vol. 101 (34), 12467-12472 [0199]
- LEE et al. *J. Immunol. Methods*, 2004, vol. 284 (1-2), 119-132 [0199]
- WINTER et al. *Ann. Rev. Immunol.*, 1994, vol. 12, 433-455 [0200]
- GRIFFITHS et al. *EMBO J.*, 1993, vol. 12, 725-734 [0200]
- HOOGENBOOM ; WINTER. *J. Mol. Biol.*, 1992, vol. 227, 381-388 [0200]
- MILSTEIN ; CUELLO. *Nature*, 1983, vol. 305, 537 [0203]
- TRAUNECKER et al. *EMBO J.*, 1991, vol. 10, 3655 [0203]
- BRENNAN et al. *Science*, 1985, vol. 229, 81 [0203]
- KOSTELNY et al. *J. Immunol.*, 1992, vol. 148 (5), 1547-1553 [0203]
- GRUBER et al. *J. Immunol.*, 1994, vol. 152, 5368 [0203]
- TUTT et al. *J. Immunol.*, 1991, vol. 147, 60 [0203]
- CHOWDHURY. *Methods Mol. Biol.*, 2008, vol. 207, 179-196 [0210]
- CUNNINGHAM ; WELLS. *Science*, 1989, vol. 244, 1081-1085 [0212]
- WRIGHT et al. *TIBTECH*, 1997, vol. 15, 26-32 [0215]
- OKAZAKI et al. *J. Mol. Biol.*, 2004, vol. 336, 1239-1249 [0216]
- YAMANE-OHNUKI et al. *Biotech. Bioeng.*, 2004, vol. 87, 614 [0216]

- **RIPKA** et al. *Arch. Biochem. Biophys.*, 1986, vol. 249, 533-545 [0216]
- **KANDA, Y.** et al. *Biotechnol. Bioeng.*, 2006, vol. 94 (4), 680-688 [0216]
- **RAVETCH ; KINET.** *Annu. Rev. Immunol.*, 1991, vol. 9, 457-492 [0219]
- **HELLSTROM, I.** et al. *Proc. Nat'l Acad. Sci. USA*, 1986, vol. 83, 7059-7063 [0219]
- **HELLSTROM, I** et al. *Proc. Nat'l Acad. Sci. USA*, 1985, vol. 82, 1499-1502 [0219]
- **BRUGGEMANN, M.** et al. *J. Exp. Med.*, 1987, vol. 166, 1351-1361 [0219]
- **CLYNES** et al. *Proc. Nat'l Acad. Sci. USA*, 1998, vol. 95, 652-656 [0219]
- **GAZZANO-SANTORO** et al. *J. Immunol. Methods*, 1996, vol. 202, 163 [0219]
- **CRAGG, M.S.** et al. *Blood*, 2003, vol. 101, 1045-1052 [0219]
- **CRAGG, M.S. ; M.J. GLENNIE.** *Blood*, 2004, vol. 103, 2738-2743 [0219]
- **PETKOVA, S.B.** et al. *Int'l. Immunol.*, 2006, vol. 18 (12), 1759-1769 [0219]
- **SHIELDS** et al. *J. Biol. Chem.*, 2001, vol. 9 (2), 6591-6604 [0221]
- **IDUSOGIE** et al. *J. Immunol.*, 2000, vol. 164, 4178-4184 [0223]
- **GUYER** et al. *J. Immunol.*, 1976, vol. 117, 587 [0224]
- **KIM** et al. *J. Immunol.*, 1994, vol. 24, 249 [0224]
- **DUNCAN ; WINTER.** *Nature*, 1988, vol. 322, 738-40 [0225]
- **KAM** et al. *Proc. Natl. Acad. Sci. USA*, 2005, vol. 102, 11600-11605 [0228]
- **CHARLTON.** *Methods in Molecular Biology*. Humana Press, 2003, vol. 248, 245-254 [0231]
- **GERNGROSS.** *Nat. Biotech.*, 2004, vol. 22, 1409-1414 [0232]
- **LI** et al. *Nat. Biotech.*, 2006, vol. 24, 210-215 [0232]
- **GRAHAM** et al. *J. Gen Virol.*, 1977, vol. 36, 59 [0235]
- **MATHER.** *Biol. Reprod.*, 1980, vol. 23, 243-251 [0235]
- **MATHER** et al. *Annals N.Y. Acad. Sci.*, 1982, vol. 383, 44-68 [0235]
- **URLAUB** et al. *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 4216 [0235]
- **YAZAKI ; WU.** *Methods in Molecular Biology*. Humana Press, 2003, vol. 248, 255-268 [0235]
- Epitope Mapping Protocols. **MORRIS.** *Methods in Molecular Biology*. Humana Press, 1996, vol. 66 [0238]
- **HARLOW ; LANE.** *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laboratory, 1988 [0239]
- **POLAKIS P.** *Current Opinion in Pharmacology*, 2005, vol. 5, 382-387 [0241]
- **TEICHER, B.A.** *Current Cancer Drug Targets*, 2009, vol. 9, 982-1004 [0242]
- **CARTER, P.J. ; SENTER P.D.** *The Cancer Jour.*, 2008, vol. 14 (3), 154-169 [0242]
- **CHARI, R.V.** *Acc. Chem. Res.*, 2008, vol. 41, 98-107 [0242]
- **LYON, R.** et al. *Methods in Enzym.*, 2012, vol. 502, 123-138 [0246]
- **KLUSSMAN** et al. *Bioconjugate Chemistry*, 2004, vol. 15 (4), 765-773 [0248]
- **CHARI** et al. *Cancer Research*, 1992, vol. 52, 127-131 [0251] [0277] [0279]
- **DORONINA** et al. *Nat. Biotechnol.*, 2003, vol. 21, 778-784 [0254] [0432]
- **HAMANN** et al. *Expert Opin. Ther. Patents*, 2005, vol. 15, 1087-1103 [0256]
- **HAY** et al. *Bioorg. Med. Chem. Lett.*, 1999, vol. 9, 2237 [0257]
- **RODRIGUES** et al. *Chemistry Biology*, 1995, vol. 2, 223 [0257]
- **STORM** et al. *J. Amer. Chem. Soc.*, 1972, vol. 94, 5815 [0257]
- **AMSBERRY** et al. *J. Org. Chem.*, 1990, vol. 55, 5867 [0257]
- **KINGSBURY** et al. *J. Med. Chem.*, 1984, vol. 27, 1447 [0257]
- **SUN** et al. *Bioorganic & Medicinal Chemistry Letters*, 2002, vol. 12, 2213-2215 [0258]
- **SUN** et al. *Bioorganic & Medicinal Chemistry*, 2003, vol. 11, 1761-1768 [0258]
- **E. SCHRÖDER ; K. LÜBKE.** *The Peptides*. Academic Press, 1965, vol. 1, 76-136 [0261] [0297]
- **TOKI** et al. *J. Org. Chem.*, 2002, vol. 67, 1866-1872 [0264]
- **DUBOWCHIK** et al. *Tetrahedron Letters*, 1997, vol. 38 [0264]
- **WALKER, M.A.** *J. Org. Chem.*, 1995, vol. 60, 5352-5355 [0264]
- **FRISCH** et al. *Bioconjugate Chem.*, 1996, vol. 7, 180-186 [0264]
- **YU** et al. *PNAS*, 2002, vol. 99, 7968-7973 [0268]
- **CHARI** et al. *Cancer Res.*, 1992, vol. 52, 127-131 [0272]
- **LIU** et al. *Proc. Natl. Acad. Sci USA*, 1996, vol. 93, 8618-8623 [0272]
- **WIDDISON** et al. *J. Med. Chem.*, 2006, vol. 49, 4392-4408 [0273]
- **LIU** et al. *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 8618-8623 [0277]
- **WOYKE** et al. *Antimicrob. Agents and Chemother*, 2001, vol. 45 (12), 3580-3584 [0280]
- **PETTIT** et al. *Antimicrob. Agents Chemother*, 1998, vol. 42, 2961-2965 [0280]
- **DORONINA** et al. *Nature Biotechnology*, 2003, vol. 21 (7), 778-784 [0280]
- **FRANCISCO** et al. *Blood*, 2003, vol. 102 (4), 1458-1465 [0280]
- **DORONINA** et al. *Bioconjugate Chem.*, 2006, vol. 17, 114-124 [0296] [0298]
- **PETTIT** et al. *J. Am. Chem. Soc.*, 1989, vol. 111, 5463-5465 [0297]

- **PETTIT et al.** *Anti-Cancer Drug Design*, 1998, vol. 13, 243-277 **[0297]**
- **PETTIT, G.R. et al.** *Synthesis*, 1996, 719-725 **[0297]**
- **PETTIT et al.** *J. Chem. Soc. Perkin Trans.*, 1996, vol. 1 (5), 859-863 **[0297]**
- **DORONINA.** *Nat. Biotechnol.*, 2003, vol. 21 (7), 778-784 **[0297]**
- **DORONINA et al.** *Nat. Biotech.*, 2003, vol. 21, 778-784 **[0298]**
- **HINMAN et al.** *Cancer Research*, 1993, vol. 53, 3336-3342 **[0299]**
- **LODE et al.** *Cancer Research*, 1998, vol. 58, 2925-2928 **[0299]**
- **LEIMGRUBER et al.** *J. Am. Chem. Soc.*, 1965, vol. 87, 5793-5795 **[0300]**
- **LEIMGRUBER et al.** *J. Am. Chem. Soc.*, 1965, vol. 87, 5791-5793 **[0300]**
- **THURSTON et al.** *Chem. Rev.*, 1994, 433-465 **[0300]**
- **KOHN.** In *Antibiotics III*. Springer-Verlag, 1975, 3-11 **[0300]**
- **HURLEY ; NEEDHAM-VANDEVANTER.** *Acc. Chem. Res.*, 1986, vol. 19, 230-237 **[0300]**
- **HARTLEY et al.** *Cancer Res.*, 2010, vol. 70 (17), 6849-6858 **[0300]**
- **ANTONOW.** *J. Med. Chem.*, 2010, vol. 53 (7), 2927-2941 **[0300]**
- **HOWARD et al.** *Bioorganic and Med. Chem. Letters*, 2009, vol. 19 (22), 6463-6466 **[0300]**
- **C. PETERSON et al.** Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia. *Anthracycline Antibiotics In Cancer Therapy* **[0330]**
- **N.R. BACHUR.** *Free Radical Damage*, 97-102 **[0330]**
- **KRATZ et al.** *Current Med. Chem.*, 2006, vol. 13, 477-523 **[0331]**
- **JEFFREY et al.** *Bioorganic & Med. Chem. Letters*, 2006, vol. 16, 358-362 **[0331]**
- **TORGOV et al.** *Bioconj. Chem.*, 2005, vol. 16, 717-721 **[0331]**
- **NAGY et al.** *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97, 829-834 **[0331]**
- **DUBOWCHIK et al.** *Bioorg. & Med. Chem. Letters*, 2002, vol. 12, 1529-1532 **[0331]**
- **KING et al.** *J. Med. Chem.*, 2002, vol. 45, 4336-4343 **[0331]**
- **SALEH et al.** *J. Clin. Oncology*, 2000, vol. 18, 2282-2292 **[0331]**
- **AJANI et al.** *Cancer Jour.*, 2000, vol. 6, 78-81 **[0331]**
- **TOLCHER et al.** *J. Clin. Oncology*, 1999, vol. 17, 478-484 **[0331]**
- **QUINTIERI et al.** *Clinical Cancer Research*, 2005, vol. 11 (4), 1608-1617 **[0332]**
- **GRANDI et al.** *Cancer Treat. Rev.*, 1990, vol. 17, 133 **[0332]**
- **RIPAMONTI et al.** *Brit. J. Cancer*, 1992, vol. 65, 703 **[0332]**
- **SUN et al.** *Proceedings of the American Society for Clinical Oncology*, 2003, vol. 22 **[0332]**
- **QUINTIERI.** Proceedings of the American Association of Cancer Research. 2003, vol. 44 **[0332]**
- **PACCiarini et al.** *Jour. Clin. Oncology*, 2006, vol. 24, 14116 **[0332]**
- **MANDLER et al.** *J. Nat. Cancer Inst.*, 2000, vol. 92 (19), 1573-1581 **[0341]**
- **MANDLER et al.** *Bioorganic & Med. Chem. Letters*, 2000, vol. 10, 1025-1028 **[0341]**
- **MANDLER et al.** *Bioconjugate Chem.*, 2002, vol. 13, 786-791 **[0341]**
- **FRAKER et al.** *Biochem. Biophys. Res. Commun.*, 1978, vol. 80, 49-57 **[0344]**
- **CHATAL.** Monoclonal Antibodies in Immunoscintigraphy. CRC Press, 1989 **[0344]**
- **NEUBERGER et al.** *Nature*, 1984, vol. 312, 604-608 **[0345]**
- **MCDONAGH et al.** *Prot. Engr. Design & Selection*, 2006, vol. 19 (7), 299-307 **[0350]**
- **HAMBLETT et al.** *Clin. Cancer Res.*, 2004, vol. 10, 7063-7070 **[0350]**
- Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate. **HAMBLETT, K.J. et al.** 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR. American Association for Cancer Research, 27 March 2004, vol. 45 **[0350]**
- Controlling the location of drug attachment in antibody-drug conjugates. **ALLEY, S.C. et al.** 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR. American Association for Cancer Research, 27 March 2004, vol. 45 **[0350]**
- **GEOGHEGAN ; STROH.** *Bioconjugate Chem.*, 1992, vol. 3, 138-146 **[0353]**
- **VAN DONGEN et al.** *The Oncologist*, 2007, vol. 12, 1379-1389 **[0359]**
- **VEREL et al.** *J. Nucl. Med.*, 2003, vol. 44, 1271-1281 **[0359]**
- Remington's Pharmaceutical Sciences. 1980 **[0363]** **[0366]**
- **CROUCH et al.** *J. Immunol. Meth.*, 1993, vol. 160, 81-88 **[0371]**
- **CREE et al.** *AntiCancer Drugs*, 1995, vol. 6, 398-404 **[0371]**
- **BUBENDORF L et al.** *J Pathol.*, September 2001, vol. 195 (1), 72-9 **[0388]**
- **KABAT et al.** Sequences of proteins of immunological interest. Public Health Service, National Institutes of Health, 1991 **[0402]**
- **FOOTE ; WINTER.** *J. Mol. Biol.*, 1992, vol. 224, 487-499 **[0405]**
- **MACCALLUM et al.** *J. Mol. Biol.*, 1996, vol. 262, 732-745 **[0405]**
- **HOLMES et al.** *Science*, 1992, vol. 256, 1205-1210 **[0417]**